{"id": "AIMed.d102.s859_AIMed.d102.s859.p0", "text": "The retinoblastoma-susceptibility gene product binds directly to the human TATA-binding protein-associated factor TAFII250.", "text_with_entity_marker": "The [E1]retinoblastoma[/E1]-susceptibility gene product binds directly to the human [E2]TATA-binding protein[/E2]-associated factor TAFII250.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "retinoblastoma", "entity_1_idx": [[4, 18]], "entity_1_idx_in_text_with_entity_marker": [8, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TATA-binding protein", "entity_2_idx": [[75, 95]], "entity_2_idx_in_text_with_entity_marker": [88, 108], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d102.s859_AIMed.d102.s859.p1", "text": "The retinoblastoma-susceptibility gene product binds directly to the human TATA-binding protein-associated factor TAFII250.", "text_with_entity_marker": "The [E1]retinoblastoma[/E1]-susceptibility gene product binds directly to the human [E2]TATA-binding protein-associated factor[/E2] TAFII250.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "retinoblastoma", "entity_1_idx": [[4, 18]], "entity_1_idx_in_text_with_entity_marker": [8, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TATA-binding protein-associated factor", "entity_2_idx": [[75, 113]], "entity_2_idx_in_text_with_entity_marker": [88, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d102.s859_AIMed.d102.s859.p2", "text": "The retinoblastoma-susceptibility gene product binds directly to the human TATA-binding protein-associated factor TAFII250.", "text_with_entity_marker": "The [E1]retinoblastoma[/E1]-susceptibility gene product binds directly to the human TATA-binding protein-associated factor [E2]TAFII250[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "retinoblastoma", "entity_1_idx": [[4, 18]], "entity_1_idx_in_text_with_entity_marker": [8, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII250", "entity_2_idx": [[114, 122]], "entity_2_idx_in_text_with_entity_marker": [127, 135], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d102.s859_AIMed.d102.s859.p3", "text": "The retinoblastoma-susceptibility gene product binds directly to the human TATA-binding protein-associated factor TAFII250.", "text_with_entity_marker": "The retinoblastoma-susceptibility gene product binds directly to the human [E1-E2]TATA-binding protein[/E1]-associated factor[/E2] TAFII250.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA-binding protein", "entity_1_idx": [[75, 95]], "entity_1_idx_in_text_with_entity_marker": [82, 102], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TATA-binding protein[/E1]-associated factor", "entity_2_idx": [[75, 113]], "entity_2_idx_in_text_with_entity_marker": [82, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d102.s859_AIMed.d102.s859.p4", "text": "The retinoblastoma-susceptibility gene product binds directly to the human TATA-binding protein-associated factor TAFII250.", "text_with_entity_marker": "The retinoblastoma-susceptibility gene product binds directly to the human [E1]TATA-binding protein[/E1]-associated factor [E2]TAFII250[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA-binding protein", "entity_1_idx": [[75, 95]], "entity_1_idx_in_text_with_entity_marker": [79, 99], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII250", "entity_2_idx": [[114, 122]], "entity_2_idx_in_text_with_entity_marker": [127, 135], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d102.s859_AIMed.d102.s859.p5", "text": "The retinoblastoma-susceptibility gene product binds directly to the human TATA-binding protein-associated factor TAFII250.", "text_with_entity_marker": "The retinoblastoma-susceptibility gene product binds directly to the human [E1]TATA-binding protein-associated factor[/E1] [E2]TAFII250[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA-binding protein-associated factor", "entity_1_idx": [[75, 113]], "entity_1_idx_in_text_with_entity_marker": [79, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII250", "entity_2_idx": [[114, 122]], "entity_2_idx_in_text_with_entity_marker": [127, 135], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d102.s860_AIMed.d102.s860.p0", "text": "RB, the protein product of the retinoblastoma tumor-suppressor gene, regulates the activity of specific transcription factors.", "text_with_entity_marker": "[E1]RB[/E1], the protein product of the [E2]retinoblastoma[/E2] tumor-suppressor gene, regulates the activity of specific transcription factors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RB", "entity_1_idx": [[0, 2]], "entity_1_idx_in_text_with_entity_marker": [4, 6], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "retinoblastoma", "entity_2_idx": [[31, 45]], "entity_2_idx_in_text_with_entity_marker": [44, 58], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d102.s862_AIMed.d102.s862.p0", "text": "Here we report that stimulation of Sp1-mediated transcription by RB is partially abrogated at the nonpermissive temperature in ts13 cells.", "text_with_entity_marker": "Here we report that stimulation of [E1]Sp1[/E1]-mediated transcription by [E2]RB[/E2] is partially abrogated at the nonpermissive temperature in ts13 cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Sp1", "entity_1_idx": [[35, 38]], "entity_1_idx_in_text_with_entity_marker": [39, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RB", "entity_2_idx": [[65, 67]], "entity_2_idx_in_text_with_entity_marker": [78, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d102.s863_AIMed.d102.s863.p0", "text": "These cells contain a temperature-sensitive mutation in the TATA-binding protein-associated factor TAFII250, first identified as the cell cycle regulatory protein CCG1.", "text_with_entity_marker": "These cells contain a temperature-sensitive mutation in the [E1-E2]TATA-binding protein[/E1]-associated factor[/E2] TAFII250, first identified as the cell cycle regulatory protein CCG1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA-binding protein", "entity_1_idx": [[60, 80]], "entity_1_idx_in_text_with_entity_marker": [67, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TATA-binding protein[/E1]-associated factor", "entity_2_idx": [[60, 98]], "entity_2_idx_in_text_with_entity_marker": [67, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d102.s863_AIMed.d102.s863.p1", "text": "These cells contain a temperature-sensitive mutation in the TATA-binding protein-associated factor TAFII250, first identified as the cell cycle regulatory protein CCG1.", "text_with_entity_marker": "These cells contain a temperature-sensitive mutation in the [E1]TATA-binding protein[/E1]-associated factor [E2]TAFII250[/E2], first identified as the cell cycle regulatory protein CCG1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA-binding protein", "entity_1_idx": [[60, 80]], "entity_1_idx_in_text_with_entity_marker": [64, 84], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII250", "entity_2_idx": [[99, 107]], "entity_2_idx_in_text_with_entity_marker": [112, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d102.s863_AIMed.d102.s863.p2", "text": "These cells contain a temperature-sensitive mutation in the TATA-binding protein-associated factor TAFII250, first identified as the cell cycle regulatory protein CCG1.", "text_with_entity_marker": "These cells contain a temperature-sensitive mutation in the [E1]TATA-binding protein[/E1]-associated factor TAFII250, first identified as the cell cycle regulatory protein [E2]CCG1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA-binding protein", "entity_1_idx": [[60, 80]], "entity_1_idx_in_text_with_entity_marker": [64, 84], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCG1", "entity_2_idx": [[163, 167]], "entity_2_idx_in_text_with_entity_marker": [176, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d102.s863_AIMed.d102.s863.p3", "text": "These cells contain a temperature-sensitive mutation in the TATA-binding protein-associated factor TAFII250, first identified as the cell cycle regulatory protein CCG1.", "text_with_entity_marker": "These cells contain a temperature-sensitive mutation in the [E1]TATA-binding protein-associated factor[/E1] [E2]TAFII250[/E2], first identified as the cell cycle regulatory protein CCG1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA-binding protein-associated factor", "entity_1_idx": [[60, 98]], "entity_1_idx_in_text_with_entity_marker": [64, 102], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII250", "entity_2_idx": [[99, 107]], "entity_2_idx_in_text_with_entity_marker": [112, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d102.s863_AIMed.d102.s863.p4", "text": "These cells contain a temperature-sensitive mutation in the TATA-binding protein-associated factor TAFII250, first identified as the cell cycle regulatory protein CCG1.", "text_with_entity_marker": "These cells contain a temperature-sensitive mutation in the [E1]TATA-binding protein-associated factor[/E1] TAFII250, first identified as the cell cycle regulatory protein [E2]CCG1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA-binding protein-associated factor", "entity_1_idx": [[60, 98]], "entity_1_idx_in_text_with_entity_marker": [64, 102], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCG1", "entity_2_idx": [[163, 167]], "entity_2_idx_in_text_with_entity_marker": [176, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d102.s863_AIMed.d102.s863.p5", "text": "These cells contain a temperature-sensitive mutation in the TATA-binding protein-associated factor TAFII250, first identified as the cell cycle regulatory protein CCG1.", "text_with_entity_marker": "These cells contain a temperature-sensitive mutation in the TATA-binding protein-associated factor [E1]TAFII250[/E1], first identified as the cell cycle regulatory protein [E2]CCG1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAFII250", "entity_1_idx": [[99, 107]], "entity_1_idx_in_text_with_entity_marker": [103, 111], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCG1", "entity_2_idx": [[163, 167]], "entity_2_idx_in_text_with_entity_marker": [176, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d102.s864_AIMed.d102.s864.p0", "text": "The stimulation of Sp1-mediated transcription by RB in ts13 cells at the nonpermissive temperature could be restored by the introduction of wild-type human TAFII250.", "text_with_entity_marker": "The stimulation of [E1]Sp1[/E1]-mediated transcription by [E2]RB[/E2] in ts13 cells at the nonpermissive temperature could be restored by the introduction of wild-type human TAFII250.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Sp1", "entity_1_idx": [[19, 22]], "entity_1_idx_in_text_with_entity_marker": [23, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RB", "entity_2_idx": [[49, 51]], "entity_2_idx_in_text_with_entity_marker": [62, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d102.s864_AIMed.d102.s864.p1", "text": "The stimulation of Sp1-mediated transcription by RB in ts13 cells at the nonpermissive temperature could be restored by the introduction of wild-type human TAFII250.", "text_with_entity_marker": "The stimulation of [E1]Sp1[/E1]-mediated transcription by RB in ts13 cells at the nonpermissive temperature could be restored by the introduction of wild-type human [E2]TAFII250[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Sp1", "entity_1_idx": [[19, 22]], "entity_1_idx_in_text_with_entity_marker": [23, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII250", "entity_2_idx": [[156, 164]], "entity_2_idx_in_text_with_entity_marker": [169, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d102.s864_AIMed.d102.s864.p2", "text": "The stimulation of Sp1-mediated transcription by RB in ts13 cells at the nonpermissive temperature could be restored by the introduction of wild-type human TAFII250.", "text_with_entity_marker": "The stimulation of Sp1-mediated transcription by [E1]RB[/E1] in ts13 cells at the nonpermissive temperature could be restored by the introduction of wild-type human [E2]TAFII250[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RB", "entity_1_idx": [[49, 51]], "entity_1_idx_in_text_with_entity_marker": [53, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII250", "entity_2_idx": [[156, 164]], "entity_2_idx_in_text_with_entity_marker": [169, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d102.s865_AIMed.d102.s865.p0", "text": "Furthermore, we demonstrate that RB binds directly to hTAFII250 in vitro and in vivo.", "text_with_entity_marker": "Furthermore, we demonstrate that [E1]RB[/E1] binds directly to [E2]hTAFII250[/E2] in vitro and in vivo.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "RB", "entity_1_idx": [[33, 35]], "entity_1_idx_in_text_with_entity_marker": [37, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hTAFII250", "entity_2_idx": [[54, 63]], "entity_2_idx_in_text_with_entity_marker": [67, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d102.s866_AIMed.d102.s866.p0", "text": "These results suggest that RB can confer transcriptional regulation and possibly cell cycle control and tumor suppression through an interaction with TFIID, in particular with TAFII250.", "text_with_entity_marker": "These results suggest that [E1]RB[/E1] can confer transcriptional regulation and possibly cell cycle control and tumor suppression through an interaction with [E2]TFIID[/E2], in particular with TAFII250.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RB", "entity_1_idx": [[27, 29]], "entity_1_idx_in_text_with_entity_marker": [31, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIID", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d102.s866_AIMed.d102.s866.p1", "text": "These results suggest that RB can confer transcriptional regulation and possibly cell cycle control and tumor suppression through an interaction with TFIID, in particular with TAFII250.", "text_with_entity_marker": "These results suggest that [E1]RB[/E1] can confer transcriptional regulation and possibly cell cycle control and tumor suppression through an interaction with TFIID, in particular with [E2]TAFII250[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "RB", "entity_1_idx": [[27, 29]], "entity_1_idx_in_text_with_entity_marker": [31, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII250", "entity_2_idx": [[176, 184]], "entity_2_idx_in_text_with_entity_marker": [189, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d102.s866_AIMed.d102.s866.p2", "text": "These results suggest that RB can confer transcriptional regulation and possibly cell cycle control and tumor suppression through an interaction with TFIID, in particular with TAFII250.", "text_with_entity_marker": "These results suggest that RB can confer transcriptional regulation and possibly cell cycle control and tumor suppression through an interaction with [E1]TFIID[/E1], in particular with [E2]TAFII250[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[150, 155]], "entity_1_idx_in_text_with_entity_marker": [154, 159], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII250", "entity_2_idx": [[176, 184]], "entity_2_idx_in_text_with_entity_marker": [189, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1384_AIMed.d165.s1384.p0", "text": "Interactions involving the human RNA polymerase II transcription/nucleotide excision repair complex TFIIH, the nucleotide excision repair protein XPG, and Cockayne syndrome group B (CSB) protein.", "text_with_entity_marker": "Interactions involving the human RNA polymerase II transcription/nucleotide excision repair complex [E1]TFIIH[/E1], the nucleotide excision repair protein [E2]XPG[/E2], and Cockayne syndrome group B (CSB) protein.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIH", "entity_1_idx": [[100, 105]], "entity_1_idx_in_text_with_entity_marker": [104, 109], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "XPG", "entity_2_idx": [[146, 149]], "entity_2_idx_in_text_with_entity_marker": [159, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1384_AIMed.d165.s1384.p1", "text": "Interactions involving the human RNA polymerase II transcription/nucleotide excision repair complex TFIIH, the nucleotide excision repair protein XPG, and Cockayne syndrome group B (CSB) protein.", "text_with_entity_marker": "Interactions involving the human RNA polymerase II transcription/nucleotide excision repair complex [E1]TFIIH[/E1], the nucleotide excision repair protein XPG, and Cockayne syndrome group B ([E2]CSB[/E2]) protein.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIH", "entity_1_idx": [[100, 105]], "entity_1_idx_in_text_with_entity_marker": [104, 109], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CSB", "entity_2_idx": [[182, 185]], "entity_2_idx_in_text_with_entity_marker": [195, 198], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1384_AIMed.d165.s1384.p2", "text": "Interactions involving the human RNA polymerase II transcription/nucleotide excision repair complex TFIIH, the nucleotide excision repair protein XPG, and Cockayne syndrome group B (CSB) protein.", "text_with_entity_marker": "Interactions involving the human RNA polymerase II transcription/nucleotide excision repair complex [E1]TFIIH[/E1], the nucleotide excision repair protein XPG, and [E2]Cockayne syndrome group B (CSB) protein[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIH", "entity_1_idx": [[100, 105]], "entity_1_idx_in_text_with_entity_marker": [104, 109], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cockayne syndrome group B (CSB) protein", "entity_2_idx": [[155, 194]], "entity_2_idx_in_text_with_entity_marker": [168, 207], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1384_AIMed.d165.s1384.p3", "text": "Interactions involving the human RNA polymerase II transcription/nucleotide excision repair complex TFIIH, the nucleotide excision repair protein XPG, and Cockayne syndrome group B (CSB) protein.", "text_with_entity_marker": "Interactions involving the human RNA polymerase II transcription/nucleotide excision repair complex TFIIH, the nucleotide excision repair protein [E1]XPG[/E1], and Cockayne syndrome group B ([E2]CSB[/E2]) protein.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "XPG", "entity_1_idx": [[146, 149]], "entity_1_idx_in_text_with_entity_marker": [150, 153], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CSB", "entity_2_idx": [[182, 185]], "entity_2_idx_in_text_with_entity_marker": [195, 198], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1384_AIMed.d165.s1384.p4", "text": "Interactions involving the human RNA polymerase II transcription/nucleotide excision repair complex TFIIH, the nucleotide excision repair protein XPG, and Cockayne syndrome group B (CSB) protein.", "text_with_entity_marker": "Interactions involving the human RNA polymerase II transcription/nucleotide excision repair complex TFIIH, the nucleotide excision repair protein [E1]XPG[/E1], and [E2]Cockayne syndrome group B (CSB) protein[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "XPG", "entity_1_idx": [[146, 149]], "entity_1_idx_in_text_with_entity_marker": [150, 153], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cockayne syndrome group B (CSB) protein", "entity_2_idx": [[155, 194]], "entity_2_idx_in_text_with_entity_marker": [168, 207], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1384_AIMed.d165.s1384.p5", "text": "Interactions involving the human RNA polymerase II transcription/nucleotide excision repair complex TFIIH, the nucleotide excision repair protein XPG, and Cockayne syndrome group B (CSB) protein.", "text_with_entity_marker": "Interactions involving the human RNA polymerase II transcription/nucleotide excision repair complex TFIIH, the nucleotide excision repair protein XPG, and [E1]Cockayne syndrome group B (CSB) protein[/E1][E2]CSB[/E2]) protein.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Cockayne syndrome group B (CSB) protein", "entity_1_idx": [[155, 194]], "entity_1_idx_in_text_with_entity_marker": [159, 198], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CSB", "entity_2_idx": [[182, 185]], "entity_2_idx_in_text_with_entity_marker": [207, 210], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1388_AIMed.d165.s1388.p0", "text": "At least two of the subunits of TFIIH (XPB and XPD proteins) are implicated in the disease xeroderma pigmentosum (XP).", "text_with_entity_marker": "At least two of the subunits of [E1]TFIIH[/E1] ([E2]XPB[/E2] and XPD proteins) are implicated in the disease xeroderma pigmentosum (XP).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIH", "entity_1_idx": [[32, 37]], "entity_1_idx_in_text_with_entity_marker": [36, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "XPB", "entity_2_idx": [[39, 42]], "entity_2_idx_in_text_with_entity_marker": [52, 55], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1388_AIMed.d165.s1388.p1", "text": "At least two of the subunits of TFIIH (XPB and XPD proteins) are implicated in the disease xeroderma pigmentosum (XP).", "text_with_entity_marker": "At least two of the subunits of [E1]TFIIH[/E1] (XPB and [E2]XPD[/E2] proteins) are implicated in the disease xeroderma pigmentosum (XP).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIH", "entity_1_idx": [[32, 37]], "entity_1_idx_in_text_with_entity_marker": [36, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "XPD", "entity_2_idx": [[47, 50]], "entity_2_idx_in_text_with_entity_marker": [60, 63], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1388_AIMed.d165.s1388.p2", "text": "At least two of the subunits of TFIIH (XPB and XPD proteins) are implicated in the disease xeroderma pigmentosum (XP).", "text_with_entity_marker": "At least two of the subunits of TFIIH ([E1]XPB[/E1] and [E2]XPD[/E2] proteins) are implicated in the disease xeroderma pigmentosum (XP).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "XPB", "entity_1_idx": [[39, 42]], "entity_1_idx_in_text_with_entity_marker": [43, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "XPD", "entity_2_idx": [[47, 50]], "entity_2_idx_in_text_with_entity_marker": [60, 63], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p0", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned [E1]XPB[/E1], [E2]XPD[/E2], p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "XPB", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "XPD", "entity_2_idx": [[54, 57]], "entity_2_idx_in_text_with_entity_marker": [67, 70], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p1", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned [E1]XPB[/E1], XPD, [E2]p62[/E2], p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "XPB", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p62", "entity_2_idx": [[59, 62]], "entity_2_idx_in_text_with_entity_marker": [72, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p2", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned [E1]XPB[/E1], XPD, p62, [E2]p44[/E2], and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "XPB", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p44", "entity_2_idx": [[64, 67]], "entity_2_idx_in_text_with_entity_marker": [77, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p3", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned [E1]XPB[/E1], XPD, p62, p44, and [E2]p34[/E2] genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "XPB", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p34", "entity_2_idx": [[73, 76]], "entity_2_idx_in_text_with_entity_marker": [86, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p4", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned [E1]XPB[/E1], XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of [E2]TFIIH[/E2]) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "XPB", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIH", "entity_2_idx": [[128, 133]], "entity_2_idx_in_text_with_entity_marker": [141, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p5", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned XPB, [E1]XPD[/E1], [E2]p62[/E2], p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "XPD", "entity_1_idx": [[54, 57]], "entity_1_idx_in_text_with_entity_marker": [58, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p62", "entity_2_idx": [[59, 62]], "entity_2_idx_in_text_with_entity_marker": [72, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p6", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned XPB, [E1]XPD[/E1], p62, [E2]p44[/E2], and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "XPD", "entity_1_idx": [[54, 57]], "entity_1_idx_in_text_with_entity_marker": [58, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p44", "entity_2_idx": [[64, 67]], "entity_2_idx_in_text_with_entity_marker": [77, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p7", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned XPB, [E1]XPD[/E1], p62, p44, and [E2]p34[/E2] genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "XPD", "entity_1_idx": [[54, 57]], "entity_1_idx_in_text_with_entity_marker": [58, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p34", "entity_2_idx": [[73, 76]], "entity_2_idx_in_text_with_entity_marker": [86, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p8", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned XPB, [E1]XPD[/E1], p62, p44, and p34 genes (all of which encode polypeptide subunits of [E2]TFIIH[/E2]) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "XPD", "entity_1_idx": [[54, 57]], "entity_1_idx_in_text_with_entity_marker": [58, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIH", "entity_2_idx": [[128, 133]], "entity_2_idx_in_text_with_entity_marker": [141, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p9", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned XPB, XPD, [E1]p62[/E1], [E2]p44[/E2], and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p62", "entity_1_idx": [[59, 62]], "entity_1_idx_in_text_with_entity_marker": [63, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p44", "entity_2_idx": [[64, 67]], "entity_2_idx_in_text_with_entity_marker": [77, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p10", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned XPB, XPD, [E1]p62[/E1], p44, and [E2]p34[/E2] genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p62", "entity_1_idx": [[59, 62]], "entity_1_idx_in_text_with_entity_marker": [63, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p34", "entity_2_idx": [[73, 76]], "entity_2_idx_in_text_with_entity_marker": [86, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p11", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned XPB, XPD, [E1]p62[/E1], p44, and p34 genes (all of which encode polypeptide subunits of [E2]TFIIH[/E2]) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p62", "entity_1_idx": [[59, 62]], "entity_1_idx_in_text_with_entity_marker": [63, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIH", "entity_2_idx": [[128, 133]], "entity_2_idx_in_text_with_entity_marker": [141, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p12", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned XPB, XPD, p62, [E1]p44[/E1], and [E2]p34[/E2] genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p44", "entity_1_idx": [[64, 67]], "entity_1_idx_in_text_with_entity_marker": [68, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p34", "entity_2_idx": [[73, 76]], "entity_2_idx_in_text_with_entity_marker": [86, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p13", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned XPB, XPD, p62, [E1]p44[/E1], and p34 genes (all of which encode polypeptide subunits of [E2]TFIIH[/E2]) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p44", "entity_1_idx": [[64, 67]], "entity_1_idx_in_text_with_entity_marker": [68, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIH", "entity_2_idx": [[128, 133]], "entity_2_idx_in_text_with_entity_marker": [141, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p14", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and [E1]p34[/E1] genes (all of which encode polypeptide subunits of [E2]TFIIH[/E2]) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p34", "entity_1_idx": [[73, 76]], "entity_1_idx_in_text_with_entity_marker": [77, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIH", "entity_2_idx": [[128, 133]], "entity_2_idx_in_text_with_entity_marker": [141, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1390_AIMed.d165.s1390.p0", "text": "Additionally we have examined interactions between TFIIH components, the human NER protein XPG, and the CSB protein which is implicated in Cockayne syndrome (CS).", "text_with_entity_marker": "Additionally we have examined interactions between [E1]TFIIH[/E1] components, the human NER protein [E2]XPG[/E2], and the CSB protein which is implicated in Cockayne syndrome (CS).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIH", "entity_1_idx": [[51, 56]], "entity_1_idx_in_text_with_entity_marker": [55, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "XPG", "entity_2_idx": [[91, 94]], "entity_2_idx_in_text_with_entity_marker": [104, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1390_AIMed.d165.s1390.p1", "text": "Additionally we have examined interactions between TFIIH components, the human NER protein XPG, and the CSB protein which is implicated in Cockayne syndrome (CS).", "text_with_entity_marker": "Additionally we have examined interactions between [E1]TFIIH[/E1] components, the human NER protein XPG, and the [E2]CSB[/E2] protein which is implicated in Cockayne syndrome (CS).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIH", "entity_1_idx": [[51, 56]], "entity_1_idx_in_text_with_entity_marker": [55, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CSB", "entity_2_idx": [[104, 107]], "entity_2_idx_in_text_with_entity_marker": [117, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1390_AIMed.d165.s1390.p2", "text": "Additionally we have examined interactions between TFIIH components, the human NER protein XPG, and the CSB protein which is implicated in Cockayne syndrome (CS).", "text_with_entity_marker": "Additionally we have examined interactions between TFIIH components, the human NER protein [E1]XPG[/E1], and the [E2]CSB[/E2] protein which is implicated in Cockayne syndrome (CS).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "XPG", "entity_1_idx": [[91, 94]], "entity_1_idx_in_text_with_entity_marker": [95, 98], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CSB", "entity_2_idx": [[104, 107]], "entity_2_idx_in_text_with_entity_marker": [117, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1391_AIMed.d165.s1391.p0", "text": "Our analyses demonstrate that the XPB, XPD, p44, and p62 proteins interact with each other.", "text_with_entity_marker": "Our analyses demonstrate that the [E1]XPB[/E1], [E2]XPD[/E2], p44, and p62 proteins interact with each other.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "XPB", "entity_1_idx": [[34, 37]], "entity_1_idx_in_text_with_entity_marker": [38, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "XPD", "entity_2_idx": [[39, 42]], "entity_2_idx_in_text_with_entity_marker": [52, 55], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1391_AIMed.d165.s1391.p1", "text": "Our analyses demonstrate that the XPB, XPD, p44, and p62 proteins interact with each other.", "text_with_entity_marker": "Our analyses demonstrate that the [E1]XPB[/E1], XPD, [E2]p44[/E2], and p62 proteins interact with each other.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "XPB", "entity_1_idx": [[34, 37]], "entity_1_idx_in_text_with_entity_marker": [38, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p44", "entity_2_idx": [[44, 47]], "entity_2_idx_in_text_with_entity_marker": [57, 60], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1391_AIMed.d165.s1391.p2", "text": "Our analyses demonstrate that the XPB, XPD, p44, and p62 proteins interact with each other.", "text_with_entity_marker": "Our analyses demonstrate that the [E1]XPB[/E1], XPD, p44, and [E2]p62[/E2] proteins interact with each other.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "XPB", "entity_1_idx": [[34, 37]], "entity_1_idx_in_text_with_entity_marker": [38, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p62", "entity_2_idx": [[53, 56]], "entity_2_idx_in_text_with_entity_marker": [66, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1391_AIMed.d165.s1391.p3", "text": "Our analyses demonstrate that the XPB, XPD, p44, and p62 proteins interact with each other.", "text_with_entity_marker": "Our analyses demonstrate that the XPB, [E1]XPD[/E1], [E2]p44[/E2], and p62 proteins interact with each other.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "XPD", "entity_1_idx": [[39, 42]], "entity_1_idx_in_text_with_entity_marker": [43, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p44", "entity_2_idx": [[44, 47]], "entity_2_idx_in_text_with_entity_marker": [57, 60], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1391_AIMed.d165.s1391.p4", "text": "Our analyses demonstrate that the XPB, XPD, p44, and p62 proteins interact with each other.", "text_with_entity_marker": "Our analyses demonstrate that the XPB, [E1]XPD[/E1], p44, and [E2]p62[/E2] proteins interact with each other.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "XPD", "entity_1_idx": [[39, 42]], "entity_1_idx_in_text_with_entity_marker": [43, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p62", "entity_2_idx": [[53, 56]], "entity_2_idx_in_text_with_entity_marker": [66, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1391_AIMed.d165.s1391.p5", "text": "Our analyses demonstrate that the XPB, XPD, p44, and p62 proteins interact with each other.", "text_with_entity_marker": "Our analyses demonstrate that the XPB, XPD, [E1]p44[/E1], and [E2]p62[/E2] proteins interact with each other.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p44", "entity_1_idx": [[44, 47]], "entity_1_idx_in_text_with_entity_marker": [48, 51], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p62", "entity_2_idx": [[53, 56]], "entity_2_idx_in_text_with_entity_marker": [66, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1392_AIMed.d165.s1392.p0", "text": "XPG protein interacts with multiple subunits of TFIIH and with CSB protein.", "text_with_entity_marker": "[E1]XPG[/E1] protein interacts with multiple subunits of [E2]TFIIH[/E2] and with CSB protein.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "XPG", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIH", "entity_2_idx": [[48, 53]], "entity_2_idx_in_text_with_entity_marker": [61, 66], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1392_AIMed.d165.s1392.p1", "text": "XPG protein interacts with multiple subunits of TFIIH and with CSB protein.", "text_with_entity_marker": "[E1]XPG[/E1] protein interacts with multiple subunits of TFIIH and with [E2]CSB[/E2] protein.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "XPG", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CSB", "entity_2_idx": [[63, 66]], "entity_2_idx_in_text_with_entity_marker": [76, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1392_AIMed.d165.s1392.p2", "text": "XPG protein interacts with multiple subunits of TFIIH and with CSB protein.", "text_with_entity_marker": "XPG protein interacts with multiple subunits of [E1]TFIIH[/E1] and with [E2]CSB[/E2] protein.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIH", "entity_1_idx": [[48, 53]], "entity_1_idx_in_text_with_entity_marker": [52, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CSB", "entity_2_idx": [[63, 66]], "entity_2_idx_in_text_with_entity_marker": [76, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d23.s189_AIMed.d23.s189.p0", "text": "In the present study, we examined the presence of glucocorticoid receptors (GRs) and cyclooxygenase-2 (COX-2) in the nasal polyps of nonallergic patients as compared with normal controls.", "text_with_entity_marker": "In the present study, we examined the presence of glucocorticoid receptors (GRs) and [E1]cyclooxygenase-2[/E1] ([E2]COX-2[/E2]) in the nasal polyps of nonallergic patients as compared with normal controls.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclooxygenase-2", "entity_1_idx": [[85, 101]], "entity_1_idx_in_text_with_entity_marker": [89, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "COX-2", "entity_2_idx": [[103, 108]], "entity_2_idx_in_text_with_entity_marker": [116, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d23.s194_AIMed.d23.s194.p0", "text": "In contrast, in normal nasal tissues, COX-2 labeling was only found in the vascular wall, and the expression was weaker--a finding demonstrating that COX-2 is upregulated in nasal polyps.", "text_with_entity_marker": "In contrast, in normal nasal tissues, [E1]COX-2[/E1] labeling was only found in the vascular wall, and the expression was weaker--a finding demonstrating that [E2]COX-2[/E2] is upregulated in nasal polyps.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "COX-2", "entity_1_idx": [[38, 43]], "entity_1_idx_in_text_with_entity_marker": [42, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "COX-2", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d23.s195_AIMed.d23.s195.p0", "text": "Therefore, 1) the presence of GRs and COX-2 in nasal polyps from nonallergic patients, as well as upregulation of COX-2 expression, suggests that inflammation may play an important role in the pathophysiology of nasal polyps; and 2) glucocorticoid could be a potential treatment method for suppressing inflammatory processes.", "text_with_entity_marker": "Therefore, 1) the presence of GRs and [E1]COX-2[/E1] in nasal polyps from nonallergic patients, as well as upregulation of [E2]COX-2[/E2] expression, suggests that inflammation may play an important role in the pathophysiology of nasal polyps; and 2) glucocorticoid could be a potential treatment method for suppressing inflammatory processes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "COX-2", "entity_1_idx": [[38, 43]], "entity_1_idx_in_text_with_entity_marker": [42, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "COX-2", "entity_2_idx": [[114, 119]], "entity_2_idx_in_text_with_entity_marker": [127, 132], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1579_AIMed.d186.s1579.p0", "text": "cDNA cloning and characterization of the human interleukin 13 receptor alpha chain.", "text_with_entity_marker": "cDNA cloning and characterization of the human [E1-E2]interleukin 13[/E1] receptor[/E2] alpha chain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin 13", "entity_1_idx": [[47, 61]], "entity_1_idx_in_text_with_entity_marker": [54, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin 13[/E1] receptor", "entity_2_idx": [[47, 70]], "entity_2_idx_in_text_with_entity_marker": [54, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1579_AIMed.d186.s1579.p1", "text": "cDNA cloning and characterization of the human interleukin 13 receptor alpha chain.", "text_with_entity_marker": "cDNA cloning and characterization of the human [E1-E2]interleukin 13[/E1] receptor alpha chain[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin 13", "entity_1_idx": [[47, 61]], "entity_1_idx_in_text_with_entity_marker": [54, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin 13[/E1] receptor alpha chain", "entity_2_idx": [[47, 82]], "entity_2_idx_in_text_with_entity_marker": [54, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1579_AIMed.d186.s1579.p2", "text": "cDNA cloning and characterization of the human interleukin 13 receptor alpha chain.", "text_with_entity_marker": "cDNA cloning and characterization of the human [E1-E2]interleukin 13 receptor[/E1] alpha chain[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin 13 receptor", "entity_1_idx": [[47, 70]], "entity_1_idx_in_text_with_entity_marker": [54, 77], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin 13 receptor[/E1] alpha chain", "entity_2_idx": [[47, 82]], "entity_2_idx_in_text_with_entity_marker": [54, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1580_AIMed.d186.s1580.p0", "text": "We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13Ralpha).", "text_with_entity_marker": "We have cloned cDNAs corresponding to the human [E1-E2]interleukin 13[/E1] receptor[/E2] alpha chain (IL-13Ralpha).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin 13", "entity_1_idx": [[48, 62]], "entity_1_idx_in_text_with_entity_marker": [55, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin 13[/E1] receptor", "entity_2_idx": [[48, 71]], "entity_2_idx_in_text_with_entity_marker": [55, 83], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1580_AIMed.d186.s1580.p1", "text": "We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13Ralpha).", "text_with_entity_marker": "We have cloned cDNAs corresponding to the human [E1-E2]interleukin 13[/E1] receptor alpha chain[/E2] (IL-13Ralpha).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin 13", "entity_1_idx": [[48, 62]], "entity_1_idx_in_text_with_entity_marker": [55, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin 13[/E1] receptor alpha chain", "entity_2_idx": [[48, 83]], "entity_2_idx_in_text_with_entity_marker": [55, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1580_AIMed.d186.s1580.p2", "text": "We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13Ralpha).", "text_with_entity_marker": "We have cloned cDNAs corresponding to the human [E1]interleukin 13[/E1] receptor alpha chain ([E2]IL-13Ralpha[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin 13", "entity_1_idx": [[48, 62]], "entity_1_idx_in_text_with_entity_marker": [52, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13Ralpha", "entity_2_idx": [[85, 96]], "entity_2_idx_in_text_with_entity_marker": [98, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1580_AIMed.d186.s1580.p3", "text": "We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13Ralpha).", "text_with_entity_marker": "We have cloned cDNAs corresponding to the human [E1-E2]interleukin 13 receptor[/E1] alpha chain[/E2] (IL-13Ralpha).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin 13 receptor", "entity_1_idx": [[48, 71]], "entity_1_idx_in_text_with_entity_marker": [55, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin 13 receptor[/E1] alpha chain", "entity_2_idx": [[48, 83]], "entity_2_idx_in_text_with_entity_marker": [55, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1580_AIMed.d186.s1580.p4", "text": "We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13Ralpha).", "text_with_entity_marker": "We have cloned cDNAs corresponding to the human [E1]interleukin 13 receptor[/E1] alpha chain ([E2]IL-13Ralpha[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin 13 receptor", "entity_1_idx": [[48, 71]], "entity_1_idx_in_text_with_entity_marker": [52, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13Ralpha", "entity_2_idx": [[85, 96]], "entity_2_idx_in_text_with_entity_marker": [98, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1580_AIMed.d186.s1580.p5", "text": "We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13Ralpha).", "text_with_entity_marker": "We have cloned cDNAs corresponding to the human [E1]interleukin 13 receptor alpha chain[/E1] ([E2]IL-13Ralpha[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin 13 receptor alpha chain", "entity_1_idx": [[48, 83]], "entity_1_idx_in_text_with_entity_marker": [52, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13Ralpha", "entity_2_idx": [[85, 96]], "entity_2_idx_in_text_with_entity_marker": [98, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1582_AIMed.d186.s1582.p0", "text": "Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.", "text_with_entity_marker": "Only weak [E1]IL-13[/E1] binding activity was found in cells transfected with only [E2]IL-13Ralpha[/E2]; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-13", "entity_1_idx": [[10, 15]], "entity_1_idx_in_text_with_entity_marker": [14, 19], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13Ralpha", "entity_2_idx": [[74, 85]], "entity_2_idx_in_text_with_entity_marker": [87, 98], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1582_AIMed.d186.s1582.p1", "text": "Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.", "text_with_entity_marker": "Only weak [E1]IL-13[/E1] binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both [E2]IL-13Ralpha[/E2] and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-13", "entity_1_idx": [[10, 15]], "entity_1_idx_in_text_with_entity_marker": [14, 19], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13Ralpha", "entity_2_idx": [[120, 131]], "entity_2_idx_in_text_with_entity_marker": [133, 144], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1582_AIMed.d186.s1582.p2", "text": "Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.", "text_with_entity_marker": "Only weak [E1]IL-13[/E1] binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and [E2]IL-4Ralpha[/E2] resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-13", "entity_1_idx": [[10, 15]], "entity_1_idx_in_text_with_entity_marker": [14, 19], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4Ralpha", "entity_2_idx": [[136, 146]], "entity_2_idx_in_text_with_entity_marker": [149, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1582_AIMed.d186.s1582.p3", "text": "Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.", "text_with_entity_marker": "Only weak [E1]IL-13[/E1] binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the [E2]IL-13[/E2] receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-13", "entity_1_idx": [[10, 15]], "entity_1_idx_in_text_with_entity_marker": [14, 19], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13", "entity_2_idx": [[284, 289]], "entity_2_idx_in_text_with_entity_marker": [297, 302], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1582_AIMed.d186.s1582.p4", "text": "Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.", "text_with_entity_marker": "Only weak [E1]IL-13[/E1] binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the [E2]IL-13 receptor[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-13", "entity_1_idx": [[10, 15]], "entity_1_idx_in_text_with_entity_marker": [14, 19], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13 receptor", "entity_2_idx": [[284, 298]], "entity_2_idx_in_text_with_entity_marker": [297, 311], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1582_AIMed.d186.s1582.p5", "text": "Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.", "text_with_entity_marker": "Only weak IL-13 binding activity was found in cells transfected with only [E1]IL-13Ralpha[/E1]; however, the combination of both [E2]IL-13Ralpha[/E2] and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-13Ralpha", "entity_1_idx": [[74, 85]], "entity_1_idx_in_text_with_entity_marker": [78, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13Ralpha", "entity_2_idx": [[120, 131]], "entity_2_idx_in_text_with_entity_marker": [133, 144], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1582_AIMed.d186.s1582.p6", "text": "Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.", "text_with_entity_marker": "Only weak IL-13 binding activity was found in cells transfected with only [E1]IL-13Ralpha[/E1]; however, the combination of both IL-13Ralpha and [E2]IL-4Ralpha[/E2] resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-13Ralpha", "entity_1_idx": [[74, 85]], "entity_1_idx_in_text_with_entity_marker": [78, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4Ralpha", "entity_2_idx": [[136, 146]], "entity_2_idx_in_text_with_entity_marker": [149, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1582_AIMed.d186.s1582.p7", "text": "Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.", "text_with_entity_marker": "Only weak IL-13 binding activity was found in cells transfected with only [E1]IL-13Ralpha[/E1]; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the [E2]IL-13[/E2] receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-13Ralpha", "entity_1_idx": [[74, 85]], "entity_1_idx_in_text_with_entity_marker": [78, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13", "entity_2_idx": [[284, 289]], "entity_2_idx_in_text_with_entity_marker": [297, 302], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1582_AIMed.d186.s1582.p8", "text": "Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.", "text_with_entity_marker": "Only weak IL-13 binding activity was found in cells transfected with only [E1]IL-13Ralpha[/E1]; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the [E2]IL-13 receptor[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-13Ralpha", "entity_1_idx": [[74, 85]], "entity_1_idx_in_text_with_entity_marker": [78, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13 receptor", "entity_2_idx": [[284, 298]], "entity_2_idx_in_text_with_entity_marker": [297, 311], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1582_AIMed.d186.s1582.p9", "text": "Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.", "text_with_entity_marker": "Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both [E1]IL-13Ralpha[/E1] and [E2]IL-4Ralpha[/E2] resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-13Ralpha", "entity_1_idx": [[120, 131]], "entity_1_idx_in_text_with_entity_marker": [124, 135], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4Ralpha", "entity_2_idx": [[136, 146]], "entity_2_idx_in_text_with_entity_marker": [149, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1582_AIMed.d186.s1582.p10", "text": "Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.", "text_with_entity_marker": "Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both [E1]IL-13Ralpha[/E1] and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the [E2]IL-13[/E2] receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-13Ralpha", "entity_1_idx": [[120, 131]], "entity_1_idx_in_text_with_entity_marker": [124, 135], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13", "entity_2_idx": [[284, 289]], "entity_2_idx_in_text_with_entity_marker": [297, 302], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1582_AIMed.d186.s1582.p11", "text": "Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.", "text_with_entity_marker": "Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both [E1]IL-13Ralpha[/E1] and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the [E2]IL-13 receptor[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-13Ralpha", "entity_1_idx": [[120, 131]], "entity_1_idx_in_text_with_entity_marker": [124, 135], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13 receptor", "entity_2_idx": [[284, 298]], "entity_2_idx_in_text_with_entity_marker": [297, 311], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1582_AIMed.d186.s1582.p12", "text": "Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.", "text_with_entity_marker": "Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and [E1]IL-4Ralpha[/E1] resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the [E2]IL-13[/E2] receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-4Ralpha", "entity_1_idx": [[136, 146]], "entity_1_idx_in_text_with_entity_marker": [140, 150], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13", "entity_2_idx": [[284, 289]], "entity_2_idx_in_text_with_entity_marker": [297, 302], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1582_AIMed.d186.s1582.p13", "text": "Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.", "text_with_entity_marker": "Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and [E1]IL-4Ralpha[/E1] resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the [E2]IL-13 receptor[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-4Ralpha", "entity_1_idx": [[136, 146]], "entity_1_idx_in_text_with_entity_marker": [140, 150], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13 receptor", "entity_2_idx": [[284, 298]], "entity_2_idx_in_text_with_entity_marker": [297, 311], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1582_AIMed.d186.s1582.p14", "text": "Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.", "text_with_entity_marker": "Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the [E1-E2]IL-13[/E1] receptor[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-13", "entity_1_idx": [[284, 289]], "entity_1_idx_in_text_with_entity_marker": [291, 296], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13[/E1] receptor", "entity_2_idx": [[284, 298]], "entity_2_idx_in_text_with_entity_marker": [291, 310], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1583_AIMed.d186.s1583.p0", "text": "Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.", "text_with_entity_marker": "Whereas [E1]IL-13Ralpha[/E1] serves as an alternative accessory protein to the common [E2]cytokine receptor gamma chain[/E2] (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-13Ralpha", "entity_1_idx": [[8, 19]], "entity_1_idx_in_text_with_entity_marker": [12, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cytokine receptor gamma chain", "entity_2_idx": [[77, 106]], "entity_2_idx_in_text_with_entity_marker": [90, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1583_AIMed.d186.s1583.p1", "text": "Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.", "text_with_entity_marker": "Whereas [E1]IL-13Ralpha[/E1] serves as an alternative accessory protein to the common cytokine receptor gamma chain ([E2]gammac[/E2]) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-13Ralpha", "entity_1_idx": [[8, 19]], "entity_1_idx_in_text_with_entity_marker": [12, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gammac", "entity_2_idx": [[108, 114]], "entity_2_idx_in_text_with_entity_marker": [121, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1583_AIMed.d186.s1583.p2", "text": "Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.", "text_with_entity_marker": "Whereas [E1]IL-13Ralpha[/E1] serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for [E2]IL-4[/E2] signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-13Ralpha", "entity_1_idx": [[8, 19]], "entity_1_idx_in_text_with_entity_marker": [12, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4", "entity_2_idx": [[120, 124]], "entity_2_idx_in_text_with_entity_marker": [133, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1583_AIMed.d186.s1583.p3", "text": "Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.", "text_with_entity_marker": "Whereas [E1]IL-13Ralpha[/E1] serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of [E2]gammac[/E2] in allowing enhanced IL-2 binding activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-13Ralpha", "entity_1_idx": [[8, 19]], "entity_1_idx_in_text_with_entity_marker": [12, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gammac", "entity_2_idx": [[173, 179]], "entity_2_idx_in_text_with_entity_marker": [186, 192], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1583_AIMed.d186.s1583.p4", "text": "Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.", "text_with_entity_marker": "Whereas [E1]IL-13Ralpha[/E1] serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced [E2]IL-2[/E2] binding activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-13Ralpha", "entity_1_idx": [[8, 19]], "entity_1_idx_in_text_with_entity_marker": [12, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[201, 205]], "entity_2_idx_in_text_with_entity_marker": [214, 218], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1583_AIMed.d186.s1583.p5", "text": "Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.", "text_with_entity_marker": "Whereas IL-13Ralpha serves as an alternative accessory protein to the common [E1]cytokine receptor gamma chain[/E1] ([E2]gammac[/E2]) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cytokine receptor gamma chain", "entity_1_idx": [[77, 106]], "entity_1_idx_in_text_with_entity_marker": [81, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gammac", "entity_2_idx": [[108, 114]], "entity_2_idx_in_text_with_entity_marker": [121, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1583_AIMed.d186.s1583.p6", "text": "Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.", "text_with_entity_marker": "Whereas IL-13Ralpha serves as an alternative accessory protein to the common [E1]cytokine receptor gamma chain[/E1] (gammac) for [E2]IL-4[/E2] signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cytokine receptor gamma chain", "entity_1_idx": [[77, 106]], "entity_1_idx_in_text_with_entity_marker": [81, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4", "entity_2_idx": [[120, 124]], "entity_2_idx_in_text_with_entity_marker": [133, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1583_AIMed.d186.s1583.p7", "text": "Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.", "text_with_entity_marker": "Whereas IL-13Ralpha serves as an alternative accessory protein to the common [E1]cytokine receptor gamma chain[/E1] (gammac) for IL-4 signaling, it could not replace the function of [E2]gammac[/E2] in allowing enhanced IL-2 binding activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cytokine receptor gamma chain", "entity_1_idx": [[77, 106]], "entity_1_idx_in_text_with_entity_marker": [81, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gammac", "entity_2_idx": [[173, 179]], "entity_2_idx_in_text_with_entity_marker": [186, 192], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1583_AIMed.d186.s1583.p8", "text": "Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.", "text_with_entity_marker": "Whereas IL-13Ralpha serves as an alternative accessory protein to the common [E1]cytokine receptor gamma chain[/E1] (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced [E2]IL-2[/E2] binding activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cytokine receptor gamma chain", "entity_1_idx": [[77, 106]], "entity_1_idx_in_text_with_entity_marker": [81, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[201, 205]], "entity_2_idx_in_text_with_entity_marker": [214, 218], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1583_AIMed.d186.s1583.p9", "text": "Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.", "text_with_entity_marker": "Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain ([E1]gammac[/E1]) for [E2]IL-4[/E2] signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gammac", "entity_1_idx": [[108, 114]], "entity_1_idx_in_text_with_entity_marker": [112, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4", "entity_2_idx": [[120, 124]], "entity_2_idx_in_text_with_entity_marker": [133, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1583_AIMed.d186.s1583.p10", "text": "Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.", "text_with_entity_marker": "Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain ([E1]gammac[/E1]) for IL-4 signaling, it could not replace the function of [E2]gammac[/E2] in allowing enhanced IL-2 binding activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gammac", "entity_1_idx": [[108, 114]], "entity_1_idx_in_text_with_entity_marker": [112, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gammac", "entity_2_idx": [[173, 179]], "entity_2_idx_in_text_with_entity_marker": [186, 192], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1583_AIMed.d186.s1583.p11", "text": "Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.", "text_with_entity_marker": "Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain ([E1]gammac[/E1]) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced [E2]IL-2[/E2] binding activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gammac", "entity_1_idx": [[108, 114]], "entity_1_idx_in_text_with_entity_marker": [112, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[201, 205]], "entity_2_idx_in_text_with_entity_marker": [214, 218], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1583_AIMed.d186.s1583.p12", "text": "Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.", "text_with_entity_marker": "Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for [E1]IL-4[/E1] signaling, it could not replace the function of [E2]gammac[/E2] in allowing enhanced IL-2 binding activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-4", "entity_1_idx": [[120, 124]], "entity_1_idx_in_text_with_entity_marker": [124, 128], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gammac", "entity_2_idx": [[173, 179]], "entity_2_idx_in_text_with_entity_marker": [186, 192], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1583_AIMed.d186.s1583.p13", "text": "Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.", "text_with_entity_marker": "Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for [E1]IL-4[/E1] signaling, it could not replace the function of gammac in allowing enhanced [E2]IL-2[/E2] binding activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-4", "entity_1_idx": [[120, 124]], "entity_1_idx_in_text_with_entity_marker": [124, 128], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[201, 205]], "entity_2_idx_in_text_with_entity_marker": [214, 218], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1583_AIMed.d186.s1583.p14", "text": "Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.", "text_with_entity_marker": "Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of [E1]gammac[/E1] in allowing enhanced [E2]IL-2[/E2] binding activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gammac", "entity_1_idx": [[173, 179]], "entity_1_idx_in_text_with_entity_marker": [177, 183], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[201, 205]], "entity_2_idx_in_text_with_entity_marker": [214, 218], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1584_AIMed.d186.s1584.p0", "text": "Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.", "text_with_entity_marker": "Nevertheless, the overall size and length of the cytoplasmic domain of [E1]IL-13Ralpha[/E1] and [E2]gammac[/E2] are similar, and like gammac, IL-13Ralpha is located on chromosome X.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-13Ralpha", "entity_1_idx": [[71, 82]], "entity_1_idx_in_text_with_entity_marker": [75, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gammac", "entity_2_idx": [[87, 93]], "entity_2_idx_in_text_with_entity_marker": [100, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1584_AIMed.d186.s1584.p1", "text": "Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.", "text_with_entity_marker": "Nevertheless, the overall size and length of the cytoplasmic domain of [E1]IL-13Ralpha[/E1] and gammac are similar, and like [E2]gammac[/E2], IL-13Ralpha is located on chromosome X.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-13Ralpha", "entity_1_idx": [[71, 82]], "entity_1_idx_in_text_with_entity_marker": [75, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gammac", "entity_2_idx": [[116, 122]], "entity_2_idx_in_text_with_entity_marker": [129, 135], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1584_AIMed.d186.s1584.p2", "text": "Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.", "text_with_entity_marker": "Nevertheless, the overall size and length of the cytoplasmic domain of [E1]IL-13Ralpha[/E1] and gammac are similar, and like gammac, [E2]IL-13Ralpha[/E2] is located on chromosome X.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-13Ralpha", "entity_1_idx": [[71, 82]], "entity_1_idx_in_text_with_entity_marker": [75, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13Ralpha", "entity_2_idx": [[124, 135]], "entity_2_idx_in_text_with_entity_marker": [137, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1584_AIMed.d186.s1584.p3", "text": "Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.", "text_with_entity_marker": "Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and [E1]gammac[/E1] are similar, and like [E2]gammac[/E2], IL-13Ralpha is located on chromosome X.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gammac", "entity_1_idx": [[87, 93]], "entity_1_idx_in_text_with_entity_marker": [91, 97], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gammac", "entity_2_idx": [[116, 122]], "entity_2_idx_in_text_with_entity_marker": [129, 135], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1584_AIMed.d186.s1584.p4", "text": "Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.", "text_with_entity_marker": "Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and [E1]gammac[/E1] are similar, and like gammac, [E2]IL-13Ralpha[/E2] is located on chromosome X.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gammac", "entity_1_idx": [[87, 93]], "entity_1_idx_in_text_with_entity_marker": [91, 97], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13Ralpha", "entity_2_idx": [[124, 135]], "entity_2_idx_in_text_with_entity_marker": [137, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1584_AIMed.d186.s1584.p5", "text": "Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.", "text_with_entity_marker": "Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like [E1]gammac[/E1], [E2]IL-13Ralpha[/E2] is located on chromosome X.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gammac", "entity_1_idx": [[116, 122]], "entity_1_idx_in_text_with_entity_marker": [120, 126], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13Ralpha", "entity_2_idx": [[124, 135]], "entity_2_idx_in_text_with_entity_marker": [137, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d71.s603_AIMed.d71.s603.p0", "text": "The proto-oncogene c-jun is a component of the AP-1 transcription factor family involved in the mediation of nuclear events elicited by extracellular stimuli.", "text_with_entity_marker": "The proto-oncogene [E1]c-jun[/E1] is a component of the [E2]AP-1[/E2] transcription factor family involved in the mediation of nuclear events elicited by extracellular stimuli.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-jun", "entity_1_idx": [[19, 24]], "entity_1_idx_in_text_with_entity_marker": [23, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AP-1", "entity_2_idx": [[47, 51]], "entity_2_idx_in_text_with_entity_marker": [60, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d71.s606_AIMed.d71.s606.p0", "text": "We present evidence that mitogen-activated protein-serine (MAP) kinases (pp54 and pp42/44) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of c-jun.", "text_with_entity_marker": "We present evidence that [E1]mitogen-activated protein-serine (MAP) kinases[/E1] ([E2]pp54[/E2] and pp42/44) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of c-jun.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "mitogen-activated protein-serine (MAP) kinases", "entity_1_idx": [[25, 71]], "entity_1_idx_in_text_with_entity_marker": [29, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pp54", "entity_2_idx": [[73, 77]], "entity_2_idx_in_text_with_entity_marker": [86, 90], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d71.s606_AIMed.d71.s606.p1", "text": "We present evidence that mitogen-activated protein-serine (MAP) kinases (pp54 and pp42/44) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of c-jun.", "text_with_entity_marker": "We present evidence that [E1]mitogen-activated protein-serine (MAP) kinases[/E1] (pp54 and [E2]pp42[/E2]/44) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of c-jun.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "mitogen-activated protein-serine (MAP) kinases", "entity_1_idx": [[25, 71]], "entity_1_idx_in_text_with_entity_marker": [29, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pp42", "entity_2_idx": [[82, 86]], "entity_2_idx_in_text_with_entity_marker": [95, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d71.s606_AIMed.d71.s606.p2", "text": "We present evidence that mitogen-activated protein-serine (MAP) kinases (pp54 and pp42/44) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of c-jun.", "text_with_entity_marker": "We present evidence that [E1]mitogen-activated protein-serine (MAP) kinases[/E1] (pp54 and pp42/44) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of [E2]c-jun[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "mitogen-activated protein-serine (MAP) kinases", "entity_1_idx": [[25, 71]], "entity_1_idx_in_text_with_entity_marker": [29, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-jun", "entity_2_idx": [[210, 215]], "entity_2_idx_in_text_with_entity_marker": [223, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d71.s606_AIMed.d71.s606.p3", "text": "We present evidence that mitogen-activated protein-serine (MAP) kinases (pp54 and pp42/44) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of c-jun.", "text_with_entity_marker": "We present evidence that mitogen-activated protein-serine (MAP) kinases ([E1]pp54[/E1] and [E2]pp42[/E2]/44) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of c-jun.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pp54", "entity_1_idx": [[73, 77]], "entity_1_idx_in_text_with_entity_marker": [77, 81], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pp42", "entity_2_idx": [[82, 86]], "entity_2_idx_in_text_with_entity_marker": [95, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d71.s606_AIMed.d71.s606.p4", "text": "We present evidence that mitogen-activated protein-serine (MAP) kinases (pp54 and pp42/44) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of c-jun.", "text_with_entity_marker": "We present evidence that mitogen-activated protein-serine (MAP) kinases ([E1]pp54[/E1] and pp42/44) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of [E2]c-jun[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "pp54", "entity_1_idx": [[73, 77]], "entity_1_idx_in_text_with_entity_marker": [77, 81], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-jun", "entity_2_idx": [[210, 215]], "entity_2_idx_in_text_with_entity_marker": [223, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d71.s606_AIMed.d71.s606.p5", "text": "We present evidence that mitogen-activated protein-serine (MAP) kinases (pp54 and pp42/44) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of c-jun.", "text_with_entity_marker": "We present evidence that mitogen-activated protein-serine (MAP) kinases (pp54 and [E1]pp42[/E1]/44) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of [E2]c-jun[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "pp42", "entity_1_idx": [[82, 86]], "entity_1_idx_in_text_with_entity_marker": [86, 90], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-jun", "entity_2_idx": [[210, 215]], "entity_2_idx_in_text_with_entity_marker": [223, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d71.s607_AIMed.d71.s607.p0", "text": "The MAP kinase enzymes pp54 and pp42/44 are regulated by tyrosine as well as serine/threonine phosphorylation.", "text_with_entity_marker": "The [E1]MAP kinase[/E1] enzymes [E2]pp54[/E2] and pp42/44 are regulated by tyrosine as well as serine/threonine phosphorylation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MAP kinase", "entity_1_idx": [[4, 14]], "entity_1_idx_in_text_with_entity_marker": [8, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pp54", "entity_2_idx": [[23, 27]], "entity_2_idx_in_text_with_entity_marker": [36, 40], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d71.s607_AIMed.d71.s607.p1", "text": "The MAP kinase enzymes pp54 and pp42/44 are regulated by tyrosine as well as serine/threonine phosphorylation.", "text_with_entity_marker": "The [E1]MAP kinase[/E1] enzymes pp54 and [E2]pp42[/E2]/44 are regulated by tyrosine as well as serine/threonine phosphorylation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MAP kinase", "entity_1_idx": [[4, 14]], "entity_1_idx_in_text_with_entity_marker": [8, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pp42", "entity_2_idx": [[32, 36]], "entity_2_idx_in_text_with_entity_marker": [45, 49], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d71.s607_AIMed.d71.s607.p2", "text": "The MAP kinase enzymes pp54 and pp42/44 are regulated by tyrosine as well as serine/threonine phosphorylation.", "text_with_entity_marker": "The MAP kinase enzymes [E1]pp54[/E1] and [E2]pp42[/E2]/44 are regulated by tyrosine as well as serine/threonine phosphorylation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pp54", "entity_1_idx": [[23, 27]], "entity_1_idx_in_text_with_entity_marker": [27, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pp42", "entity_2_idx": [[32, 36]], "entity_2_idx_in_text_with_entity_marker": [45, 49], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d71.s608_AIMed.d71.s608.p0", "text": "MAP kinase activation of c-jun may underlie the common stimulation of this transcription factor by mitogens, growth factors and oncogenes.", "text_with_entity_marker": "[E1]MAP kinase[/E1] activation of [E2]c-jun[/E2] may underlie the common stimulation of this transcription factor by mitogens, growth factors and oncogenes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MAP kinase", "entity_1_idx": [[0, 10]], "entity_1_idx_in_text_with_entity_marker": [4, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-jun", "entity_2_idx": [[25, 30]], "entity_2_idx_in_text_with_entity_marker": [38, 43], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p0", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte [E1]NADPH oxidase[/E1] is a complex of membrane [E2]cytochrome b558[/E2] (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NADPH oxidase", "entity_1_idx": [[14, 27]], "entity_1_idx_in_text_with_entity_marker": [18, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cytochrome b558", "entity_2_idx": [[53, 68]], "entity_2_idx_in_text_with_entity_marker": [66, 81], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p1", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte [E1]NADPH oxidase[/E1] is a complex of membrane cytochrome b558 (comprised of subunits [E2]p22-phox[/E2] and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NADPH oxidase", "entity_1_idx": [[14, 27]], "entity_1_idx_in_text_with_entity_marker": [18, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p22-phox", "entity_2_idx": [[92, 100]], "entity_2_idx_in_text_with_entity_marker": [105, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p2", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte [E1]NADPH oxidase[/E1] is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and [E2]gp91-phox[/E2]) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NADPH oxidase", "entity_1_idx": [[14, 27]], "entity_1_idx_in_text_with_entity_marker": [18, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp91-phox", "entity_2_idx": [[105, 114]], "entity_2_idx_in_text_with_entity_marker": [118, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p3", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte [E1]NADPH oxidase[/E1] is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins ([E2]p47-phox[/E2], p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NADPH oxidase", "entity_1_idx": [[14, 27]], "entity_1_idx_in_text_with_entity_marker": [18, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p47-phox", "entity_2_idx": [[144, 152]], "entity_2_idx_in_text_with_entity_marker": [157, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p4", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte [E1]NADPH oxidase[/E1] is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, [E2]p67-phox[/E2], and p21rac) that translocate to membrane and bind to cytochrome b558.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NADPH oxidase", "entity_1_idx": [[14, 27]], "entity_1_idx_in_text_with_entity_marker": [18, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p67-phox", "entity_2_idx": [[154, 162]], "entity_2_idx_in_text_with_entity_marker": [167, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p5", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte [E1]NADPH oxidase[/E1] is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and [E2]p21rac[/E2]) that translocate to membrane and bind to cytochrome b558.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NADPH oxidase", "entity_1_idx": [[14, 27]], "entity_1_idx_in_text_with_entity_marker": [18, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p21rac", "entity_2_idx": [[168, 174]], "entity_2_idx_in_text_with_entity_marker": [181, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p6", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte [E1]NADPH oxidase[/E1] is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to [E2]cytochrome b558[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NADPH oxidase", "entity_1_idx": [[14, 27]], "entity_1_idx_in_text_with_entity_marker": [18, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cytochrome b558", "entity_2_idx": [[217, 232]], "entity_2_idx_in_text_with_entity_marker": [230, 245], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p7", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte NADPH oxidase is a complex of membrane [E1]cytochrome b558[/E1] (comprised of subunits [E2]p22-phox[/E2] and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cytochrome b558", "entity_1_idx": [[53, 68]], "entity_1_idx_in_text_with_entity_marker": [57, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p22-phox", "entity_2_idx": [[92, 100]], "entity_2_idx_in_text_with_entity_marker": [105, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p8", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte NADPH oxidase is a complex of membrane [E1]cytochrome b558[/E1] (comprised of subunits p22-phox and [E2]gp91-phox[/E2]) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cytochrome b558", "entity_1_idx": [[53, 68]], "entity_1_idx_in_text_with_entity_marker": [57, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp91-phox", "entity_2_idx": [[105, 114]], "entity_2_idx_in_text_with_entity_marker": [118, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p9", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte NADPH oxidase is a complex of membrane [E1]cytochrome b558[/E1] (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins ([E2]p47-phox[/E2], p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cytochrome b558", "entity_1_idx": [[53, 68]], "entity_1_idx_in_text_with_entity_marker": [57, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p47-phox", "entity_2_idx": [[144, 152]], "entity_2_idx_in_text_with_entity_marker": [157, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p10", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte NADPH oxidase is a complex of membrane [E1]cytochrome b558[/E1] (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, [E2]p67-phox[/E2], and p21rac) that translocate to membrane and bind to cytochrome b558.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cytochrome b558", "entity_1_idx": [[53, 68]], "entity_1_idx_in_text_with_entity_marker": [57, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p67-phox", "entity_2_idx": [[154, 162]], "entity_2_idx_in_text_with_entity_marker": [167, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p11", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte NADPH oxidase is a complex of membrane [E1]cytochrome b558[/E1] (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and [E2]p21rac[/E2]) that translocate to membrane and bind to cytochrome b558.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cytochrome b558", "entity_1_idx": [[53, 68]], "entity_1_idx_in_text_with_entity_marker": [57, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p21rac", "entity_2_idx": [[168, 174]], "entity_2_idx_in_text_with_entity_marker": [181, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p12", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte NADPH oxidase is a complex of membrane [E1]cytochrome b558[/E1] (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to [E2]cytochrome b558[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cytochrome b558", "entity_1_idx": [[53, 68]], "entity_1_idx_in_text_with_entity_marker": [57, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cytochrome b558", "entity_2_idx": [[217, 232]], "entity_2_idx_in_text_with_entity_marker": [230, 245], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p13", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits [E1]p22-phox[/E1] and [E2]gp91-phox[/E2]) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p22-phox", "entity_1_idx": [[92, 100]], "entity_1_idx_in_text_with_entity_marker": [96, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp91-phox", "entity_2_idx": [[105, 114]], "entity_2_idx_in_text_with_entity_marker": [118, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p14", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits [E1]p22-phox[/E1] and gp91-phox) and three cytosol proteins ([E2]p47-phox[/E2], p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p22-phox", "entity_1_idx": [[92, 100]], "entity_1_idx_in_text_with_entity_marker": [96, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p47-phox", "entity_2_idx": [[144, 152]], "entity_2_idx_in_text_with_entity_marker": [157, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p15", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits [E1]p22-phox[/E1] and gp91-phox) and three cytosol proteins (p47-phox, [E2]p67-phox[/E2], and p21rac) that translocate to membrane and bind to cytochrome b558.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p22-phox", "entity_1_idx": [[92, 100]], "entity_1_idx_in_text_with_entity_marker": [96, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p67-phox", "entity_2_idx": [[154, 162]], "entity_2_idx_in_text_with_entity_marker": [167, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p16", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits [E1]p22-phox[/E1] and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and [E2]p21rac[/E2]) that translocate to membrane and bind to cytochrome b558.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p22-phox", "entity_1_idx": [[92, 100]], "entity_1_idx_in_text_with_entity_marker": [96, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p21rac", "entity_2_idx": [[168, 174]], "entity_2_idx_in_text_with_entity_marker": [181, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p17", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits [E1]p22-phox[/E1] and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to [E2]cytochrome b558[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p22-phox", "entity_1_idx": [[92, 100]], "entity_1_idx_in_text_with_entity_marker": [96, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cytochrome b558", "entity_2_idx": [[217, 232]], "entity_2_idx_in_text_with_entity_marker": [230, 245], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p18", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and [E1]gp91-phox[/E1]) and three cytosol proteins ([E2]p47-phox[/E2], p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp91-phox", "entity_1_idx": [[105, 114]], "entity_1_idx_in_text_with_entity_marker": [109, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p47-phox", "entity_2_idx": [[144, 152]], "entity_2_idx_in_text_with_entity_marker": [157, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p19", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and [E1]gp91-phox[/E1]) and three cytosol proteins (p47-phox, [E2]p67-phox[/E2], and p21rac) that translocate to membrane and bind to cytochrome b558.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp91-phox", "entity_1_idx": [[105, 114]], "entity_1_idx_in_text_with_entity_marker": [109, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p67-phox", "entity_2_idx": [[154, 162]], "entity_2_idx_in_text_with_entity_marker": [167, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p20", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and [E1]gp91-phox[/E1]) and three cytosol proteins (p47-phox, p67-phox, and [E2]p21rac[/E2]) that translocate to membrane and bind to cytochrome b558.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp91-phox", "entity_1_idx": [[105, 114]], "entity_1_idx_in_text_with_entity_marker": [109, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p21rac", "entity_2_idx": [[168, 174]], "entity_2_idx_in_text_with_entity_marker": [181, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p21", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and [E1]gp91-phox[/E1]) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to [E2]cytochrome b558[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp91-phox", "entity_1_idx": [[105, 114]], "entity_1_idx_in_text_with_entity_marker": [109, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cytochrome b558", "entity_2_idx": [[217, 232]], "entity_2_idx_in_text_with_entity_marker": [230, 245], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p22", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins ([E1]p47-phox[/E1], [E2]p67-phox[/E2], and p21rac) that translocate to membrane and bind to cytochrome b558.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p47-phox", "entity_1_idx": [[144, 152]], "entity_1_idx_in_text_with_entity_marker": [148, 156], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p67-phox", "entity_2_idx": [[154, 162]], "entity_2_idx_in_text_with_entity_marker": [167, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p23", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins ([E1]p47-phox[/E1], p67-phox, and [E2]p21rac[/E2]) that translocate to membrane and bind to cytochrome b558.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p47-phox", "entity_1_idx": [[144, 152]], "entity_1_idx_in_text_with_entity_marker": [148, 156], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p21rac", "entity_2_idx": [[168, 174]], "entity_2_idx_in_text_with_entity_marker": [181, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p24", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins ([E1]p47-phox[/E1], p67-phox, and p21rac) that translocate to membrane and bind to [E2]cytochrome b558[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p47-phox", "entity_1_idx": [[144, 152]], "entity_1_idx_in_text_with_entity_marker": [148, 156], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cytochrome b558", "entity_2_idx": [[217, 232]], "entity_2_idx_in_text_with_entity_marker": [230, 245], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p25", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, [E1]p67-phox[/E1], and [E2]p21rac[/E2]) that translocate to membrane and bind to cytochrome b558.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p67-phox", "entity_1_idx": [[154, 162]], "entity_1_idx_in_text_with_entity_marker": [158, 166], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p21rac", "entity_2_idx": [[168, 174]], "entity_2_idx_in_text_with_entity_marker": [181, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p26", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, [E1]p67-phox[/E1], and p21rac) that translocate to membrane and bind to [E2]cytochrome b558[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p67-phox", "entity_1_idx": [[154, 162]], "entity_1_idx_in_text_with_entity_marker": [158, 166], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cytochrome b558", "entity_2_idx": [[217, 232]], "entity_2_idx_in_text_with_entity_marker": [230, 245], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1438_AIMed.d170.s1438.p27", "text": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.", "text_with_entity_marker": "The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and [E1]p21rac[/E1]) that translocate to membrane and bind to [E2]cytochrome b558[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p21rac", "entity_1_idx": [[168, 174]], "entity_1_idx_in_text_with_entity_marker": [172, 178], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cytochrome b558", "entity_2_idx": [[217, 232]], "entity_2_idx_in_text_with_entity_marker": [230, 245], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1439_AIMed.d170.s1439.p0", "text": "This is the first report to demonstrate that two of cytosolic components of cytochrome b558, p47-phox binding to p67-phox each other.", "text_with_entity_marker": "This is the first report to demonstrate that two of cytosolic components of [E1]cytochrome b558[/E1], [E2]p47-phox[/E2] binding to p67-phox each other.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cytochrome b558", "entity_1_idx": [[76, 91]], "entity_1_idx_in_text_with_entity_marker": [80, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p47-phox", "entity_2_idx": [[93, 101]], "entity_2_idx_in_text_with_entity_marker": [106, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1439_AIMed.d170.s1439.p1", "text": "This is the first report to demonstrate that two of cytosolic components of cytochrome b558, p47-phox binding to p67-phox each other.", "text_with_entity_marker": "This is the first report to demonstrate that two of cytosolic components of [E1]cytochrome b558[/E1], p47-phox binding to [E2]p67-phox[/E2] each other.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cytochrome b558", "entity_1_idx": [[76, 91]], "entity_1_idx_in_text_with_entity_marker": [80, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p67-phox", "entity_2_idx": [[113, 121]], "entity_2_idx_in_text_with_entity_marker": [126, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d170.s1439_AIMed.d170.s1439.p2", "text": "This is the first report to demonstrate that two of cytosolic components of cytochrome b558, p47-phox binding to p67-phox each other.", "text_with_entity_marker": "This is the first report to demonstrate that two of cytosolic components of cytochrome b558, [E1]p47-phox[/E1] binding to [E2]p67-phox[/E2] each other.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p47-phox", "entity_1_idx": [[93, 101]], "entity_1_idx_in_text_with_entity_marker": [97, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p67-phox", "entity_2_idx": [[113, 121]], "entity_2_idx_in_text_with_entity_marker": [126, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d161.s1353_AIMed.d161.s1353.p0", "text": "Use of the two hybrid system to detect the association of the protein-tyrosine-phosphatase, SHPTP2, with another SH2-containing protein, Grb7.", "text_with_entity_marker": "Use of the two hybrid system to detect the association of the protein-tyrosine-phosphatase, [E1]SHPTP2[/E1], with another SH2-containing protein, [E2]Grb7[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "SHPTP2", "entity_1_idx": [[92, 98]], "entity_1_idx_in_text_with_entity_marker": [96, 102], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Grb7", "entity_2_idx": [[137, 141]], "entity_2_idx_in_text_with_entity_marker": [150, 154], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d161.s1355_AIMed.d161.s1355.p0", "text": "SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.", "text_with_entity_marker": "[E1]SHPTP2[/E1] associates with the [E2]platelet-derived growth factor[/E2] (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SHPTP2", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "platelet-derived growth factor", "entity_2_idx": [[27, 57]], "entity_2_idx_in_text_with_entity_marker": [40, 70], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d161.s1355_AIMed.d161.s1355.p1", "text": "SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.", "text_with_entity_marker": "[E1]SHPTP2[/E1] associates with the platelet-derived growth factor ([E2]PDGF[/E2]) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SHPTP2", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PDGF", "entity_2_idx": [[59, 63]], "entity_2_idx_in_text_with_entity_marker": [72, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d161.s1355_AIMed.d161.s1355.p2", "text": "SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.", "text_with_entity_marker": "[E1]SHPTP2[/E1] associates with the [E2]platelet-derived growth factor (PDGF) receptor[/E2] after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "SHPTP2", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "platelet-derived growth factor (PDGF) receptor", "entity_2_idx": [[27, 73]], "entity_2_idx_in_text_with_entity_marker": [40, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d161.s1355_AIMed.d161.s1355.p3", "text": "SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.", "text_with_entity_marker": "[E1]SHPTP2[/E1] associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of [E2]SHPTP2[/E2] to this receptor promotes tyrosine phosphorylation of SHPTP2.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SHPTP2", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SHPTP2", "entity_2_idx": [[115, 121]], "entity_2_idx_in_text_with_entity_marker": [128, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d161.s1355_AIMed.d161.s1355.p4", "text": "SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.", "text_with_entity_marker": "[E1]SHPTP2[/E1] associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of [E2]SHPTP2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SHPTP2", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SHPTP2", "entity_2_idx": [[176, 182]], "entity_2_idx_in_text_with_entity_marker": [189, 195], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d161.s1355_AIMed.d161.s1355.p5", "text": "SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.", "text_with_entity_marker": "SHPTP2 associates with the [E1]platelet-derived growth factor[/E1] ([E2]PDGF[/E2]) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "platelet-derived growth factor", "entity_1_idx": [[27, 57]], "entity_1_idx_in_text_with_entity_marker": [31, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PDGF", "entity_2_idx": [[59, 63]], "entity_2_idx_in_text_with_entity_marker": [72, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d161.s1355_AIMed.d161.s1355.p6", "text": "SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.", "text_with_entity_marker": "SHPTP2 associates with the [E1-E2]platelet-derived growth factor[/E1] (PDGF) receptor[/E2] after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "platelet-derived growth factor", "entity_1_idx": [[27, 57]], "entity_1_idx_in_text_with_entity_marker": [34, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "platelet-derived growth factor[/E1] (PDGF) receptor", "entity_2_idx": [[27, 73]], "entity_2_idx_in_text_with_entity_marker": [34, 85], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d161.s1355_AIMed.d161.s1355.p7", "text": "SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.", "text_with_entity_marker": "SHPTP2 associates with the [E1]platelet-derived growth factor[/E1] (PDGF) receptor after ligand stimulation, and binding of [E2]SHPTP2[/E2] to this receptor promotes tyrosine phosphorylation of SHPTP2.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "platelet-derived growth factor", "entity_1_idx": [[27, 57]], "entity_1_idx_in_text_with_entity_marker": [31, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SHPTP2", "entity_2_idx": [[115, 121]], "entity_2_idx_in_text_with_entity_marker": [128, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d161.s1355_AIMed.d161.s1355.p8", "text": "SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.", "text_with_entity_marker": "SHPTP2 associates with the [E1]platelet-derived growth factor[/E1] (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of [E2]SHPTP2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "platelet-derived growth factor", "entity_1_idx": [[27, 57]], "entity_1_idx_in_text_with_entity_marker": [31, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SHPTP2", "entity_2_idx": [[176, 182]], "entity_2_idx_in_text_with_entity_marker": [189, 195], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d161.s1355_AIMed.d161.s1355.p9", "text": "SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.", "text_with_entity_marker": "SHPTP2 associates with the [E1]platelet-derived growth factor (PDGF) receptor[/E1][E2]PDGF[/E2]) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "platelet-derived growth factor (PDGF) receptor", "entity_1_idx": [[27, 73]], "entity_1_idx_in_text_with_entity_marker": [31, 77], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PDGF", "entity_2_idx": [[59, 63]], "entity_2_idx_in_text_with_entity_marker": [86, 90], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d161.s1355_AIMed.d161.s1355.p10", "text": "SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.", "text_with_entity_marker": "SHPTP2 associates with the platelet-derived growth factor ([E1]PDGF[/E1]) receptor after ligand stimulation, and binding of [E2]SHPTP2[/E2] to this receptor promotes tyrosine phosphorylation of SHPTP2.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PDGF", "entity_1_idx": [[59, 63]], "entity_1_idx_in_text_with_entity_marker": [63, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SHPTP2", "entity_2_idx": [[115, 121]], "entity_2_idx_in_text_with_entity_marker": [128, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d161.s1355_AIMed.d161.s1355.p11", "text": "SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.", "text_with_entity_marker": "SHPTP2 associates with the platelet-derived growth factor ([E1]PDGF[/E1]) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of [E2]SHPTP2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PDGF", "entity_1_idx": [[59, 63]], "entity_1_idx_in_text_with_entity_marker": [63, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SHPTP2", "entity_2_idx": [[176, 182]], "entity_2_idx_in_text_with_entity_marker": [189, 195], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d161.s1355_AIMed.d161.s1355.p12", "text": "SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.", "text_with_entity_marker": "SHPTP2 associates with the [E1]platelet-derived growth factor (PDGF) receptor[/E1] after ligand stimulation, and binding of [E2]SHPTP2[/E2] to this receptor promotes tyrosine phosphorylation of SHPTP2.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "platelet-derived growth factor (PDGF) receptor", "entity_1_idx": [[27, 73]], "entity_1_idx_in_text_with_entity_marker": [31, 77], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SHPTP2", "entity_2_idx": [[115, 121]], "entity_2_idx_in_text_with_entity_marker": [128, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d161.s1355_AIMed.d161.s1355.p13", "text": "SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.", "text_with_entity_marker": "SHPTP2 associates with the [E1]platelet-derived growth factor (PDGF) receptor[/E1] after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of [E2]SHPTP2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "platelet-derived growth factor (PDGF) receptor", "entity_1_idx": [[27, 73]], "entity_1_idx_in_text_with_entity_marker": [31, 77], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SHPTP2", "entity_2_idx": [[176, 182]], "entity_2_idx_in_text_with_entity_marker": [189, 195], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d161.s1355_AIMed.d161.s1355.p14", "text": "SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.", "text_with_entity_marker": "SHPTP2 associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of [E1]SHPTP2[/E1] to this receptor promotes tyrosine phosphorylation of [E2]SHPTP2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SHPTP2", "entity_1_idx": [[115, 121]], "entity_1_idx_in_text_with_entity_marker": [119, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SHPTP2", "entity_2_idx": [[176, 182]], "entity_2_idx_in_text_with_entity_marker": [189, 195], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d161.s1357_AIMed.d161.s1357.p0", "text": "Using SHPTP2 as bait and supplying an exogenous tyrosine kinase gene to the yeast cells, we have found that SHPTP2 interacts with another signaling protein, Grb7.", "text_with_entity_marker": "Using [E1]SHPTP2[/E1] as bait and supplying an exogenous tyrosine kinase gene to the yeast cells, we have found that [E2]SHPTP2[/E2] interacts with another signaling protein, Grb7.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SHPTP2", "entity_1_idx": [[6, 12]], "entity_1_idx_in_text_with_entity_marker": [10, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SHPTP2", "entity_2_idx": [[108, 114]], "entity_2_idx_in_text_with_entity_marker": [121, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d161.s1357_AIMed.d161.s1357.p1", "text": "Using SHPTP2 as bait and supplying an exogenous tyrosine kinase gene to the yeast cells, we have found that SHPTP2 interacts with another signaling protein, Grb7.", "text_with_entity_marker": "Using [E1]SHPTP2[/E1] as bait and supplying an exogenous tyrosine kinase gene to the yeast cells, we have found that SHPTP2 interacts with another signaling protein, [E2]Grb7[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SHPTP2", "entity_1_idx": [[6, 12]], "entity_1_idx_in_text_with_entity_marker": [10, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Grb7", "entity_2_idx": [[157, 161]], "entity_2_idx_in_text_with_entity_marker": [170, 174], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d161.s1357_AIMed.d161.s1357.p2", "text": "Using SHPTP2 as bait and supplying an exogenous tyrosine kinase gene to the yeast cells, we have found that SHPTP2 interacts with another signaling protein, Grb7.", "text_with_entity_marker": "Using SHPTP2 as bait and supplying an exogenous tyrosine kinase gene to the yeast cells, we have found that [E1]SHPTP2[/E1] interacts with another signaling protein, [E2]Grb7[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "SHPTP2", "entity_1_idx": [[108, 114]], "entity_1_idx_in_text_with_entity_marker": [112, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Grb7", "entity_2_idx": [[157, 161]], "entity_2_idx_in_text_with_entity_marker": [170, 174], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d161.s1358_AIMed.d161.s1358.p0", "text": "We have localized the region of interaction to tyrosine 580 in the carboxyl end of SHPTP2 and to the SH2 domain in the carboxy-terminus of Grb7.", "text_with_entity_marker": "We have localized the region of interaction to tyrosine 580 in the carboxyl end of [E1]SHPTP2[/E1] and to the SH2 domain in the carboxy-terminus of [E2]Grb7[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SHPTP2", "entity_1_idx": [[83, 89]], "entity_1_idx_in_text_with_entity_marker": [87, 93], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Grb7", "entity_2_idx": [[139, 143]], "entity_2_idx_in_text_with_entity_marker": [152, 156], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d161.s1359_AIMed.d161.s1359.p0", "text": "We demonstrate that Grb7 binds to SHPTP2 in vitro under conditions where the latter is tyrosine-phosphorylated.", "text_with_entity_marker": "We demonstrate that [E1]Grb7[/E1] binds to [E2]SHPTP2[/E2] in vitro under conditions where the latter is tyrosine-phosphorylated.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Grb7", "entity_1_idx": [[20, 24]], "entity_1_idx_in_text_with_entity_marker": [24, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SHPTP2", "entity_2_idx": [[34, 40]], "entity_2_idx_in_text_with_entity_marker": [47, 53], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s659_AIMed.d78.s659.p0", "text": "A newly identified member of tumor necrosis factor receptor superfamily ( TR6 ) suppresses LIGHT-mediated apoptosis .", "text_with_entity_marker": "A newly identified member of tumor necrosis factor receptor superfamily ( [E1]TR6[/E1] ) suppresses [E2]LIGHT[/E2]-mediated apoptosis .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR6", "entity_1_idx": [[74, 77]], "entity_1_idx_in_text_with_entity_marker": [78, 81], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIGHT", "entity_2_idx": [[91, 96]], "entity_2_idx_in_text_with_entity_marker": [104, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s660_AIMed.d78.s660.p0", "text": "TR6 ( decoy receptor 3 ( DcR3 ) ) is a new member of the tumor necrosis factor receptor ( TNFR ) family .", "text_with_entity_marker": "[E1]TR6[/E1] ( [E2]decoy receptor 3[/E2] ( DcR3 ) ) is a new member of the tumor necrosis factor receptor ( TNFR ) family .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR6", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "decoy receptor 3", "entity_2_idx": [[6, 22]], "entity_2_idx_in_text_with_entity_marker": [19, 35], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s660_AIMed.d78.s660.p1", "text": "TR6 ( decoy receptor 3 ( DcR3 ) ) is a new member of the tumor necrosis factor receptor ( TNFR ) family .", "text_with_entity_marker": "[E1]TR6[/E1] ( decoy receptor 3 ( [E2]DcR3[/E2] ) ) is a new member of the tumor necrosis factor receptor ( TNFR ) family .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR6", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "DcR3", "entity_2_idx": [[25, 29]], "entity_2_idx_in_text_with_entity_marker": [38, 42], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s660_AIMed.d78.s660.p2", "text": "TR6 ( decoy receptor 3 ( DcR3 ) ) is a new member of the tumor necrosis factor receptor ( TNFR ) family .", "text_with_entity_marker": "TR6 ( [E1]decoy receptor 3[/E1] ( [E2]DcR3[/E2] ) ) is a new member of the tumor necrosis factor receptor ( TNFR ) family .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "decoy receptor 3", "entity_1_idx": [[6, 22]], "entity_1_idx_in_text_with_entity_marker": [10, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "DcR3", "entity_2_idx": [[25, 29]], "entity_2_idx_in_text_with_entity_marker": [38, 42], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s665_AIMed.d78.s665.p0", "text": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .", "text_with_entity_marker": "Here , we demonstrate that [E1]TR6[/E1] specifically binds two cellular ligands , [E2]LIGHT[/E2] ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TR6", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIGHT", "entity_2_idx": [[73, 78]], "entity_2_idx_in_text_with_entity_marker": [86, 91], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s665_AIMed.d78.s665.p1", "text": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .", "text_with_entity_marker": "Here , we demonstrate that [E1]TR6[/E1] specifically binds two cellular ligands , LIGHT ( [E2]herpes virus entry mediator ( HVEM ) - L[/E2] ) and Fas ligand ( FasL / CD95L ) .", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TR6", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "herpes virus entry mediator ( HVEM ) - L", "entity_2_idx": [[81, 121]], "entity_2_idx_in_text_with_entity_marker": [94, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s665_AIMed.d78.s665.p2", "text": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .", "text_with_entity_marker": "Here , we demonstrate that [E1]TR6[/E1] specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and [E2]Fas[/E2] ligand ( FasL / CD95L ) .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR6", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[128, 131]], "entity_2_idx_in_text_with_entity_marker": [141, 144], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s665_AIMed.d78.s665.p3", "text": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .", "text_with_entity_marker": "Here , we demonstrate that [E1]TR6[/E1] specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and [E2]Fas ligand[/E2] ( FasL / CD95L ) .", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TR6", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas ligand", "entity_2_idx": [[128, 138]], "entity_2_idx_in_text_with_entity_marker": [141, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s665_AIMed.d78.s665.p4", "text": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .", "text_with_entity_marker": "Here , we demonstrate that [E1]TR6[/E1] specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( [E2]FasL[/E2] / CD95L ) .", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TR6", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FasL", "entity_2_idx": [[141, 145]], "entity_2_idx_in_text_with_entity_marker": [154, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s665_AIMed.d78.s665.p5", "text": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .", "text_with_entity_marker": "Here , we demonstrate that [E1]TR6[/E1] specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / [E2]CD95L[/E2] ) .", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TR6", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD95L", "entity_2_idx": [[148, 153]], "entity_2_idx_in_text_with_entity_marker": [161, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s665_AIMed.d78.s665.p6", "text": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .", "text_with_entity_marker": "Here , we demonstrate that TR6 specifically binds two cellular ligands , [E1]LIGHT[/E1] ( [E2]herpes virus entry mediator ( HVEM ) - L[/E2] ) and Fas ligand ( FasL / CD95L ) .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LIGHT", "entity_1_idx": [[73, 78]], "entity_1_idx_in_text_with_entity_marker": [77, 82], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "herpes virus entry mediator ( HVEM ) - L", "entity_2_idx": [[81, 121]], "entity_2_idx_in_text_with_entity_marker": [94, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s665_AIMed.d78.s665.p7", "text": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .", "text_with_entity_marker": "Here , we demonstrate that TR6 specifically binds two cellular ligands , [E1]LIGHT[/E1] ( herpes virus entry mediator ( HVEM ) - L ) and [E2]Fas[/E2] ligand ( FasL / CD95L ) .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LIGHT", "entity_1_idx": [[73, 78]], "entity_1_idx_in_text_with_entity_marker": [77, 82], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[128, 131]], "entity_2_idx_in_text_with_entity_marker": [141, 144], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s665_AIMed.d78.s665.p8", "text": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .", "text_with_entity_marker": "Here , we demonstrate that TR6 specifically binds two cellular ligands , [E1]LIGHT[/E1] ( herpes virus entry mediator ( HVEM ) - L ) and [E2]Fas ligand[/E2] ( FasL / CD95L ) .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LIGHT", "entity_1_idx": [[73, 78]], "entity_1_idx_in_text_with_entity_marker": [77, 82], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas ligand", "entity_2_idx": [[128, 138]], "entity_2_idx_in_text_with_entity_marker": [141, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s665_AIMed.d78.s665.p9", "text": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .", "text_with_entity_marker": "Here , we demonstrate that TR6 specifically binds two cellular ligands , [E1]LIGHT[/E1] ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( [E2]FasL[/E2] / CD95L ) .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LIGHT", "entity_1_idx": [[73, 78]], "entity_1_idx_in_text_with_entity_marker": [77, 82], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FasL", "entity_2_idx": [[141, 145]], "entity_2_idx_in_text_with_entity_marker": [154, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s665_AIMed.d78.s665.p10", "text": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .", "text_with_entity_marker": "Here , we demonstrate that TR6 specifically binds two cellular ligands , [E1]LIGHT[/E1] ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / [E2]CD95L[/E2] ) .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LIGHT", "entity_1_idx": [[73, 78]], "entity_1_idx_in_text_with_entity_marker": [77, 82], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD95L", "entity_2_idx": [[148, 153]], "entity_2_idx_in_text_with_entity_marker": [161, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s665_AIMed.d78.s665.p11", "text": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .", "text_with_entity_marker": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( [E1]herpes virus entry mediator ( HVEM ) - L[/E1] ) and [E2]Fas[/E2] ligand ( FasL / CD95L ) .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "herpes virus entry mediator ( HVEM ) - L", "entity_1_idx": [[81, 121]], "entity_1_idx_in_text_with_entity_marker": [85, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[128, 131]], "entity_2_idx_in_text_with_entity_marker": [141, 144], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s665_AIMed.d78.s665.p12", "text": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .", "text_with_entity_marker": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( [E1]herpes virus entry mediator ( HVEM ) - L[/E1] ) and [E2]Fas ligand[/E2] ( FasL / CD95L ) .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "herpes virus entry mediator ( HVEM ) - L", "entity_1_idx": [[81, 121]], "entity_1_idx_in_text_with_entity_marker": [85, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas ligand", "entity_2_idx": [[128, 138]], "entity_2_idx_in_text_with_entity_marker": [141, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s665_AIMed.d78.s665.p13", "text": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .", "text_with_entity_marker": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( [E1]herpes virus entry mediator ( HVEM ) - L[/E1] ) and Fas ligand ( [E2]FasL[/E2] / CD95L ) .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "herpes virus entry mediator ( HVEM ) - L", "entity_1_idx": [[81, 121]], "entity_1_idx_in_text_with_entity_marker": [85, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FasL", "entity_2_idx": [[141, 145]], "entity_2_idx_in_text_with_entity_marker": [154, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s665_AIMed.d78.s665.p14", "text": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .", "text_with_entity_marker": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( [E1]herpes virus entry mediator ( HVEM ) - L[/E1] ) and Fas ligand ( FasL / [E2]CD95L[/E2] ) .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "herpes virus entry mediator ( HVEM ) - L", "entity_1_idx": [[81, 121]], "entity_1_idx_in_text_with_entity_marker": [85, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD95L", "entity_2_idx": [[148, 153]], "entity_2_idx_in_text_with_entity_marker": [161, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s665_AIMed.d78.s665.p15", "text": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .", "text_with_entity_marker": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and [E1-E2]Fas[/E1] ligand[/E2] ( FasL / CD95L ) .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[128, 131]], "entity_1_idx_in_text_with_entity_marker": [135, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas[/E1] ligand", "entity_2_idx": [[128, 138]], "entity_2_idx_in_text_with_entity_marker": [135, 150], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s665_AIMed.d78.s665.p16", "text": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .", "text_with_entity_marker": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and [E1]Fas[/E1] ligand ( [E2]FasL[/E2] / CD95L ) .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[128, 131]], "entity_1_idx_in_text_with_entity_marker": [132, 135], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FasL", "entity_2_idx": [[141, 145]], "entity_2_idx_in_text_with_entity_marker": [154, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s665_AIMed.d78.s665.p17", "text": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .", "text_with_entity_marker": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and [E1]Fas[/E1] ligand ( FasL / [E2]CD95L[/E2] ) .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[128, 131]], "entity_1_idx_in_text_with_entity_marker": [132, 135], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD95L", "entity_2_idx": [[148, 153]], "entity_2_idx_in_text_with_entity_marker": [161, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s665_AIMed.d78.s665.p18", "text": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .", "text_with_entity_marker": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and [E1]Fas ligand[/E1] ( [E2]FasL[/E2] / CD95L ) .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas ligand", "entity_1_idx": [[128, 138]], "entity_1_idx_in_text_with_entity_marker": [132, 142], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FasL", "entity_2_idx": [[141, 145]], "entity_2_idx_in_text_with_entity_marker": [154, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s665_AIMed.d78.s665.p19", "text": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .", "text_with_entity_marker": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and [E1]Fas ligand[/E1] ( FasL / [E2]CD95L[/E2] ) .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas ligand", "entity_1_idx": [[128, 138]], "entity_1_idx_in_text_with_entity_marker": [132, 142], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD95L", "entity_2_idx": [[148, 153]], "entity_2_idx_in_text_with_entity_marker": [161, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s665_AIMed.d78.s665.p20", "text": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .", "text_with_entity_marker": "Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( [E1]FasL[/E1] / [E2]CD95L[/E2] ) .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FasL", "entity_1_idx": [[141, 145]], "entity_1_idx_in_text_with_entity_marker": [145, 149], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD95L", "entity_2_idx": [[148, 153]], "entity_2_idx_in_text_with_entity_marker": [161, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s667_AIMed.d78.s667.p0", "text": "TR6 inhibited LIGHT-induced cytotoxicity in HT29 cells .", "text_with_entity_marker": "[E1]TR6[/E1] inhibited [E2]LIGHT[/E2]-induced cytotoxicity in HT29 cells .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR6", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIGHT", "entity_2_idx": [[14, 19]], "entity_2_idx_in_text_with_entity_marker": [27, 32], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s668_AIMed.d78.s668.p0", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .", "text_with_entity_marker": "It has been shown that [E1]LIGHT[/E1] triggers apoptosis of various tumor cells including HT29 cells that express both [E2]lymphotoxin beta[/E2] receptor ( LTbetaR ) and HVEM / TR2 receptors .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LIGHT", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "lymphotoxin beta", "entity_2_idx": [[110, 126]], "entity_2_idx_in_text_with_entity_marker": [123, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s668_AIMed.d78.s668.p1", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .", "text_with_entity_marker": "It has been shown that [E1]LIGHT[/E1] triggers apoptosis of various tumor cells including HT29 cells that express both [E2]lymphotoxin beta receptor[/E2] ( LTbetaR ) and HVEM / TR2 receptors .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LIGHT", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "lymphotoxin beta receptor", "entity_2_idx": [[110, 135]], "entity_2_idx_in_text_with_entity_marker": [123, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s668_AIMed.d78.s668.p2", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .", "text_with_entity_marker": "It has been shown that [E1]LIGHT[/E1] triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( [E2]LTbetaR[/E2] ) and HVEM / TR2 receptors .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LIGHT", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LTbetaR", "entity_2_idx": [[138, 145]], "entity_2_idx_in_text_with_entity_marker": [151, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s668_AIMed.d78.s668.p3", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .", "text_with_entity_marker": "It has been shown that [E1]LIGHT[/E1] triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and [E2]HVEM[/E2] / TR2 receptors .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LIGHT", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HVEM", "entity_2_idx": [[152, 156]], "entity_2_idx_in_text_with_entity_marker": [165, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s668_AIMed.d78.s668.p4", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .", "text_with_entity_marker": "It has been shown that [E1]LIGHT[/E1] triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / [E2]TR2[/E2] receptors .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LIGHT", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TR2", "entity_2_idx": [[159, 162]], "entity_2_idx_in_text_with_entity_marker": [172, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s668_AIMed.d78.s668.p5", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .", "text_with_entity_marker": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both [E1-E2]lymphotoxin beta[/E1] receptor[/E2] ( LTbetaR ) and HVEM / TR2 receptors .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "lymphotoxin beta", "entity_1_idx": [[110, 126]], "entity_1_idx_in_text_with_entity_marker": [117, 133], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "lymphotoxin beta[/E1] receptor", "entity_2_idx": [[110, 135]], "entity_2_idx_in_text_with_entity_marker": [117, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s668_AIMed.d78.s668.p6", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .", "text_with_entity_marker": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both [E1]lymphotoxin beta[/E1] receptor ( [E2]LTbetaR[/E2] ) and HVEM / TR2 receptors .", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "lymphotoxin beta", "entity_1_idx": [[110, 126]], "entity_1_idx_in_text_with_entity_marker": [114, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LTbetaR", "entity_2_idx": [[138, 145]], "entity_2_idx_in_text_with_entity_marker": [151, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s668_AIMed.d78.s668.p7", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .", "text_with_entity_marker": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both [E1]lymphotoxin beta[/E1] receptor ( LTbetaR ) and [E2]HVEM[/E2] / TR2 receptors .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "lymphotoxin beta", "entity_1_idx": [[110, 126]], "entity_1_idx_in_text_with_entity_marker": [114, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HVEM", "entity_2_idx": [[152, 156]], "entity_2_idx_in_text_with_entity_marker": [165, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s668_AIMed.d78.s668.p8", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .", "text_with_entity_marker": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both [E1]lymphotoxin beta[/E1] receptor ( LTbetaR ) and HVEM / [E2]TR2[/E2] receptors .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "lymphotoxin beta", "entity_1_idx": [[110, 126]], "entity_1_idx_in_text_with_entity_marker": [114, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TR2", "entity_2_idx": [[159, 162]], "entity_2_idx_in_text_with_entity_marker": [172, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s668_AIMed.d78.s668.p9", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .", "text_with_entity_marker": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both [E1]lymphotoxin beta receptor[/E1] ( [E2]LTbetaR[/E2] ) and HVEM / TR2 receptors .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "lymphotoxin beta receptor", "entity_1_idx": [[110, 135]], "entity_1_idx_in_text_with_entity_marker": [114, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LTbetaR", "entity_2_idx": [[138, 145]], "entity_2_idx_in_text_with_entity_marker": [151, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s668_AIMed.d78.s668.p10", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .", "text_with_entity_marker": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both [E1]lymphotoxin beta receptor[/E1] ( LTbetaR ) and [E2]HVEM[/E2] / TR2 receptors .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "lymphotoxin beta receptor", "entity_1_idx": [[110, 135]], "entity_1_idx_in_text_with_entity_marker": [114, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HVEM", "entity_2_idx": [[152, 156]], "entity_2_idx_in_text_with_entity_marker": [165, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s668_AIMed.d78.s668.p11", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .", "text_with_entity_marker": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both [E1]lymphotoxin beta receptor[/E1] ( LTbetaR ) and HVEM / [E2]TR2[/E2] receptors .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "lymphotoxin beta receptor", "entity_1_idx": [[110, 135]], "entity_1_idx_in_text_with_entity_marker": [114, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TR2", "entity_2_idx": [[159, 162]], "entity_2_idx_in_text_with_entity_marker": [172, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s668_AIMed.d78.s668.p12", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .", "text_with_entity_marker": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( [E1]LTbetaR[/E1] ) and [E2]HVEM[/E2] / TR2 receptors .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LTbetaR", "entity_1_idx": [[138, 145]], "entity_1_idx_in_text_with_entity_marker": [142, 149], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HVEM", "entity_2_idx": [[152, 156]], "entity_2_idx_in_text_with_entity_marker": [165, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s668_AIMed.d78.s668.p13", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .", "text_with_entity_marker": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( [E1]LTbetaR[/E1] ) and HVEM / [E2]TR2[/E2] receptors .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LTbetaR", "entity_1_idx": [[138, 145]], "entity_1_idx_in_text_with_entity_marker": [142, 149], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TR2", "entity_2_idx": [[159, 162]], "entity_2_idx_in_text_with_entity_marker": [172, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s668_AIMed.d78.s668.p14", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .", "text_with_entity_marker": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and [E1]HVEM[/E1] / [E2]TR2[/E2] receptors .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HVEM", "entity_1_idx": [[152, 156]], "entity_1_idx_in_text_with_entity_marker": [156, 160], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TR2", "entity_2_idx": [[159, 162]], "entity_2_idx_in_text_with_entity_marker": [172, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s669_AIMed.d78.s669.p0", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT-mediated HT29 cell death .", "text_with_entity_marker": "Our data suggest that [E1]TR6[/E1] inhibits the interactions of [E2]LIGHT[/E2] with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT-mediated HT29 cell death .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR6", "entity_1_idx": [[22, 25]], "entity_1_idx_in_text_with_entity_marker": [26, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIGHT", "entity_2_idx": [[55, 60]], "entity_2_idx_in_text_with_entity_marker": [68, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s669_AIMed.d78.s669.p1", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT-mediated HT29 cell death .", "text_with_entity_marker": "Our data suggest that [E1]TR6[/E1] inhibits the interactions of LIGHT with [E2]HVEM[/E2] / TR2 and LTbetaR , thereby suppressing LIGHT-mediated HT29 cell death .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR6", "entity_1_idx": [[22, 25]], "entity_1_idx_in_text_with_entity_marker": [26, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HVEM", "entity_2_idx": [[66, 70]], "entity_2_idx_in_text_with_entity_marker": [79, 83], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s669_AIMed.d78.s669.p2", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT-mediated HT29 cell death .", "text_with_entity_marker": "Our data suggest that [E1]TR6[/E1] inhibits the interactions of LIGHT with HVEM / [E2]TR2[/E2] and LTbetaR , thereby suppressing LIGHT-mediated HT29 cell death .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR6", "entity_1_idx": [[22, 25]], "entity_1_idx_in_text_with_entity_marker": [26, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TR2", "entity_2_idx": [[73, 76]], "entity_2_idx_in_text_with_entity_marker": [86, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s669_AIMed.d78.s669.p3", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT-mediated HT29 cell death .", "text_with_entity_marker": "Our data suggest that [E1]TR6[/E1] inhibits the interactions of LIGHT with HVEM / TR2 and [E2]LTbetaR[/E2] , thereby suppressing LIGHT-mediated HT29 cell death .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR6", "entity_1_idx": [[22, 25]], "entity_1_idx_in_text_with_entity_marker": [26, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LTbetaR", "entity_2_idx": [[81, 88]], "entity_2_idx_in_text_with_entity_marker": [94, 101], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s669_AIMed.d78.s669.p4", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT-mediated HT29 cell death .", "text_with_entity_marker": "Our data suggest that [E1]TR6[/E1] inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing [E2]LIGHT[/E2]-mediated HT29 cell death .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR6", "entity_1_idx": [[22, 25]], "entity_1_idx_in_text_with_entity_marker": [26, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIGHT", "entity_2_idx": [[111, 116]], "entity_2_idx_in_text_with_entity_marker": [124, 129], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s669_AIMed.d78.s669.p5", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT-mediated HT29 cell death .", "text_with_entity_marker": "Our data suggest that TR6 inhibits the interactions of [E1]LIGHT[/E1] with [E2]HVEM[/E2] / TR2 and LTbetaR , thereby suppressing LIGHT-mediated HT29 cell death .", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LIGHT", "entity_1_idx": [[55, 60]], "entity_1_idx_in_text_with_entity_marker": [59, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HVEM", "entity_2_idx": [[66, 70]], "entity_2_idx_in_text_with_entity_marker": [79, 83], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s669_AIMed.d78.s669.p6", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT-mediated HT29 cell death .", "text_with_entity_marker": "Our data suggest that TR6 inhibits the interactions of [E1]LIGHT[/E1] with HVEM / [E2]TR2[/E2] and LTbetaR , thereby suppressing LIGHT-mediated HT29 cell death .", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LIGHT", "entity_1_idx": [[55, 60]], "entity_1_idx_in_text_with_entity_marker": [59, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TR2", "entity_2_idx": [[73, 76]], "entity_2_idx_in_text_with_entity_marker": [86, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s669_AIMed.d78.s669.p7", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT-mediated HT29 cell death .", "text_with_entity_marker": "Our data suggest that TR6 inhibits the interactions of [E1]LIGHT[/E1] with HVEM / TR2 and [E2]LTbetaR[/E2] , thereby suppressing LIGHT-mediated HT29 cell death .", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LIGHT", "entity_1_idx": [[55, 60]], "entity_1_idx_in_text_with_entity_marker": [59, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LTbetaR", "entity_2_idx": [[81, 88]], "entity_2_idx_in_text_with_entity_marker": [94, 101], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s669_AIMed.d78.s669.p8", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT-mediated HT29 cell death .", "text_with_entity_marker": "Our data suggest that TR6 inhibits the interactions of [E1]LIGHT[/E1] with HVEM / TR2 and LTbetaR , thereby suppressing [E2]LIGHT[/E2]-mediated HT29 cell death .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LIGHT", "entity_1_idx": [[55, 60]], "entity_1_idx_in_text_with_entity_marker": [59, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIGHT", "entity_2_idx": [[111, 116]], "entity_2_idx_in_text_with_entity_marker": [124, 129], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s669_AIMed.d78.s669.p9", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT-mediated HT29 cell death .", "text_with_entity_marker": "Our data suggest that TR6 inhibits the interactions of LIGHT with [E1]HVEM[/E1] / [E2]TR2[/E2] and LTbetaR , thereby suppressing LIGHT-mediated HT29 cell death .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HVEM", "entity_1_idx": [[66, 70]], "entity_1_idx_in_text_with_entity_marker": [70, 74], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TR2", "entity_2_idx": [[73, 76]], "entity_2_idx_in_text_with_entity_marker": [86, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s669_AIMed.d78.s669.p10", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT-mediated HT29 cell death .", "text_with_entity_marker": "Our data suggest that TR6 inhibits the interactions of LIGHT with [E1]HVEM[/E1] / TR2 and [E2]LTbetaR[/E2] , thereby suppressing LIGHT-mediated HT29 cell death .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HVEM", "entity_1_idx": [[66, 70]], "entity_1_idx_in_text_with_entity_marker": [70, 74], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LTbetaR", "entity_2_idx": [[81, 88]], "entity_2_idx_in_text_with_entity_marker": [94, 101], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s669_AIMed.d78.s669.p11", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT-mediated HT29 cell death .", "text_with_entity_marker": "Our data suggest that TR6 inhibits the interactions of LIGHT with [E1]HVEM[/E1] / TR2 and LTbetaR , thereby suppressing [E2]LIGHT[/E2]-mediated HT29 cell death .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HVEM", "entity_1_idx": [[66, 70]], "entity_1_idx_in_text_with_entity_marker": [70, 74], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIGHT", "entity_2_idx": [[111, 116]], "entity_2_idx_in_text_with_entity_marker": [124, 129], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s669_AIMed.d78.s669.p12", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT-mediated HT29 cell death .", "text_with_entity_marker": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / [E1]TR2[/E1] and [E2]LTbetaR[/E2] , thereby suppressing LIGHT-mediated HT29 cell death .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR2", "entity_1_idx": [[73, 76]], "entity_1_idx_in_text_with_entity_marker": [77, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LTbetaR", "entity_2_idx": [[81, 88]], "entity_2_idx_in_text_with_entity_marker": [94, 101], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s669_AIMed.d78.s669.p13", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT-mediated HT29 cell death .", "text_with_entity_marker": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / [E1]TR2[/E1] and LTbetaR , thereby suppressing [E2]LIGHT[/E2]-mediated HT29 cell death .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR2", "entity_1_idx": [[73, 76]], "entity_1_idx_in_text_with_entity_marker": [77, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIGHT", "entity_2_idx": [[111, 116]], "entity_2_idx_in_text_with_entity_marker": [124, 129], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s669_AIMed.d78.s669.p14", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT-mediated HT29 cell death .", "text_with_entity_marker": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and [E1]LTbetaR[/E1] , thereby suppressing [E2]LIGHT[/E2]-mediated HT29 cell death .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LTbetaR", "entity_1_idx": [[81, 88]], "entity_1_idx_in_text_with_entity_marker": [85, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIGHT", "entity_2_idx": [[111, 116]], "entity_2_idx_in_text_with_entity_marker": [124, 129], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s670_AIMed.d78.s670.p0", "text": "Thus , TR6 may play a regulatory role for suppressing in FasL- and LIGHT-mediated cell death .", "text_with_entity_marker": "Thus , [E1]TR6[/E1] may play a regulatory role for suppressing in [E2]FasL[/E2]- and LIGHT-mediated cell death .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR6", "entity_1_idx": [[7, 10]], "entity_1_idx_in_text_with_entity_marker": [11, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FasL", "entity_2_idx": [[57, 61]], "entity_2_idx_in_text_with_entity_marker": [70, 74], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s670_AIMed.d78.s670.p1", "text": "Thus , TR6 may play a regulatory role for suppressing in FasL- and LIGHT-mediated cell death .", "text_with_entity_marker": "Thus , [E1]TR6[/E1] may play a regulatory role for suppressing in FasL- and [E2]LIGHT[/E2]-mediated cell death .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR6", "entity_1_idx": [[7, 10]], "entity_1_idx_in_text_with_entity_marker": [11, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIGHT", "entity_2_idx": [[67, 72]], "entity_2_idx_in_text_with_entity_marker": [80, 85], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d78.s670_AIMed.d78.s670.p2", "text": "Thus , TR6 may play a regulatory role for suppressing in FasL- and LIGHT-mediated cell death .", "text_with_entity_marker": "Thus , TR6 may play a regulatory role for suppressing in [E1]FasL[/E1]- and [E2]LIGHT[/E2]-mediated cell death .", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FasL", "entity_1_idx": [[57, 61]], "entity_1_idx_in_text_with_entity_marker": [61, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIGHT", "entity_2_idx": [[67, 72]], "entity_2_idx_in_text_with_entity_marker": [80, 85], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d46.s402_AIMed.d46.s402.p0", "text": "BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II.", "text_with_entity_marker": "[E1]BMP-2[/E1] antagonists emerge from alterations in the low-affinity binding epitope for receptor [E2]BMPR-II[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMP-2", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMPR-II", "entity_2_idx": [[91, 98]], "entity_2_idx_in_text_with_entity_marker": [104, 111], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d46.s403_AIMed.d46.s403.p0", "text": "Bone morphogenetic protein-2 (BMP-2) induces bone formation and regeneration in adult vertebrates and regulates important developmental processes in all animals.", "text_with_entity_marker": "[E1]Bone morphogenetic protein-2[/E1] ([E2]BMP-2[/E2]) induces bone formation and regeneration in adult vertebrates and regulates important developmental processes in all animals.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bone morphogenetic protein-2", "entity_1_idx": [[0, 28]], "entity_1_idx_in_text_with_entity_marker": [4, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMP-2", "entity_2_idx": [[30, 35]], "entity_2_idx_in_text_with_entity_marker": [43, 48], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d46.s404_AIMed.d46.s404.p0", "text": "BMP-2 is a homodimeric cysteine knot protein that, as a member of the transforming growth factor-beta (TGF-beta) superfamily, signals by oligomerizing type I and type II receptor serine-kinases in the cell membrane.", "text_with_entity_marker": "[E1]BMP-2[/E1] is a homodimeric cysteine knot protein that, as a member of the [E2]transforming growth factor-beta[/E2] (TGF-beta) superfamily, signals by oligomerizing type I and type II receptor serine-kinases in the cell membrane.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMP-2", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "transforming growth factor-beta", "entity_2_idx": [[70, 101]], "entity_2_idx_in_text_with_entity_marker": [83, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d46.s404_AIMed.d46.s404.p1", "text": "BMP-2 is a homodimeric cysteine knot protein that, as a member of the transforming growth factor-beta (TGF-beta) superfamily, signals by oligomerizing type I and type II receptor serine-kinases in the cell membrane.", "text_with_entity_marker": "[E1]BMP-2[/E1] is a homodimeric cysteine knot protein that, as a member of the transforming growth factor-beta ([E2]TGF-beta[/E2]) superfamily, signals by oligomerizing type I and type II receptor serine-kinases in the cell membrane.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMP-2", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TGF-beta", "entity_2_idx": [[103, 111]], "entity_2_idx_in_text_with_entity_marker": [116, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d46.s404_AIMed.d46.s404.p2", "text": "BMP-2 is a homodimeric cysteine knot protein that, as a member of the transforming growth factor-beta (TGF-beta) superfamily, signals by oligomerizing type I and type II receptor serine-kinases in the cell membrane.", "text_with_entity_marker": "BMP-2 is a homodimeric cysteine knot protein that, as a member of the [E1]transforming growth factor-beta[/E1] ([E2]TGF-beta[/E2]) superfamily, signals by oligomerizing type I and type II receptor serine-kinases in the cell membrane.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "transforming growth factor-beta", "entity_1_idx": [[70, 101]], "entity_1_idx_in_text_with_entity_marker": [74, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TGF-beta", "entity_2_idx": [[103, 111]], "entity_2_idx_in_text_with_entity_marker": [116, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d46.s405_AIMed.d46.s405.p0", "text": "The binding epitopes of BMP-2 for BMPR-IA (type I) and BMPR-II or ActR-II (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.", "text_with_entity_marker": "The binding epitopes of [E1]BMP-2[/E1] for [E2]BMPR-IA[/E2] (type I) and BMPR-II or ActR-II (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "BMP-2", "entity_1_idx": [[24, 29]], "entity_1_idx_in_text_with_entity_marker": [28, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMPR-IA", "entity_2_idx": [[34, 41]], "entity_2_idx_in_text_with_entity_marker": [47, 54], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d46.s405_AIMed.d46.s405.p1", "text": "The binding epitopes of BMP-2 for BMPR-IA (type I) and BMPR-II or ActR-II (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.", "text_with_entity_marker": "The binding epitopes of [E1]BMP-2[/E1] for BMPR-IA (type I) and [E2]BMPR-II[/E2] or ActR-II (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "BMP-2", "entity_1_idx": [[24, 29]], "entity_1_idx_in_text_with_entity_marker": [28, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMPR-II", "entity_2_idx": [[55, 62]], "entity_2_idx_in_text_with_entity_marker": [68, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d46.s405_AIMed.d46.s405.p2", "text": "The binding epitopes of BMP-2 for BMPR-IA (type I) and BMPR-II or ActR-II (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.", "text_with_entity_marker": "The binding epitopes of [E1]BMP-2[/E1] for BMPR-IA (type I) and BMPR-II or [E2]ActR-II[/E2] (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "BMP-2", "entity_1_idx": [[24, 29]], "entity_1_idx_in_text_with_entity_marker": [28, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ActR-II", "entity_2_idx": [[66, 73]], "entity_2_idx_in_text_with_entity_marker": [79, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d46.s405_AIMed.d46.s405.p3", "text": "The binding epitopes of BMP-2 for BMPR-IA (type I) and BMPR-II or ActR-II (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.", "text_with_entity_marker": "The binding epitopes of [E1]BMP-2[/E1] for BMPR-IA (type I) and BMPR-II or ActR-II (type II) were characterized using [E2]BMP-2[/E2] mutant proteins for analysis of interactions with receptor ectodomains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMP-2", "entity_1_idx": [[24, 29]], "entity_1_idx_in_text_with_entity_marker": [28, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMP-2", "entity_2_idx": [[109, 114]], "entity_2_idx_in_text_with_entity_marker": [122, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d46.s405_AIMed.d46.s405.p4", "text": "The binding epitopes of BMP-2 for BMPR-IA (type I) and BMPR-II or ActR-II (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.", "text_with_entity_marker": "The binding epitopes of BMP-2 for [E1]BMPR-IA[/E1] (type I) and [E2]BMPR-II[/E2] or ActR-II (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMPR-IA", "entity_1_idx": [[34, 41]], "entity_1_idx_in_text_with_entity_marker": [38, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMPR-II", "entity_2_idx": [[55, 62]], "entity_2_idx_in_text_with_entity_marker": [68, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d46.s405_AIMed.d46.s405.p5", "text": "The binding epitopes of BMP-2 for BMPR-IA (type I) and BMPR-II or ActR-II (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.", "text_with_entity_marker": "The binding epitopes of BMP-2 for [E1]BMPR-IA[/E1] (type I) and BMPR-II or [E2]ActR-II[/E2] (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMPR-IA", "entity_1_idx": [[34, 41]], "entity_1_idx_in_text_with_entity_marker": [38, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ActR-II", "entity_2_idx": [[66, 73]], "entity_2_idx_in_text_with_entity_marker": [79, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d46.s405_AIMed.d46.s405.p6", "text": "The binding epitopes of BMP-2 for BMPR-IA (type I) and BMPR-II or ActR-II (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.", "text_with_entity_marker": "The binding epitopes of BMP-2 for [E1]BMPR-IA[/E1] (type I) and BMPR-II or ActR-II (type II) were characterized using [E2]BMP-2[/E2] mutant proteins for analysis of interactions with receptor ectodomains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMPR-IA", "entity_1_idx": [[34, 41]], "entity_1_idx_in_text_with_entity_marker": [38, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMP-2", "entity_2_idx": [[109, 114]], "entity_2_idx_in_text_with_entity_marker": [122, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d46.s405_AIMed.d46.s405.p7", "text": "The binding epitopes of BMP-2 for BMPR-IA (type I) and BMPR-II or ActR-II (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.", "text_with_entity_marker": "The binding epitopes of BMP-2 for BMPR-IA (type I) and [E1]BMPR-II[/E1] or [E2]ActR-II[/E2] (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMPR-II", "entity_1_idx": [[55, 62]], "entity_1_idx_in_text_with_entity_marker": [59, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ActR-II", "entity_2_idx": [[66, 73]], "entity_2_idx_in_text_with_entity_marker": [79, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d46.s405_AIMed.d46.s405.p8", "text": "The binding epitopes of BMP-2 for BMPR-IA (type I) and BMPR-II or ActR-II (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.", "text_with_entity_marker": "The binding epitopes of BMP-2 for BMPR-IA (type I) and [E1]BMPR-II[/E1] or ActR-II (type II) were characterized using [E2]BMP-2[/E2] mutant proteins for analysis of interactions with receptor ectodomains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMPR-II", "entity_1_idx": [[55, 62]], "entity_1_idx_in_text_with_entity_marker": [59, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMP-2", "entity_2_idx": [[109, 114]], "entity_2_idx_in_text_with_entity_marker": [122, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d46.s405_AIMed.d46.s405.p9", "text": "The binding epitopes of BMP-2 for BMPR-IA (type I) and BMPR-II or ActR-II (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.", "text_with_entity_marker": "The binding epitopes of BMP-2 for BMPR-IA (type I) and BMPR-II or [E1]ActR-II[/E1] (type II) were characterized using [E2]BMP-2[/E2] mutant proteins for analysis of interactions with receptor ectodomains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ActR-II", "entity_1_idx": [[66, 73]], "entity_1_idx_in_text_with_entity_marker": [70, 77], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMP-2", "entity_2_idx": [[109, 114]], "entity_2_idx_in_text_with_entity_marker": [122, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d46.s406_AIMed.d46.s406.p0", "text": "A large epitope 1 for high-affinity BMPR-IA binding was detected spanning the interface of the BMP-2 dimer.", "text_with_entity_marker": "A large epitope 1 for high-affinity [E1]BMPR-IA[/E1] binding was detected spanning the interface of the [E2]BMP-2[/E2] dimer.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "BMPR-IA", "entity_1_idx": [[36, 43]], "entity_1_idx_in_text_with_entity_marker": [40, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMP-2", "entity_2_idx": [[95, 100]], "entity_2_idx_in_text_with_entity_marker": [108, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d202.s1737_AIMed.d202.s1737.p0", "text": "Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1beta.", "text_with_entity_marker": "Crystal structure of the [E1]type-I interleukin-1 receptor[/E1][E2]interleukin-1[/E2] receptor complexed with interleukin-1beta.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "type-I interleukin-1 receptor", "entity_1_idx": [[25, 54]], "entity_1_idx_in_text_with_entity_marker": [29, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-1", "entity_2_idx": [[32, 45]], "entity_2_idx_in_text_with_entity_marker": [67, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d202.s1737_AIMed.d202.s1737.p1", "text": "Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1beta.", "text_with_entity_marker": "Crystal structure of the type-I [E1]interleukin-1[/E1] receptor complexed with [E2]interleukin-1beta[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-1", "entity_1_idx": [[32, 45]], "entity_1_idx_in_text_with_entity_marker": [36, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-1beta", "entity_2_idx": [[70, 87]], "entity_2_idx_in_text_with_entity_marker": [83, 100], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d202.s1737_AIMed.d202.s1737.p2", "text": "Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1beta.", "text_with_entity_marker": "Crystal structure of the [E1]type-I interleukin-1 receptor[/E1] complexed with [E2]interleukin-1beta[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "type-I interleukin-1 receptor", "entity_1_idx": [[25, 54]], "entity_1_idx_in_text_with_entity_marker": [29, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-1beta", "entity_2_idx": [[70, 87]], "entity_2_idx_in_text_with_entity_marker": [83, 100], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d202.s1738_AIMed.d202.s1738.p0", "text": "Interleukin-1 (IL-1) is an important mediator of inflammatory disease.", "text_with_entity_marker": "[E1]Interleukin-1[/E1] ([E2]IL-1[/E2]) is an important mediator of inflammatory disease.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Interleukin-1", "entity_1_idx": [[0, 13]], "entity_1_idx_in_text_with_entity_marker": [4, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1", "entity_2_idx": [[15, 19]], "entity_2_idx_in_text_with_entity_marker": [28, 32], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d202.s1739_AIMed.d202.s1739.p0", "text": "The IL-1 family currently consists of two agonists, IL-1alpha and IL-1beta, and one antagonist, IL-1ra.", "text_with_entity_marker": "The [E1]IL-1[/E1] family currently consists of two agonists, [E2]IL-1alpha[/E2] and IL-1beta, and one antagonist, IL-1ra.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1", "entity_1_idx": [[4, 8]], "entity_1_idx_in_text_with_entity_marker": [8, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1alpha", "entity_2_idx": [[52, 61]], "entity_2_idx_in_text_with_entity_marker": [65, 74], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d202.s1739_AIMed.d202.s1739.p1", "text": "The IL-1 family currently consists of two agonists, IL-1alpha and IL-1beta, and one antagonist, IL-1ra.", "text_with_entity_marker": "The [E1]IL-1[/E1] family currently consists of two agonists, IL-1alpha and [E2]IL-1beta[/E2], and one antagonist, IL-1ra.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1", "entity_1_idx": [[4, 8]], "entity_1_idx_in_text_with_entity_marker": [8, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1beta", "entity_2_idx": [[66, 74]], "entity_2_idx_in_text_with_entity_marker": [79, 87], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d202.s1739_AIMed.d202.s1739.p2", "text": "The IL-1 family currently consists of two agonists, IL-1alpha and IL-1beta, and one antagonist, IL-1ra.", "text_with_entity_marker": "The [E1]IL-1[/E1] family currently consists of two agonists, IL-1alpha and IL-1beta, and one antagonist, [E2]IL-1ra[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1", "entity_1_idx": [[4, 8]], "entity_1_idx_in_text_with_entity_marker": [8, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1ra", "entity_2_idx": [[96, 102]], "entity_2_idx_in_text_with_entity_marker": [109, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d202.s1739_AIMed.d202.s1739.p3", "text": "The IL-1 family currently consists of two agonists, IL-1alpha and IL-1beta, and one antagonist, IL-1ra.", "text_with_entity_marker": "The IL-1 family currently consists of two agonists, [E1]IL-1alpha[/E1] and [E2]IL-1beta[/E2], and one antagonist, IL-1ra.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1alpha", "entity_1_idx": [[52, 61]], "entity_1_idx_in_text_with_entity_marker": [56, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1beta", "entity_2_idx": [[66, 74]], "entity_2_idx_in_text_with_entity_marker": [79, 87], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d202.s1739_AIMed.d202.s1739.p4", "text": "The IL-1 family currently consists of two agonists, IL-1alpha and IL-1beta, and one antagonist, IL-1ra.", "text_with_entity_marker": "The IL-1 family currently consists of two agonists, [E1]IL-1alpha[/E1] and IL-1beta, and one antagonist, [E2]IL-1ra[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1alpha", "entity_1_idx": [[52, 61]], "entity_1_idx_in_text_with_entity_marker": [56, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1ra", "entity_2_idx": [[96, 102]], "entity_2_idx_in_text_with_entity_marker": [109, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d202.s1739_AIMed.d202.s1739.p5", "text": "The IL-1 family currently consists of two agonists, IL-1alpha and IL-1beta, and one antagonist, IL-1ra.", "text_with_entity_marker": "The IL-1 family currently consists of two agonists, IL-1alpha and [E1]IL-1beta[/E1], and one antagonist, [E2]IL-1ra[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1beta", "entity_1_idx": [[66, 74]], "entity_1_idx_in_text_with_entity_marker": [70, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1ra", "entity_2_idx": [[96, 102]], "entity_2_idx_in_text_with_entity_marker": [109, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d202.s1740_AIMed.d202.s1740.p0", "text": "Each of these molecules binds to the type I IL-1 receptor (IL1R).", "text_with_entity_marker": "Each of these molecules binds to the [E1]type I IL-1 receptor[/E1][E2]IL-1[/E2] receptor (IL1R).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "type I IL-1 receptor", "entity_1_idx": [[37, 57]], "entity_1_idx_in_text_with_entity_marker": [41, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1", "entity_2_idx": [[44, 48]], "entity_2_idx_in_text_with_entity_marker": [70, 74], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d202.s1740_AIMed.d202.s1740.p1", "text": "Each of these molecules binds to the type I IL-1 receptor (IL1R).", "text_with_entity_marker": "Each of these molecules binds to the type I [E1]IL-1[/E1] receptor ([E2]IL1R[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1", "entity_1_idx": [[44, 48]], "entity_1_idx_in_text_with_entity_marker": [48, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL1R", "entity_2_idx": [[59, 63]], "entity_2_idx_in_text_with_entity_marker": [72, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d202.s1740_AIMed.d202.s1740.p2", "text": "Each of these molecules binds to the type I IL-1 receptor (IL1R).", "text_with_entity_marker": "Each of these molecules binds to the [E1]type I IL-1 receptor[/E1] ([E2]IL1R[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "type I IL-1 receptor", "entity_1_idx": [[37, 57]], "entity_1_idx_in_text_with_entity_marker": [41, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL1R", "entity_2_idx": [[59, 63]], "entity_2_idx_in_text_with_entity_marker": [72, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d202.s1741_AIMed.d202.s1741.p0", "text": "The binding of IL-1alpha or IL-1beta to IL1R is an early step in IL-1 signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs.", "text_with_entity_marker": "The binding of [E1]IL-1alpha[/E1] or [E2]IL-1beta[/E2] to IL1R is an early step in IL-1 signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1alpha", "entity_1_idx": [[15, 24]], "entity_1_idx_in_text_with_entity_marker": [19, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1beta", "entity_2_idx": [[28, 36]], "entity_2_idx_in_text_with_entity_marker": [41, 49], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d202.s1741_AIMed.d202.s1741.p1", "text": "The binding of IL-1alpha or IL-1beta to IL1R is an early step in IL-1 signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs.", "text_with_entity_marker": "The binding of [E1]IL-1alpha[/E1] or IL-1beta to [E2]IL1R[/E2] is an early step in IL-1 signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-1alpha", "entity_1_idx": [[15, 24]], "entity_1_idx_in_text_with_entity_marker": [19, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL1R", "entity_2_idx": [[40, 44]], "entity_2_idx_in_text_with_entity_marker": [53, 57], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d202.s1741_AIMed.d202.s1741.p2", "text": "The binding of IL-1alpha or IL-1beta to IL1R is an early step in IL-1 signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs.", "text_with_entity_marker": "The binding of [E1]IL-1alpha[/E1] or IL-1beta to IL1R is an early step in [E2]IL-1[/E2] signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1alpha", "entity_1_idx": [[15, 24]], "entity_1_idx_in_text_with_entity_marker": [19, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1", "entity_2_idx": [[65, 69]], "entity_2_idx_in_text_with_entity_marker": [78, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d202.s1741_AIMed.d202.s1741.p3", "text": "The binding of IL-1alpha or IL-1beta to IL1R is an early step in IL-1 signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs.", "text_with_entity_marker": "The binding of IL-1alpha or [E1]IL-1beta[/E1] to [E2]IL1R[/E2] is an early step in IL-1 signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-1beta", "entity_1_idx": [[28, 36]], "entity_1_idx_in_text_with_entity_marker": [32, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL1R", "entity_2_idx": [[40, 44]], "entity_2_idx_in_text_with_entity_marker": [53, 57], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d202.s1741_AIMed.d202.s1741.p4", "text": "The binding of IL-1alpha or IL-1beta to IL1R is an early step in IL-1 signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs.", "text_with_entity_marker": "The binding of IL-1alpha or [E1]IL-1beta[/E1] to IL1R is an early step in [E2]IL-1[/E2] signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1beta", "entity_1_idx": [[28, 36]], "entity_1_idx_in_text_with_entity_marker": [32, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1", "entity_2_idx": [[65, 69]], "entity_2_idx_in_text_with_entity_marker": [78, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d202.s1741_AIMed.d202.s1741.p5", "text": "The binding of IL-1alpha or IL-1beta to IL1R is an early step in IL-1 signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs.", "text_with_entity_marker": "The binding of IL-1alpha or IL-1beta to [E1]IL1R[/E1] is an early step in [E2]IL-1[/E2] signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL1R", "entity_1_idx": [[40, 44]], "entity_1_idx_in_text_with_entity_marker": [44, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1", "entity_2_idx": [[65, 69]], "entity_2_idx_in_text_with_entity_marker": [78, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d202.s1742_AIMed.d202.s1742.p0", "text": "Here we report the three-dimensional structure of IL-1beta bound to the extracellular domain of IL1R (s-IL1R) at 2.5 A resolution.", "text_with_entity_marker": "Here we report the three-dimensional structure of [E1]IL-1beta[/E1] bound to the extracellular domain of [E2]IL1R[/E2] (s-IL1R) at 2.5 A resolution.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-1beta", "entity_1_idx": [[50, 58]], "entity_1_idx_in_text_with_entity_marker": [54, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL1R", "entity_2_idx": [[96, 100]], "entity_2_idx_in_text_with_entity_marker": [109, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d202.s1742_AIMed.d202.s1742.p1", "text": "Here we report the three-dimensional structure of IL-1beta bound to the extracellular domain of IL1R (s-IL1R) at 2.5 A resolution.", "text_with_entity_marker": "Here we report the three-dimensional structure of [E1]IL-1beta[/E1] bound to the extracellular domain of IL1R ([E2]s-IL1R[/E2]) at 2.5 A resolution.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-1beta", "entity_1_idx": [[50, 58]], "entity_1_idx_in_text_with_entity_marker": [54, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "s-IL1R", "entity_2_idx": [[102, 108]], "entity_2_idx_in_text_with_entity_marker": [115, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d202.s1742_AIMed.d202.s1742.p2", "text": "Here we report the three-dimensional structure of IL-1beta bound to the extracellular domain of IL1R (s-IL1R) at 2.5 A resolution.", "text_with_entity_marker": "Here we report the three-dimensional structure of IL-1beta bound to the extracellular domain of [E1]IL1R[/E1] ([E2]s-IL1R[/E2]) at 2.5 A resolution.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL1R", "entity_1_idx": [[96, 100]], "entity_1_idx_in_text_with_entity_marker": [100, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "s-IL1R", "entity_2_idx": [[102, 108]], "entity_2_idx_in_text_with_entity_marker": [115, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d202.s1743_AIMed.d202.s1743.p0", "text": "IL-1beta binds to s-IL1R with a 1:1 stoichiometry.", "text_with_entity_marker": "[E1]IL-1beta[/E1] binds to [E2]s-IL1R[/E2] with a 1:1 stoichiometry.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-1beta", "entity_1_idx": [[0, 8]], "entity_1_idx_in_text_with_entity_marker": [4, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "s-IL1R", "entity_2_idx": [[18, 24]], "entity_2_idx_in_text_with_entity_marker": [31, 37], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d202.s1744_AIMed.d202.s1744.p0", "text": "The crystal structure shows that s-IL1R consists of three immunoglobulin-like domains which wrap around IL-1beta in a manner distinct from the structures of previously described cytokine-receptor complexes.", "text_with_entity_marker": "The crystal structure shows that [E1]s-IL1R[/E1] consists of three immunoglobulin-like domains which wrap around [E2]IL-1beta[/E2] in a manner distinct from the structures of previously described cytokine-receptor complexes.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "s-IL1R", "entity_1_idx": [[33, 39]], "entity_1_idx_in_text_with_entity_marker": [37, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1beta", "entity_2_idx": [[104, 112]], "entity_2_idx_in_text_with_entity_marker": [117, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s796_AIMed.d94.s796.p0", "text": "Eosinophils undergo chemotaxis, degranulate, and exhibit [C2+]i changes in response to the human CC chemokines macrophage inflammatory protein (MIP)-1 alpha, regulated on activation, normal T expressed and secreted (RANTES), and monocyte chemoattractant protein-3 (MCP-3), but the receptors involved have not been defined.", "text_with_entity_marker": "Eosinophils undergo chemotaxis, degranulate, and exhibit [C2+]i changes in response to the human CC chemokines macrophage inflammatory protein [E1](MIP)-1 alpha[/E1], regulated on activation, normal T expressed and secreted ([E2]RANTES[/E2]), and monocyte chemoattractant protein-3 (MCP-3), but the receptors involved have not been defined.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "(MIP)-1 alpha", "entity_1_idx": [[143, 156]], "entity_1_idx_in_text_with_entity_marker": [147, 160], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RANTES", "entity_2_idx": [[216, 222]], "entity_2_idx_in_text_with_entity_marker": [229, 235], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s796_AIMed.d94.s796.p1", "text": "Eosinophils undergo chemotaxis, degranulate, and exhibit [C2+]i changes in response to the human CC chemokines macrophage inflammatory protein (MIP)-1 alpha, regulated on activation, normal T expressed and secreted (RANTES), and monocyte chemoattractant protein-3 (MCP-3), but the receptors involved have not been defined.", "text_with_entity_marker": "Eosinophils undergo chemotaxis, degranulate, and exhibit [C2+]i changes in response to the human CC chemokines macrophage inflammatory protein [E1](MIP)-1 alpha[/E1], regulated on activation, normal T expressed and secreted (RANTES), and [E2]monocyte chemoattractant protein-3[/E2] (MCP-3), but the receptors involved have not been defined.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "(MIP)-1 alpha", "entity_1_idx": [[143, 156]], "entity_1_idx_in_text_with_entity_marker": [147, 160], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "monocyte chemoattractant protein-3", "entity_2_idx": [[229, 263]], "entity_2_idx_in_text_with_entity_marker": [242, 276], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s796_AIMed.d94.s796.p2", "text": "Eosinophils undergo chemotaxis, degranulate, and exhibit [C2+]i changes in response to the human CC chemokines macrophage inflammatory protein (MIP)-1 alpha, regulated on activation, normal T expressed and secreted (RANTES), and monocyte chemoattractant protein-3 (MCP-3), but the receptors involved have not been defined.", "text_with_entity_marker": "Eosinophils undergo chemotaxis, degranulate, and exhibit [C2+]i changes in response to the human CC chemokines macrophage inflammatory protein [E1](MIP)-1 alpha[/E1], regulated on activation, normal T expressed and secreted (RANTES), and monocyte chemoattractant protein-3 ([E2]MCP-3[/E2]), but the receptors involved have not been defined.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "(MIP)-1 alpha", "entity_1_idx": [[143, 156]], "entity_1_idx_in_text_with_entity_marker": [147, 160], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-3", "entity_2_idx": [[265, 270]], "entity_2_idx_in_text_with_entity_marker": [278, 283], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s796_AIMed.d94.s796.p3", "text": "Eosinophils undergo chemotaxis, degranulate, and exhibit [C2+]i changes in response to the human CC chemokines macrophage inflammatory protein (MIP)-1 alpha, regulated on activation, normal T expressed and secreted (RANTES), and monocyte chemoattractant protein-3 (MCP-3), but the receptors involved have not been defined.", "text_with_entity_marker": "Eosinophils undergo chemotaxis, degranulate, and exhibit [C2+]i changes in response to the human CC chemokines macrophage inflammatory protein (MIP)-1 alpha, regulated on activation, normal T expressed and secreted ([E1]RANTES[/E1]), and [E2]monocyte chemoattractant protein-3[/E2] (MCP-3), but the receptors involved have not been defined.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RANTES", "entity_1_idx": [[216, 222]], "entity_1_idx_in_text_with_entity_marker": [220, 226], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "monocyte chemoattractant protein-3", "entity_2_idx": [[229, 263]], "entity_2_idx_in_text_with_entity_marker": [242, 276], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s796_AIMed.d94.s796.p4", "text": "Eosinophils undergo chemotaxis, degranulate, and exhibit [C2+]i changes in response to the human CC chemokines macrophage inflammatory protein (MIP)-1 alpha, regulated on activation, normal T expressed and secreted (RANTES), and monocyte chemoattractant protein-3 (MCP-3), but the receptors involved have not been defined.", "text_with_entity_marker": "Eosinophils undergo chemotaxis, degranulate, and exhibit [C2+]i changes in response to the human CC chemokines macrophage inflammatory protein (MIP)-1 alpha, regulated on activation, normal T expressed and secreted ([E1]RANTES[/E1]), and monocyte chemoattractant protein-3 ([E2]MCP-3[/E2]), but the receptors involved have not been defined.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RANTES", "entity_1_idx": [[216, 222]], "entity_1_idx_in_text_with_entity_marker": [220, 226], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-3", "entity_2_idx": [[265, 270]], "entity_2_idx_in_text_with_entity_marker": [278, 283], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s796_AIMed.d94.s796.p5", "text": "Eosinophils undergo chemotaxis, degranulate, and exhibit [C2+]i changes in response to the human CC chemokines macrophage inflammatory protein (MIP)-1 alpha, regulated on activation, normal T expressed and secreted (RANTES), and monocyte chemoattractant protein-3 (MCP-3), but the receptors involved have not been defined.", "text_with_entity_marker": "Eosinophils undergo chemotaxis, degranulate, and exhibit [C2+]i changes in response to the human CC chemokines macrophage inflammatory protein (MIP)-1 alpha, regulated on activation, normal T expressed and secreted (RANTES), and [E1]monocyte chemoattractant protein-3[/E1] ([E2]MCP-3[/E2]), but the receptors involved have not been defined.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "monocyte chemoattractant protein-3", "entity_1_idx": [[229, 263]], "entity_1_idx_in_text_with_entity_marker": [233, 267], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-3", "entity_2_idx": [[265, 270]], "entity_2_idx_in_text_with_entity_marker": [278, 283], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s797_AIMed.d94.s797.p0", "text": "We have isolated a human cDNA encoding the first eosinophil-selective chemokine receptor, designated CC chemokine receptor 3 (CC CKR3).", "text_with_entity_marker": "We have isolated a human cDNA encoding the first eosinophil-selective chemokine receptor, designated [E1]CC chemokine receptor 3[/E1] ([E2]CC CKR3[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CC chemokine receptor 3", "entity_1_idx": [[101, 124]], "entity_1_idx_in_text_with_entity_marker": [105, 128], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CC CKR3", "entity_2_idx": [[126, 133]], "entity_2_idx_in_text_with_entity_marker": [139, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s798_AIMed.d94.s798.p0", "text": "CC CKR3 is a seven-transmembrane domain G protein-coupled receptor most closely related to the previously reported monocyte- and neutrophil-selective receptor CC CKR1 (also known as the MIP-1 alpha/RANTES receptor).", "text_with_entity_marker": "[E1]CC CKR3[/E1] is a seven-transmembrane domain G protein-coupled receptor most closely related to the previously reported monocyte- and neutrophil-selective receptor [E2]CC CKR1[/E2] (also known as the MIP-1 alpha/RANTES receptor).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CC CKR3", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CC CKR1", "entity_2_idx": [[159, 166]], "entity_2_idx_in_text_with_entity_marker": [172, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s798_AIMed.d94.s798.p1", "text": "CC CKR3 is a seven-transmembrane domain G protein-coupled receptor most closely related to the previously reported monocyte- and neutrophil-selective receptor CC CKR1 (also known as the MIP-1 alpha/RANTES receptor).", "text_with_entity_marker": "[E1]CC CKR3[/E1] is a seven-transmembrane domain G protein-coupled receptor most closely related to the previously reported monocyte- and neutrophil-selective receptor CC CKR1 (also known as the [E2]MIP-1 alpha[/E2]/RANTES receptor).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CC CKR3", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MIP-1 alpha", "entity_2_idx": [[186, 197]], "entity_2_idx_in_text_with_entity_marker": [199, 210], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s798_AIMed.d94.s798.p2", "text": "CC CKR3 is a seven-transmembrane domain G protein-coupled receptor most closely related to the previously reported monocyte- and neutrophil-selective receptor CC CKR1 (also known as the MIP-1 alpha/RANTES receptor).", "text_with_entity_marker": "[E1]CC CKR3[/E1] is a seven-transmembrane domain G protein-coupled receptor most closely related to the previously reported monocyte- and neutrophil-selective receptor CC CKR1 (also known as the MIP-1 alpha/[E2]RANTES[/E2] receptor).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CC CKR3", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RANTES", "entity_2_idx": [[198, 204]], "entity_2_idx_in_text_with_entity_marker": [211, 217], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s798_AIMed.d94.s798.p3", "text": "CC CKR3 is a seven-transmembrane domain G protein-coupled receptor most closely related to the previously reported monocyte- and neutrophil-selective receptor CC CKR1 (also known as the MIP-1 alpha/RANTES receptor).", "text_with_entity_marker": "CC CKR3 is a seven-transmembrane domain G protein-coupled receptor most closely related to the previously reported monocyte- and neutrophil-selective receptor [E1]CC CKR1[/E1] (also known as the [E2]MIP-1 alpha[/E2]/RANTES receptor).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CC CKR1", "entity_1_idx": [[159, 166]], "entity_1_idx_in_text_with_entity_marker": [163, 170], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MIP-1 alpha", "entity_2_idx": [[186, 197]], "entity_2_idx_in_text_with_entity_marker": [199, 210], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s798_AIMed.d94.s798.p4", "text": "CC CKR3 is a seven-transmembrane domain G protein-coupled receptor most closely related to the previously reported monocyte- and neutrophil-selective receptor CC CKR1 (also known as the MIP-1 alpha/RANTES receptor).", "text_with_entity_marker": "CC CKR3 is a seven-transmembrane domain G protein-coupled receptor most closely related to the previously reported monocyte- and neutrophil-selective receptor [E1]CC CKR1[/E1] (also known as the MIP-1 alpha/[E2]RANTES[/E2] receptor).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CC CKR1", "entity_1_idx": [[159, 166]], "entity_1_idx_in_text_with_entity_marker": [163, 170], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RANTES", "entity_2_idx": [[198, 204]], "entity_2_idx_in_text_with_entity_marker": [211, 217], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s798_AIMed.d94.s798.p5", "text": "CC CKR3 is a seven-transmembrane domain G protein-coupled receptor most closely related to the previously reported monocyte- and neutrophil-selective receptor CC CKR1 (also known as the MIP-1 alpha/RANTES receptor).", "text_with_entity_marker": "CC CKR3 is a seven-transmembrane domain G protein-coupled receptor most closely related to the previously reported monocyte- and neutrophil-selective receptor CC CKR1 (also known as the [E1]MIP-1 alpha[/E1]/[E2]RANTES[/E2] receptor).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP-1 alpha", "entity_1_idx": [[186, 197]], "entity_1_idx_in_text_with_entity_marker": [190, 201], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RANTES", "entity_2_idx": [[198, 204]], "entity_2_idx_in_text_with_entity_marker": [211, 217], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s799_AIMed.d94.s799.p0", "text": "When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, (MIP)-1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1.", "text_with_entity_marker": "When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, [E1](MIP)-1 alpha[/E1] [E2]MIP[/E2] and RANTES were both potent agonists for CC CKR3 and CC CKR1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "(MIP)-1 alpha", "entity_1_idx": [[92, 105]], "entity_1_idx_in_text_with_entity_marker": [96, 109], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MIP", "entity_2_idx": [[106, 109]], "entity_2_idx_in_text_with_entity_marker": [119, 122], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s799_AIMed.d94.s799.p1", "text": "When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, (MIP)-1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1.", "text_with_entity_marker": "When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, [E1](MIP)-1 alpha[/E1] MIP and [E2]RANTES[/E2] were both potent agonists for CC CKR3 and CC CKR1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "(MIP)-1 alpha", "entity_1_idx": [[92, 105]], "entity_1_idx_in_text_with_entity_marker": [96, 109], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RANTES", "entity_2_idx": [[114, 120]], "entity_2_idx_in_text_with_entity_marker": [127, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s799_AIMed.d94.s799.p2", "text": "When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, (MIP)-1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1.", "text_with_entity_marker": "When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, [E1](MIP)-1 alpha[/E1] MIP and RANTES were both potent agonists for [E2]CC CKR3[/E2] and CC CKR1.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "(MIP)-1 alpha", "entity_1_idx": [[92, 105]], "entity_1_idx_in_text_with_entity_marker": [96, 109], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CC CKR3", "entity_2_idx": [[151, 158]], "entity_2_idx_in_text_with_entity_marker": [164, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s799_AIMed.d94.s799.p3", "text": "When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, (MIP)-1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1.", "text_with_entity_marker": "When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, [E1](MIP)-1 alpha[/E1] MIP and RANTES were both potent agonists for CC CKR3 and [E2]CC CKR1[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "(MIP)-1 alpha", "entity_1_idx": [[92, 105]], "entity_1_idx_in_text_with_entity_marker": [96, 109], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CC CKR1", "entity_2_idx": [[163, 170]], "entity_2_idx_in_text_with_entity_marker": [176, 183], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s799_AIMed.d94.s799.p4", "text": "When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, (MIP)-1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1.", "text_with_entity_marker": "When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, (MIP)-1 alpha [E1]MIP[/E1] and [E2]RANTES[/E2] were both potent agonists for CC CKR3 and CC CKR1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP", "entity_1_idx": [[106, 109]], "entity_1_idx_in_text_with_entity_marker": [110, 113], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RANTES", "entity_2_idx": [[114, 120]], "entity_2_idx_in_text_with_entity_marker": [127, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s799_AIMed.d94.s799.p5", "text": "When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, (MIP)-1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1.", "text_with_entity_marker": "When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, (MIP)-1 alpha [E1]MIP[/E1] and RANTES were both potent agonists for [E2]CC CKR3[/E2] and CC CKR1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP", "entity_1_idx": [[106, 109]], "entity_1_idx_in_text_with_entity_marker": [110, 113], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CC CKR3", "entity_2_idx": [[151, 158]], "entity_2_idx_in_text_with_entity_marker": [164, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s799_AIMed.d94.s799.p6", "text": "When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, (MIP)-1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1.", "text_with_entity_marker": "When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, (MIP)-1 alpha [E1]MIP[/E1] and RANTES were both potent agonists for CC CKR3 and [E2]CC CKR1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP", "entity_1_idx": [[106, 109]], "entity_1_idx_in_text_with_entity_marker": [110, 113], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CC CKR1", "entity_2_idx": [[163, 170]], "entity_2_idx_in_text_with_entity_marker": [176, 183], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s799_AIMed.d94.s799.p7", "text": "When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, (MIP)-1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1.", "text_with_entity_marker": "When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, (MIP)-1 alpha MIP and [E1]RANTES[/E1] were both potent agonists for [E2]CC CKR3[/E2] and CC CKR1.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "RANTES", "entity_1_idx": [[114, 120]], "entity_1_idx_in_text_with_entity_marker": [118, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CC CKR3", "entity_2_idx": [[151, 158]], "entity_2_idx_in_text_with_entity_marker": [164, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s799_AIMed.d94.s799.p8", "text": "When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, (MIP)-1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1.", "text_with_entity_marker": "When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, (MIP)-1 alpha MIP and [E1]RANTES[/E1] were both potent agonists for CC CKR3 and [E2]CC CKR1[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "RANTES", "entity_1_idx": [[114, 120]], "entity_1_idx_in_text_with_entity_marker": [118, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CC CKR1", "entity_2_idx": [[163, 170]], "entity_2_idx_in_text_with_entity_marker": [176, 183], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s799_AIMed.d94.s799.p9", "text": "When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, (MIP)-1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1.", "text_with_entity_marker": "When [Ca2+]i changes were monitored in stably transfected human embryonic kidney 293 cells, (MIP)-1 alpha MIP and RANTES were both potent agonists for [E1]CC CKR3[/E1] and [E2]CC CKR1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CC CKR3", "entity_1_idx": [[151, 158]], "entity_1_idx_in_text_with_entity_marker": [155, 162], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CC CKR1", "entity_2_idx": [[163, 170]], "entity_2_idx_in_text_with_entity_marker": [176, 183], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s800_AIMed.d94.s800.p0", "text": "However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.", "text_with_entity_marker": "However, [E1]MIP-1 beta[/E1] was also an agonist for [E2]CC CKR3[/E2] but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MIP-1 beta", "entity_1_idx": [[9, 19]], "entity_1_idx_in_text_with_entity_marker": [13, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CC CKR3", "entity_2_idx": [[44, 51]], "entity_2_idx_in_text_with_entity_marker": [57, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s800_AIMed.d94.s800.p1", "text": "However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.", "text_with_entity_marker": "However, [E1]MIP-1 beta[/E1] was also an agonist for CC CKR3 but not [E2]CC CKR1[/E2]; MCP-3 was an agonist for CC CKR1 but not CC CKR3.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP-1 beta", "entity_1_idx": [[9, 19]], "entity_1_idx_in_text_with_entity_marker": [13, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CC CKR1", "entity_2_idx": [[60, 67]], "entity_2_idx_in_text_with_entity_marker": [73, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s800_AIMed.d94.s800.p2", "text": "However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.", "text_with_entity_marker": "However, [E1]MIP-1 beta[/E1] was also an agonist for CC CKR3 but not CC CKR1; [E2]MCP-3[/E2] was an agonist for CC CKR1 but not CC CKR3.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP-1 beta", "entity_1_idx": [[9, 19]], "entity_1_idx_in_text_with_entity_marker": [13, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-3", "entity_2_idx": [[69, 74]], "entity_2_idx_in_text_with_entity_marker": [82, 87], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s800_AIMed.d94.s800.p3", "text": "However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.", "text_with_entity_marker": "However, [E1]MIP-1 beta[/E1] was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for [E2]CC CKR1[/E2] but not CC CKR3.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP-1 beta", "entity_1_idx": [[9, 19]], "entity_1_idx_in_text_with_entity_marker": [13, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CC CKR1", "entity_2_idx": [[94, 101]], "entity_2_idx_in_text_with_entity_marker": [107, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s800_AIMed.d94.s800.p4", "text": "However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.", "text_with_entity_marker": "However, [E1]MIP-1 beta[/E1] was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not [E2]CC CKR3[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MIP-1 beta", "entity_1_idx": [[9, 19]], "entity_1_idx_in_text_with_entity_marker": [13, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CC CKR3", "entity_2_idx": [[110, 117]], "entity_2_idx_in_text_with_entity_marker": [123, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s800_AIMed.d94.s800.p5", "text": "However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.", "text_with_entity_marker": "However, MIP-1 beta was also an agonist for [E1]CC CKR3[/E1] but not [E2]CC CKR1[/E2]; MCP-3 was an agonist for CC CKR1 but not CC CKR3.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CC CKR3", "entity_1_idx": [[44, 51]], "entity_1_idx_in_text_with_entity_marker": [48, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CC CKR1", "entity_2_idx": [[60, 67]], "entity_2_idx_in_text_with_entity_marker": [73, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s800_AIMed.d94.s800.p6", "text": "However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.", "text_with_entity_marker": "However, MIP-1 beta was also an agonist for [E1]CC CKR3[/E1] but not CC CKR1; [E2]MCP-3[/E2] was an agonist for CC CKR1 but not CC CKR3.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CC CKR3", "entity_1_idx": [[44, 51]], "entity_1_idx_in_text_with_entity_marker": [48, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-3", "entity_2_idx": [[69, 74]], "entity_2_idx_in_text_with_entity_marker": [82, 87], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s800_AIMed.d94.s800.p7", "text": "However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.", "text_with_entity_marker": "However, MIP-1 beta was also an agonist for [E1]CC CKR3[/E1] but not CC CKR1; MCP-3 was an agonist for [E2]CC CKR1[/E2] but not CC CKR3.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CC CKR3", "entity_1_idx": [[44, 51]], "entity_1_idx_in_text_with_entity_marker": [48, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CC CKR1", "entity_2_idx": [[94, 101]], "entity_2_idx_in_text_with_entity_marker": [107, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s800_AIMed.d94.s800.p8", "text": "However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.", "text_with_entity_marker": "However, MIP-1 beta was also an agonist for [E1]CC CKR3[/E1] but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not [E2]CC CKR3[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CC CKR3", "entity_1_idx": [[44, 51]], "entity_1_idx_in_text_with_entity_marker": [48, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CC CKR3", "entity_2_idx": [[110, 117]], "entity_2_idx_in_text_with_entity_marker": [123, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s800_AIMed.d94.s800.p9", "text": "However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.", "text_with_entity_marker": "However, MIP-1 beta was also an agonist for CC CKR3 but not [E1]CC CKR1[/E1]; [E2]MCP-3[/E2] was an agonist for CC CKR1 but not CC CKR3.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CC CKR1", "entity_1_idx": [[60, 67]], "entity_1_idx_in_text_with_entity_marker": [64, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MCP-3", "entity_2_idx": [[69, 74]], "entity_2_idx_in_text_with_entity_marker": [82, 87], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s800_AIMed.d94.s800.p10", "text": "However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.", "text_with_entity_marker": "However, MIP-1 beta was also an agonist for CC CKR3 but not [E1]CC CKR1[/E1]; MCP-3 was an agonist for [E2]CC CKR1[/E2] but not CC CKR3.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CC CKR1", "entity_1_idx": [[60, 67]], "entity_1_idx_in_text_with_entity_marker": [64, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CC CKR1", "entity_2_idx": [[94, 101]], "entity_2_idx_in_text_with_entity_marker": [107, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s800_AIMed.d94.s800.p11", "text": "However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.", "text_with_entity_marker": "However, MIP-1 beta was also an agonist for CC CKR3 but not [E1]CC CKR1[/E1]; MCP-3 was an agonist for CC CKR1 but not [E2]CC CKR3[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CC CKR1", "entity_1_idx": [[60, 67]], "entity_1_idx_in_text_with_entity_marker": [64, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CC CKR3", "entity_2_idx": [[110, 117]], "entity_2_idx_in_text_with_entity_marker": [123, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s800_AIMed.d94.s800.p12", "text": "However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.", "text_with_entity_marker": "However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; [E1]MCP-3[/E1] was an agonist for [E2]CC CKR1[/E2] but not CC CKR3.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MCP-3", "entity_1_idx": [[69, 74]], "entity_1_idx_in_text_with_entity_marker": [73, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CC CKR1", "entity_2_idx": [[94, 101]], "entity_2_idx_in_text_with_entity_marker": [107, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s800_AIMed.d94.s800.p13", "text": "However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.", "text_with_entity_marker": "However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; [E1]MCP-3[/E1] was an agonist for CC CKR1 but not [E2]CC CKR3[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MCP-3", "entity_1_idx": [[69, 74]], "entity_1_idx_in_text_with_entity_marker": [73, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CC CKR3", "entity_2_idx": [[110, 117]], "entity_2_idx_in_text_with_entity_marker": [123, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d94.s800_AIMed.d94.s800.p14", "text": "However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3.", "text_with_entity_marker": "However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for [E1]CC CKR1[/E1] but not [E2]CC CKR3[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CC CKR1", "entity_1_idx": [[94, 101]], "entity_1_idx_in_text_with_entity_marker": [98, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CC CKR3", "entity_2_idx": [[110, 117]], "entity_2_idx_in_text_with_entity_marker": [123, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1665_AIMed.d196.s1665.p0", "text": "HOX11 interacts with protein phosphatases PP2A and PP1 and disrupts a G2/M cell-cycle checkpoint.", "text_with_entity_marker": "[E1]HOX11[/E1] interacts with protein phosphatases [E2]PP2A[/E2] and PP1 and disrupts a G2/M cell-cycle checkpoint.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "HOX11", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PP2A", "entity_2_idx": [[42, 46]], "entity_2_idx_in_text_with_entity_marker": [55, 59], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1665_AIMed.d196.s1665.p1", "text": "HOX11 interacts with protein phosphatases PP2A and PP1 and disrupts a G2/M cell-cycle checkpoint.", "text_with_entity_marker": "[E1]HOX11[/E1] interacts with protein phosphatases PP2A and [E2]PP1[/E2] and disrupts a G2/M cell-cycle checkpoint.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "HOX11", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PP1", "entity_2_idx": [[51, 54]], "entity_2_idx_in_text_with_entity_marker": [64, 67], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1665_AIMed.d196.s1665.p2", "text": "HOX11 interacts with protein phosphatases PP2A and PP1 and disrupts a G2/M cell-cycle checkpoint.", "text_with_entity_marker": "HOX11 interacts with protein phosphatases [E1]PP2A[/E1] and [E2]PP1[/E2] and disrupts a G2/M cell-cycle checkpoint.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PP2A", "entity_1_idx": [[42, 46]], "entity_1_idx_in_text_with_entity_marker": [46, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PP1", "entity_2_idx": [[51, 54]], "entity_2_idx_in_text_with_entity_marker": [64, 67], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1669_AIMed.d196.s1669.p0", "text": "We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.", "text_with_entity_marker": "We observed that the protein [E1]HOX11[/E1] interacted with protein [E2]serine-threonine phosphatase 2A[/E2] catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HOX11", "entity_1_idx": [[29, 34]], "entity_1_idx_in_text_with_entity_marker": [33, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "serine-threonine phosphatase 2A", "entity_2_idx": [[59, 90]], "entity_2_idx_in_text_with_entity_marker": [72, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1669_AIMed.d196.s1669.p1", "text": "We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.", "text_with_entity_marker": "We observed that the protein [E1]HOX11[/E1] interacted with protein [E2]serine-threonine phosphatase 2A catalytic subunit[/E2] (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "HOX11", "entity_1_idx": [[29, 34]], "entity_1_idx_in_text_with_entity_marker": [33, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "serine-threonine phosphatase 2A catalytic subunit", "entity_2_idx": [[59, 108]], "entity_2_idx_in_text_with_entity_marker": [72, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1669_AIMed.d196.s1669.p2", "text": "We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.", "text_with_entity_marker": "We observed that the protein [E1]HOX11[/E1] interacted with protein serine-threonine phosphatase 2A catalytic subunit ([E2]PP2AC[/E2]), as well as protein phosphatase 1 (PP1C) in mammalian cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "HOX11", "entity_1_idx": [[29, 34]], "entity_1_idx_in_text_with_entity_marker": [33, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PP2AC", "entity_2_idx": [[110, 115]], "entity_2_idx_in_text_with_entity_marker": [123, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1669_AIMed.d196.s1669.p3", "text": "We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.", "text_with_entity_marker": "We observed that the protein [E1]HOX11[/E1] interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as [E2]protein phosphatase 1[/E2] (PP1C) in mammalian cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "HOX11", "entity_1_idx": [[29, 34]], "entity_1_idx_in_text_with_entity_marker": [33, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "protein phosphatase 1", "entity_2_idx": [[129, 150]], "entity_2_idx_in_text_with_entity_marker": [142, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1669_AIMed.d196.s1669.p4", "text": "We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.", "text_with_entity_marker": "We observed that the protein [E1]HOX11[/E1] interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 ([E2]PP1C[/E2]) in mammalian cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "HOX11", "entity_1_idx": [[29, 34]], "entity_1_idx_in_text_with_entity_marker": [33, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PP1C", "entity_2_idx": [[152, 156]], "entity_2_idx_in_text_with_entity_marker": [165, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1669_AIMed.d196.s1669.p5", "text": "We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.", "text_with_entity_marker": "We observed that the protein HOX11 interacted with protein [E1-E2]serine-threonine phosphatase 2A[/E1] catalytic subunit[/E2] (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "serine-threonine phosphatase 2A", "entity_1_idx": [[59, 90]], "entity_1_idx_in_text_with_entity_marker": [66, 97], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "serine-threonine phosphatase 2A[/E1] catalytic subunit", "entity_2_idx": [[59, 108]], "entity_2_idx_in_text_with_entity_marker": [66, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1669_AIMed.d196.s1669.p6", "text": "We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.", "text_with_entity_marker": "We observed that the protein HOX11 interacted with protein [E1]serine-threonine phosphatase 2A[/E1] catalytic subunit ([E2]PP2AC[/E2]), as well as protein phosphatase 1 (PP1C) in mammalian cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "serine-threonine phosphatase 2A", "entity_1_idx": [[59, 90]], "entity_1_idx_in_text_with_entity_marker": [63, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PP2AC", "entity_2_idx": [[110, 115]], "entity_2_idx_in_text_with_entity_marker": [123, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1669_AIMed.d196.s1669.p7", "text": "We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.", "text_with_entity_marker": "We observed that the protein HOX11 interacted with protein [E1]serine-threonine phosphatase 2A[/E1] catalytic subunit (PP2AC), as well as [E2]protein phosphatase 1[/E2] (PP1C) in mammalian cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "serine-threonine phosphatase 2A", "entity_1_idx": [[59, 90]], "entity_1_idx_in_text_with_entity_marker": [63, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "protein phosphatase 1", "entity_2_idx": [[129, 150]], "entity_2_idx_in_text_with_entity_marker": [142, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1669_AIMed.d196.s1669.p8", "text": "We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.", "text_with_entity_marker": "We observed that the protein HOX11 interacted with protein [E1]serine-threonine phosphatase 2A[/E1] catalytic subunit (PP2AC), as well as protein phosphatase 1 ([E2]PP1C[/E2]) in mammalian cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "serine-threonine phosphatase 2A", "entity_1_idx": [[59, 90]], "entity_1_idx_in_text_with_entity_marker": [63, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PP1C", "entity_2_idx": [[152, 156]], "entity_2_idx_in_text_with_entity_marker": [165, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1669_AIMed.d196.s1669.p9", "text": "We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.", "text_with_entity_marker": "We observed that the protein HOX11 interacted with protein [E1]serine-threonine phosphatase 2A catalytic subunit[/E1] ([E2]PP2AC[/E2]), as well as protein phosphatase 1 (PP1C) in mammalian cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "serine-threonine phosphatase 2A catalytic subunit", "entity_1_idx": [[59, 108]], "entity_1_idx_in_text_with_entity_marker": [63, 112], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PP2AC", "entity_2_idx": [[110, 115]], "entity_2_idx_in_text_with_entity_marker": [123, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1669_AIMed.d196.s1669.p10", "text": "We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.", "text_with_entity_marker": "We observed that the protein HOX11 interacted with protein [E1]serine-threonine phosphatase 2A catalytic subunit[/E1] (PP2AC), as well as [E2]protein phosphatase 1[/E2] (PP1C) in mammalian cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "serine-threonine phosphatase 2A catalytic subunit", "entity_1_idx": [[59, 108]], "entity_1_idx_in_text_with_entity_marker": [63, 112], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "protein phosphatase 1", "entity_2_idx": [[129, 150]], "entity_2_idx_in_text_with_entity_marker": [142, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1669_AIMed.d196.s1669.p11", "text": "We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.", "text_with_entity_marker": "We observed that the protein HOX11 interacted with protein [E1]serine-threonine phosphatase 2A catalytic subunit[/E1] (PP2AC), as well as protein phosphatase 1 ([E2]PP1C[/E2]) in mammalian cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "serine-threonine phosphatase 2A catalytic subunit", "entity_1_idx": [[59, 108]], "entity_1_idx_in_text_with_entity_marker": [63, 112], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PP1C", "entity_2_idx": [[152, 156]], "entity_2_idx_in_text_with_entity_marker": [165, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1669_AIMed.d196.s1669.p12", "text": "We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.", "text_with_entity_marker": "We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit ([E1]PP2AC[/E1]), as well as [E2]protein phosphatase 1[/E2] (PP1C) in mammalian cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PP2AC", "entity_1_idx": [[110, 115]], "entity_1_idx_in_text_with_entity_marker": [114, 119], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "protein phosphatase 1", "entity_2_idx": [[129, 150]], "entity_2_idx_in_text_with_entity_marker": [142, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1669_AIMed.d196.s1669.p13", "text": "We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.", "text_with_entity_marker": "We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit ([E1]PP2AC[/E1]), as well as protein phosphatase 1 ([E2]PP1C[/E2]) in mammalian cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PP2AC", "entity_1_idx": [[110, 115]], "entity_1_idx_in_text_with_entity_marker": [114, 119], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PP1C", "entity_2_idx": [[152, 156]], "entity_2_idx_in_text_with_entity_marker": [165, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1669_AIMed.d196.s1669.p14", "text": "We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.", "text_with_entity_marker": "We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as [E1]protein phosphatase 1[/E1] ([E2]PP1C[/E2]) in mammalian cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "protein phosphatase 1", "entity_1_idx": [[129, 150]], "entity_1_idx_in_text_with_entity_marker": [133, 154], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PP1C", "entity_2_idx": [[152, 156]], "entity_2_idx_in_text_with_entity_marker": [165, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1673_AIMed.d196.s1673.p0", "text": "Thus HOX11 is a cellular oncogene that targets PP2A and PP1, both of which are targets for oncogenic viruses and chemical tumour promoters.", "text_with_entity_marker": "Thus [E1]HOX11[/E1] is a cellular oncogene that targets [E2]PP2A[/E2] and PP1, both of which are targets for oncogenic viruses and chemical tumour promoters.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "HOX11", "entity_1_idx": [[5, 10]], "entity_1_idx_in_text_with_entity_marker": [9, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PP2A", "entity_2_idx": [[47, 51]], "entity_2_idx_in_text_with_entity_marker": [60, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1673_AIMed.d196.s1673.p1", "text": "Thus HOX11 is a cellular oncogene that targets PP2A and PP1, both of which are targets for oncogenic viruses and chemical tumour promoters.", "text_with_entity_marker": "Thus [E1]HOX11[/E1] is a cellular oncogene that targets PP2A and [E2]PP1[/E2], both of which are targets for oncogenic viruses and chemical tumour promoters.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "HOX11", "entity_1_idx": [[5, 10]], "entity_1_idx_in_text_with_entity_marker": [9, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PP1", "entity_2_idx": [[56, 59]], "entity_2_idx_in_text_with_entity_marker": [69, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1673_AIMed.d196.s1673.p2", "text": "Thus HOX11 is a cellular oncogene that targets PP2A and PP1, both of which are targets for oncogenic viruses and chemical tumour promoters.", "text_with_entity_marker": "Thus HOX11 is a cellular oncogene that targets [E1]PP2A[/E1] and [E2]PP1[/E2], both of which are targets for oncogenic viruses and chemical tumour promoters.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PP2A", "entity_1_idx": [[47, 51]], "entity_1_idx_in_text_with_entity_marker": [51, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PP1", "entity_2_idx": [[56, 59]], "entity_2_idx_in_text_with_entity_marker": [69, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s234_AIMed.d28.s234.p0", "text": "We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].", "text_with_entity_marker": "We have identified a new TNF-related ligand, designated human [E1-E2]GITR[/E1] ligand[/E2] (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GITR", "entity_1_idx": [[62, 66]], "entity_1_idx_in_text_with_entity_marker": [69, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GITR[/E1] ligand", "entity_2_idx": [[62, 73]], "entity_2_idx_in_text_with_entity_marker": [69, 85], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s234_AIMed.d28.s234.p1", "text": "We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].", "text_with_entity_marker": "We have identified a new TNF-related ligand, designated human [E1]GITR[/E1] ligand ([E2]hGITRL[/E2]), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GITR", "entity_1_idx": [[62, 66]], "entity_1_idx_in_text_with_entity_marker": [66, 70], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGITRL", "entity_2_idx": [[75, 81]], "entity_2_idx_in_text_with_entity_marker": [88, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s234_AIMed.d28.s234.p2", "text": "We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].", "text_with_entity_marker": "We have identified a new TNF-related ligand, designated human [E1]GITR[/E1] ligand (hGITRL), and its human receptor ([E2]hGITR[/E2]), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GITR", "entity_1_idx": [[62, 66]], "entity_1_idx_in_text_with_entity_marker": [66, 70], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGITR", "entity_2_idx": [[108, 113]], "entity_2_idx_in_text_with_entity_marker": [121, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s234_AIMed.d28.s234.p3", "text": "We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].", "text_with_entity_marker": "We have identified a new TNF-related ligand, designated human [E1]GITR[/E1] ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related ([E2]mGITR[/E2]) protein [4].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GITR", "entity_1_idx": [[62, 66]], "entity_1_idx_in_text_with_entity_marker": [66, 70], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "mGITR", "entity_2_idx": [[199, 204]], "entity_2_idx_in_text_with_entity_marker": [212, 217], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s234_AIMed.d28.s234.p4", "text": "We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].", "text_with_entity_marker": "We have identified a new TNF-related ligand, designated human [E1]GITR[/E1] ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine [E2]glucocorticoid-induced TNFR-related (mGITR) protein[/E2] [4].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GITR", "entity_1_idx": [[62, 66]], "entity_1_idx_in_text_with_entity_marker": [66, 70], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "glucocorticoid-induced TNFR-related (mGITR) protein", "entity_2_idx": [[162, 213]], "entity_2_idx_in_text_with_entity_marker": [175, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s234_AIMed.d28.s234.p5", "text": "We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].", "text_with_entity_marker": "We have identified a new TNF-related ligand, designated human [E1]GITR ligand[/E1] ([E2]hGITRL[/E2]), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GITR ligand", "entity_1_idx": [[62, 73]], "entity_1_idx_in_text_with_entity_marker": [66, 77], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGITRL", "entity_2_idx": [[75, 81]], "entity_2_idx_in_text_with_entity_marker": [88, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s234_AIMed.d28.s234.p6", "text": "We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].", "text_with_entity_marker": "We have identified a new TNF-related ligand, designated human [E1]GITR ligand[/E1] (hGITRL), and its human receptor ([E2]hGITR[/E2]), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GITR ligand", "entity_1_idx": [[62, 73]], "entity_1_idx_in_text_with_entity_marker": [66, 77], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGITR", "entity_2_idx": [[108, 113]], "entity_2_idx_in_text_with_entity_marker": [121, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s234_AIMed.d28.s234.p7", "text": "We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].", "text_with_entity_marker": "We have identified a new TNF-related ligand, designated human [E1]GITR ligand[/E1] (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related ([E2]mGITR[/E2]) protein [4].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GITR ligand", "entity_1_idx": [[62, 73]], "entity_1_idx_in_text_with_entity_marker": [66, 77], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "mGITR", "entity_2_idx": [[199, 204]], "entity_2_idx_in_text_with_entity_marker": [212, 217], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s234_AIMed.d28.s234.p8", "text": "We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].", "text_with_entity_marker": "We have identified a new TNF-related ligand, designated human [E1]GITR ligand[/E1] (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine [E2]glucocorticoid-induced TNFR-related (mGITR) protein[/E2] [4].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GITR ligand", "entity_1_idx": [[62, 73]], "entity_1_idx_in_text_with_entity_marker": [66, 77], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "glucocorticoid-induced TNFR-related (mGITR) protein", "entity_2_idx": [[162, 213]], "entity_2_idx_in_text_with_entity_marker": [175, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s234_AIMed.d28.s234.p9", "text": "We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].", "text_with_entity_marker": "We have identified a new TNF-related ligand, designated human GITR ligand ([E1]hGITRL[/E1]), and its human receptor ([E2]hGITR[/E2]), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "hGITRL", "entity_1_idx": [[75, 81]], "entity_1_idx_in_text_with_entity_marker": [79, 85], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGITR", "entity_2_idx": [[108, 113]], "entity_2_idx_in_text_with_entity_marker": [121, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s234_AIMed.d28.s234.p10", "text": "We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].", "text_with_entity_marker": "We have identified a new TNF-related ligand, designated human GITR ligand ([E1]hGITRL[/E1]), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related ([E2]mGITR[/E2]) protein [4].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGITRL", "entity_1_idx": [[75, 81]], "entity_1_idx_in_text_with_entity_marker": [79, 85], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "mGITR", "entity_2_idx": [[199, 204]], "entity_2_idx_in_text_with_entity_marker": [212, 217], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s234_AIMed.d28.s234.p11", "text": "We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].", "text_with_entity_marker": "We have identified a new TNF-related ligand, designated human GITR ligand ([E1]hGITRL[/E1]), and its human receptor (hGITR), an ortholog of the recently discovered murine [E2]glucocorticoid-induced TNFR-related (mGITR) protein[/E2] [4].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGITRL", "entity_1_idx": [[75, 81]], "entity_1_idx_in_text_with_entity_marker": [79, 85], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "glucocorticoid-induced TNFR-related (mGITR) protein", "entity_2_idx": [[162, 213]], "entity_2_idx_in_text_with_entity_marker": [175, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s234_AIMed.d28.s234.p12", "text": "We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].", "text_with_entity_marker": "We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor ([E1]hGITR[/E1]), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related ([E2]mGITR[/E2]) protein [4].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGITR", "entity_1_idx": [[108, 113]], "entity_1_idx_in_text_with_entity_marker": [112, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "mGITR", "entity_2_idx": [[199, 204]], "entity_2_idx_in_text_with_entity_marker": [212, 217], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s234_AIMed.d28.s234.p13", "text": "We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].", "text_with_entity_marker": "We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor ([E1]hGITR[/E1]), an ortholog of the recently discovered murine [E2]glucocorticoid-induced TNFR-related (mGITR) protein[/E2] [4].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGITR", "entity_1_idx": [[108, 113]], "entity_1_idx_in_text_with_entity_marker": [112, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "glucocorticoid-induced TNFR-related (mGITR) protein", "entity_2_idx": [[162, 213]], "entity_2_idx_in_text_with_entity_marker": [175, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s234_AIMed.d28.s234.p14", "text": "We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].", "text_with_entity_marker": "We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine [E1]glucocorticoid-induced TNFR-related (mGITR) protein[/E1][E2]mGITR[/E2]) protein [4].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "glucocorticoid-induced TNFR-related (mGITR) protein", "entity_1_idx": [[162, 213]], "entity_1_idx_in_text_with_entity_marker": [166, 217], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "mGITR", "entity_2_idx": [[199, 204]], "entity_2_idx_in_text_with_entity_marker": [226, 231], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s235_AIMed.d28.s235.p0", "text": "The hGITRL gene mapped to chromosome 1q23, near the gene for the TNF homolog Fas/CD95 ligand [5].", "text_with_entity_marker": "The [E1]hGITRL[/E1] gene mapped to chromosome 1q23, near the gene for the TNF homolog [E2]Fas[/E2]/CD95 ligand [5].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGITRL", "entity_1_idx": [[4, 10]], "entity_1_idx_in_text_with_entity_marker": [8, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[77, 80]], "entity_2_idx_in_text_with_entity_marker": [90, 93], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s235_AIMed.d28.s235.p1", "text": "The hGITRL gene mapped to chromosome 1q23, near the gene for the TNF homolog Fas/CD95 ligand [5].", "text_with_entity_marker": "The [E1]hGITRL[/E1] gene mapped to chromosome 1q23, near the gene for the TNF homolog Fas/[E2]CD95 ligand[/E2] [5].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGITRL", "entity_1_idx": [[4, 10]], "entity_1_idx_in_text_with_entity_marker": [8, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD95 ligand", "entity_2_idx": [[81, 92]], "entity_2_idx_in_text_with_entity_marker": [94, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s235_AIMed.d28.s235.p2", "text": "The hGITRL gene mapped to chromosome 1q23, near the gene for the TNF homolog Fas/CD95 ligand [5].", "text_with_entity_marker": "The hGITRL gene mapped to chromosome 1q23, near the gene for the TNF homolog [E1]Fas[/E1]/[E2]CD95 ligand[/E2] [5].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[77, 80]], "entity_1_idx_in_text_with_entity_marker": [81, 84], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD95 ligand", "entity_2_idx": [[81, 92]], "entity_2_idx_in_text_with_entity_marker": [94, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s237_AIMed.d28.s237.p0", "text": "We found hGITRL mRNA in several peripheral tissues, and detected hGITRL protein on cultured vascular endothelial cells.", "text_with_entity_marker": "We found [E1]hGITRL[/E1] mRNA in several peripheral tissues, and detected [E2]hGITRL[/E2] protein on cultured vascular endothelial cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGITRL", "entity_1_idx": [[9, 15]], "entity_1_idx_in_text_with_entity_marker": [13, 19], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGITRL", "entity_2_idx": [[65, 71]], "entity_2_idx_in_text_with_entity_marker": [78, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s238_AIMed.d28.s238.p0", "text": "The levels of hGITR mRNA in tissues were generally low; in peripheral blood T cells, however, antigen-receptor stimulation led to a substantial induction of hGITR transcripts.", "text_with_entity_marker": "The levels of [E1]hGITR[/E1] mRNA in tissues were generally low; in peripheral blood T cells, however, antigen-receptor stimulation led to a substantial induction of [E2]hGITR[/E2] transcripts.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGITR", "entity_1_idx": [[14, 19]], "entity_1_idx_in_text_with_entity_marker": [18, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGITR", "entity_2_idx": [[157, 162]], "entity_2_idx_in_text_with_entity_marker": [170, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p0", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of [E1]hGITRL[/E1] and [E2]hGITR[/E2] in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGITRL", "entity_1_idx": [[18, 24]], "entity_1_idx_in_text_with_entity_marker": [22, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGITR", "entity_2_idx": [[29, 34]], "entity_2_idx_in_text_with_entity_marker": [42, 47], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p1", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of [E1]hGITRL[/E1] and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor [E2]NF-kappaB[/E2], via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGITRL", "entity_1_idx": [[18, 24]], "entity_1_idx_in_text_with_entity_marker": [22, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappaB", "entity_2_idx": [[115, 124]], "entity_2_idx_in_text_with_entity_marker": [128, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p2", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of [E1]hGITRL[/E1] and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve [E2]TNFR-associated factor 2[/E2] (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGITRL", "entity_1_idx": [[18, 24]], "entity_1_idx_in_text_with_entity_marker": [22, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFR-associated factor 2", "entity_2_idx": [[165, 189]], "entity_2_idx_in_text_with_entity_marker": [178, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p3", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of [E1]hGITRL[/E1] and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 ([E2]TRAF2[/E2]) [7] and NF-kappaB-inducing kinase (NIK) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGITRL", "entity_1_idx": [[18, 24]], "entity_1_idx_in_text_with_entity_marker": [22, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TRAF2", "entity_2_idx": [[191, 196]], "entity_2_idx_in_text_with_entity_marker": [204, 209], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p4", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of [E1]hGITRL[/E1] and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and [E2]NF-kappaB[/E2]-inducing kinase (NIK) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGITRL", "entity_1_idx": [[18, 24]], "entity_1_idx_in_text_with_entity_marker": [22, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappaB", "entity_2_idx": [[206, 215]], "entity_2_idx_in_text_with_entity_marker": [219, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p5", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of [E1]hGITRL[/E1] and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and [E2]NF-kappaB-inducing kinase[/E2] (NIK) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGITRL", "entity_1_idx": [[18, 24]], "entity_1_idx_in_text_with_entity_marker": [22, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappaB-inducing kinase", "entity_2_idx": [[206, 231]], "entity_2_idx_in_text_with_entity_marker": [219, 244], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p6", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of [E1]hGITRL[/E1] and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase ([E2]NIK[/E2]) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGITRL", "entity_1_idx": [[18, 24]], "entity_1_idx_in_text_with_entity_marker": [22, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NIK", "entity_2_idx": [[233, 236]], "entity_2_idx_in_text_with_entity_marker": [246, 249], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p7", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of hGITRL and [E1]hGITR[/E1] in embryonic kidney 293 cells activated the anti-apoptotic transcription factor [E2]NF-kappaB[/E2], via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGITR", "entity_1_idx": [[29, 34]], "entity_1_idx_in_text_with_entity_marker": [33, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappaB", "entity_2_idx": [[115, 124]], "entity_2_idx_in_text_with_entity_marker": [128, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p8", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of hGITRL and [E1]hGITR[/E1] in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve [E2]TNFR-associated factor 2[/E2] (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGITR", "entity_1_idx": [[29, 34]], "entity_1_idx_in_text_with_entity_marker": [33, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFR-associated factor 2", "entity_2_idx": [[165, 189]], "entity_2_idx_in_text_with_entity_marker": [178, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p9", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of hGITRL and [E1]hGITR[/E1] in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 ([E2]TRAF2[/E2]) [7] and NF-kappaB-inducing kinase (NIK) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGITR", "entity_1_idx": [[29, 34]], "entity_1_idx_in_text_with_entity_marker": [33, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TRAF2", "entity_2_idx": [[191, 196]], "entity_2_idx_in_text_with_entity_marker": [204, 209], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p10", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of hGITRL and [E1]hGITR[/E1] in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and [E2]NF-kappaB[/E2]-inducing kinase (NIK) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGITR", "entity_1_idx": [[29, 34]], "entity_1_idx_in_text_with_entity_marker": [33, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappaB", "entity_2_idx": [[206, 215]], "entity_2_idx_in_text_with_entity_marker": [219, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p11", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of hGITRL and [E1]hGITR[/E1] in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and [E2]NF-kappaB-inducing kinase[/E2] (NIK) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGITR", "entity_1_idx": [[29, 34]], "entity_1_idx_in_text_with_entity_marker": [33, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappaB-inducing kinase", "entity_2_idx": [[206, 231]], "entity_2_idx_in_text_with_entity_marker": [219, 244], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p12", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of hGITRL and [E1]hGITR[/E1] in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase ([E2]NIK[/E2]) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGITR", "entity_1_idx": [[29, 34]], "entity_1_idx_in_text_with_entity_marker": [33, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NIK", "entity_2_idx": [[233, 236]], "entity_2_idx_in_text_with_entity_marker": [246, 249], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p13", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor [E1]NF-kappaB[/E1], via a pathway that appeared to involve [E2]TNFR-associated factor 2[/E2] (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NF-kappaB", "entity_1_idx": [[115, 124]], "entity_1_idx_in_text_with_entity_marker": [119, 128], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFR-associated factor 2", "entity_2_idx": [[165, 189]], "entity_2_idx_in_text_with_entity_marker": [178, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p14", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor [E1]NF-kappaB[/E1], via a pathway that appeared to involve TNFR-associated factor 2 ([E2]TRAF2[/E2]) [7] and NF-kappaB-inducing kinase (NIK) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NF-kappaB", "entity_1_idx": [[115, 124]], "entity_1_idx_in_text_with_entity_marker": [119, 128], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TRAF2", "entity_2_idx": [[191, 196]], "entity_2_idx_in_text_with_entity_marker": [204, 209], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p15", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor [E1]NF-kappaB[/E1], via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and [E2]NF-kappaB[/E2]-inducing kinase (NIK) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NF-kappaB", "entity_1_idx": [[115, 124]], "entity_1_idx_in_text_with_entity_marker": [119, 128], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappaB", "entity_2_idx": [[206, 215]], "entity_2_idx_in_text_with_entity_marker": [219, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p16", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor [E1]NF-kappaB[/E1], via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and [E2]NF-kappaB-inducing kinase[/E2] (NIK) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NF-kappaB", "entity_1_idx": [[115, 124]], "entity_1_idx_in_text_with_entity_marker": [119, 128], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappaB-inducing kinase", "entity_2_idx": [[206, 231]], "entity_2_idx_in_text_with_entity_marker": [219, 244], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p17", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor [E1]NF-kappaB[/E1], via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase ([E2]NIK[/E2]) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NF-kappaB", "entity_1_idx": [[115, 124]], "entity_1_idx_in_text_with_entity_marker": [119, 128], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NIK", "entity_2_idx": [[233, 236]], "entity_2_idx_in_text_with_entity_marker": [246, 249], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p18", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve [E1]TNFR-associated factor 2[/E1] ([E2]TRAF2[/E2]) [7] and NF-kappaB-inducing kinase (NIK) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNFR-associated factor 2", "entity_1_idx": [[165, 189]], "entity_1_idx_in_text_with_entity_marker": [169, 193], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TRAF2", "entity_2_idx": [[191, 196]], "entity_2_idx_in_text_with_entity_marker": [204, 209], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p19", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve [E1]TNFR-associated factor 2[/E1] (TRAF2) [7] and [E2]NF-kappaB[/E2]-inducing kinase (NIK) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNFR-associated factor 2", "entity_1_idx": [[165, 189]], "entity_1_idx_in_text_with_entity_marker": [169, 193], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappaB", "entity_2_idx": [[206, 215]], "entity_2_idx_in_text_with_entity_marker": [219, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p20", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve [E1]TNFR-associated factor 2[/E1] (TRAF2) [7] and [E2]NF-kappaB-inducing kinase[/E2] (NIK) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNFR-associated factor 2", "entity_1_idx": [[165, 189]], "entity_1_idx_in_text_with_entity_marker": [169, 193], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappaB-inducing kinase", "entity_2_idx": [[206, 231]], "entity_2_idx_in_text_with_entity_marker": [219, 244], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p21", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve [E1]TNFR-associated factor 2[/E1] (TRAF2) [7] and NF-kappaB-inducing kinase ([E2]NIK[/E2]) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNFR-associated factor 2", "entity_1_idx": [[165, 189]], "entity_1_idx_in_text_with_entity_marker": [169, 193], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NIK", "entity_2_idx": [[233, 236]], "entity_2_idx_in_text_with_entity_marker": [246, 249], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p22", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 ([E1]TRAF2[/E1]) [7] and [E2]NF-kappaB[/E2]-inducing kinase (NIK) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRAF2", "entity_1_idx": [[191, 196]], "entity_1_idx_in_text_with_entity_marker": [195, 200], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappaB", "entity_2_idx": [[206, 215]], "entity_2_idx_in_text_with_entity_marker": [219, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p23", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 ([E1]TRAF2[/E1]) [7] and [E2]NF-kappaB-inducing kinase[/E2] (NIK) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRAF2", "entity_1_idx": [[191, 196]], "entity_1_idx_in_text_with_entity_marker": [195, 200], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappaB-inducing kinase", "entity_2_idx": [[206, 231]], "entity_2_idx_in_text_with_entity_marker": [219, 244], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p24", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 ([E1]TRAF2[/E1]) [7] and NF-kappaB-inducing kinase ([E2]NIK[/E2]) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRAF2", "entity_1_idx": [[191, 196]], "entity_1_idx_in_text_with_entity_marker": [195, 200], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NIK", "entity_2_idx": [[233, 236]], "entity_2_idx_in_text_with_entity_marker": [246, 249], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p25", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and [E1-E2]NF-kappaB[/E1]-inducing kinase[/E2] (NIK) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NF-kappaB", "entity_1_idx": [[206, 215]], "entity_1_idx_in_text_with_entity_marker": [213, 222], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappaB[/E1]-inducing kinase", "entity_2_idx": [[206, 231]], "entity_2_idx_in_text_with_entity_marker": [213, 243], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p26", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and [E1]NF-kappaB[/E1]-inducing kinase ([E2]NIK[/E2]) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NF-kappaB", "entity_1_idx": [[206, 215]], "entity_1_idx_in_text_with_entity_marker": [210, 219], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NIK", "entity_2_idx": [[233, 236]], "entity_2_idx_in_text_with_entity_marker": [246, 249], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s239_AIMed.d28.s239.p27", "text": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].", "text_with_entity_marker": "Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and [E1]NF-kappaB-inducing kinase[/E1] ([E2]NIK[/E2]) [8].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NF-kappaB-inducing kinase", "entity_1_idx": [[206, 231]], "entity_1_idx_in_text_with_entity_marker": [210, 235], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NIK", "entity_2_idx": [[233, 236]], "entity_2_idx_in_text_with_entity_marker": [246, 249], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s240_AIMed.d28.s240.p0", "text": "Cotransfection of hGITRL and hGITR in Jurkat T leukemia cells inhibited antigen-receptor-induced cell death.", "text_with_entity_marker": "Cotransfection of [E1]hGITRL[/E1] and [E2]hGITR[/E2] in Jurkat T leukemia cells inhibited antigen-receptor-induced cell death.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGITRL", "entity_1_idx": [[18, 24]], "entity_1_idx_in_text_with_entity_marker": [22, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGITR", "entity_2_idx": [[29, 34]], "entity_2_idx_in_text_with_entity_marker": [42, 47], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d28.s241_AIMed.d28.s241.p0", "text": "Thus, hGITRL and hGITR may modulate T lymphocyte survival in peripheral tissues.", "text_with_entity_marker": "Thus, [E1]hGITRL[/E1] and [E2]hGITR[/E2] may modulate T lymphocyte survival in peripheral tissues.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGITRL", "entity_1_idx": [[6, 12]], "entity_1_idx_in_text_with_entity_marker": [10, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGITR", "entity_2_idx": [[17, 22]], "entity_2_idx_in_text_with_entity_marker": [30, 35], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1945_AIMed.d224.s1945.p0", "text": "TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide.", "text_with_entity_marker": "[E1]TAP[/E1]- and [E2]tapasin[/E2]-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAP", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "tapasin", "entity_2_idx": [[9, 16]], "entity_2_idx_in_text_with_entity_marker": [22, 29], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1945_AIMed.d224.s1945.p1", "text": "TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide.", "text_with_entity_marker": "[E1]TAP[/E1]- and tapasin-dependent [E2]HLA-E[/E2] surface expression correlates with the binding of an MHC class I leader peptide.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAP", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HLA-E", "entity_2_idx": [[27, 32]], "entity_2_idx_in_text_with_entity_marker": [40, 45], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1945_AIMed.d224.s1945.p2", "text": "TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide.", "text_with_entity_marker": "TAP- and [E1]tapasin[/E1]-dependent [E2]HLA-E[/E2] surface expression correlates with the binding of an MHC class I leader peptide.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tapasin", "entity_1_idx": [[9, 16]], "entity_1_idx_in_text_with_entity_marker": [13, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HLA-E", "entity_2_idx": [[27, 32]], "entity_2_idx_in_text_with_entity_marker": [40, 45], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1949_AIMed.d224.s1949.p0", "text": "We demonstrate that HLA-E surface expression is correlated with the presence of MHC class I molecules which provide suitable leader sequence peptides capable of binding to HLA-E.", "text_with_entity_marker": "We demonstrate that [E1]HLA-E[/E1] surface expression is correlated with the presence of MHC class I molecules which provide suitable leader sequence peptides capable of binding to [E2]HLA-E[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HLA-E", "entity_1_idx": [[20, 25]], "entity_1_idx_in_text_with_entity_marker": [24, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HLA-E", "entity_2_idx": [[172, 177]], "entity_2_idx_in_text_with_entity_marker": [185, 190], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1950_AIMed.d224.s1950.p0", "text": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.", "text_with_entity_marker": "Further studies on the interaction of [E1]HLA-E[/E1] with molecules in the endoplasmic reticulum revealed that [E2]HLA-E[/E2] associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HLA-E", "entity_1_idx": [[38, 43]], "entity_1_idx_in_text_with_entity_marker": [42, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HLA-E", "entity_2_idx": [[102, 107]], "entity_2_idx_in_text_with_entity_marker": [115, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1950_AIMed.d224.s1950.p1", "text": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.", "text_with_entity_marker": "Further studies on the interaction of [E1]HLA-E[/E1] with molecules in the endoplasmic reticulum revealed that HLA-E associates with the [E2]transporter associated with antigen processing[/E2] (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HLA-E", "entity_1_idx": [[38, 43]], "entity_1_idx_in_text_with_entity_marker": [42, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "transporter associated with antigen processing", "entity_2_idx": [[128, 174]], "entity_2_idx_in_text_with_entity_marker": [141, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1950_AIMed.d224.s1950.p2", "text": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.", "text_with_entity_marker": "Further studies on the interaction of [E1]HLA-E[/E1] with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing ([E2]TAP[/E2]) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HLA-E", "entity_1_idx": [[38, 43]], "entity_1_idx_in_text_with_entity_marker": [42, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAP", "entity_2_idx": [[176, 179]], "entity_2_idx_in_text_with_entity_marker": [189, 192], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1950_AIMed.d224.s1950.p3", "text": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.", "text_with_entity_marker": "Further studies on the interaction of [E1]HLA-E[/E1] with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and [E2]calreticulin[/E2], and that HLA-E expression is TAP-dependent and tapasin-dependent.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HLA-E", "entity_1_idx": [[38, 43]], "entity_1_idx_in_text_with_entity_marker": [42, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calreticulin", "entity_2_idx": [[185, 197]], "entity_2_idx_in_text_with_entity_marker": [198, 210], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1950_AIMed.d224.s1950.p4", "text": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.", "text_with_entity_marker": "Further studies on the interaction of [E1]HLA-E[/E1] with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that [E2]HLA-E[/E2] expression is TAP-dependent and tapasin-dependent.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HLA-E", "entity_1_idx": [[38, 43]], "entity_1_idx_in_text_with_entity_marker": [42, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HLA-E", "entity_2_idx": [[208, 213]], "entity_2_idx_in_text_with_entity_marker": [221, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1950_AIMed.d224.s1950.p5", "text": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.", "text_with_entity_marker": "Further studies on the interaction of [E1]HLA-E[/E1] with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is [E2]TAP[/E2]-dependent and tapasin-dependent.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HLA-E", "entity_1_idx": [[38, 43]], "entity_1_idx_in_text_with_entity_marker": [42, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAP", "entity_2_idx": [[228, 231]], "entity_2_idx_in_text_with_entity_marker": [241, 244], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1950_AIMed.d224.s1950.p6", "text": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.", "text_with_entity_marker": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that [E1]HLA-E[/E1] associates with the [E2]transporter associated with antigen processing[/E2] (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "HLA-E", "entity_1_idx": [[102, 107]], "entity_1_idx_in_text_with_entity_marker": [106, 111], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "transporter associated with antigen processing", "entity_2_idx": [[128, 174]], "entity_2_idx_in_text_with_entity_marker": [141, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1950_AIMed.d224.s1950.p7", "text": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.", "text_with_entity_marker": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that [E1]HLA-E[/E1] associates with the transporter associated with antigen processing ([E2]TAP[/E2]) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "HLA-E", "entity_1_idx": [[102, 107]], "entity_1_idx_in_text_with_entity_marker": [106, 111], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAP", "entity_2_idx": [[176, 179]], "entity_2_idx_in_text_with_entity_marker": [189, 192], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1950_AIMed.d224.s1950.p8", "text": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.", "text_with_entity_marker": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that [E1]HLA-E[/E1] associates with the transporter associated with antigen processing (TAP) and [E2]calreticulin[/E2], and that HLA-E expression is TAP-dependent and tapasin-dependent.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "HLA-E", "entity_1_idx": [[102, 107]], "entity_1_idx_in_text_with_entity_marker": [106, 111], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calreticulin", "entity_2_idx": [[185, 197]], "entity_2_idx_in_text_with_entity_marker": [198, 210], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1950_AIMed.d224.s1950.p9", "text": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.", "text_with_entity_marker": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that [E1]HLA-E[/E1] associates with the transporter associated with antigen processing (TAP) and calreticulin, and that [E2]HLA-E[/E2] expression is TAP-dependent and tapasin-dependent.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HLA-E", "entity_1_idx": [[102, 107]], "entity_1_idx_in_text_with_entity_marker": [106, 111], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HLA-E", "entity_2_idx": [[208, 213]], "entity_2_idx_in_text_with_entity_marker": [221, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1950_AIMed.d224.s1950.p10", "text": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.", "text_with_entity_marker": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that [E1]HLA-E[/E1] associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is [E2]TAP[/E2]-dependent and tapasin-dependent.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HLA-E", "entity_1_idx": [[102, 107]], "entity_1_idx_in_text_with_entity_marker": [106, 111], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAP", "entity_2_idx": [[228, 231]], "entity_2_idx_in_text_with_entity_marker": [241, 244], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1950_AIMed.d224.s1950.p11", "text": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.", "text_with_entity_marker": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the [E1]transporter associated with antigen processing[/E1] ([E2]TAP[/E2]) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "transporter associated with antigen processing", "entity_1_idx": [[128, 174]], "entity_1_idx_in_text_with_entity_marker": [132, 178], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAP", "entity_2_idx": [[176, 179]], "entity_2_idx_in_text_with_entity_marker": [189, 192], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1950_AIMed.d224.s1950.p12", "text": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.", "text_with_entity_marker": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the [E1]transporter associated with antigen processing[/E1] (TAP) and [E2]calreticulin[/E2], and that HLA-E expression is TAP-dependent and tapasin-dependent.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "transporter associated with antigen processing", "entity_1_idx": [[128, 174]], "entity_1_idx_in_text_with_entity_marker": [132, 178], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calreticulin", "entity_2_idx": [[185, 197]], "entity_2_idx_in_text_with_entity_marker": [198, 210], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1950_AIMed.d224.s1950.p13", "text": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.", "text_with_entity_marker": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the [E1]transporter associated with antigen processing[/E1] (TAP) and calreticulin, and that [E2]HLA-E[/E2] expression is TAP-dependent and tapasin-dependent.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "transporter associated with antigen processing", "entity_1_idx": [[128, 174]], "entity_1_idx_in_text_with_entity_marker": [132, 178], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HLA-E", "entity_2_idx": [[208, 213]], "entity_2_idx_in_text_with_entity_marker": [221, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1950_AIMed.d224.s1950.p14", "text": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.", "text_with_entity_marker": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the [E1]transporter associated with antigen processing[/E1] (TAP) and calreticulin, and that HLA-E expression is [E2]TAP[/E2]-dependent and tapasin-dependent.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "transporter associated with antigen processing", "entity_1_idx": [[128, 174]], "entity_1_idx_in_text_with_entity_marker": [132, 178], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAP", "entity_2_idx": [[228, 231]], "entity_2_idx_in_text_with_entity_marker": [241, 244], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1950_AIMed.d224.s1950.p15", "text": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.", "text_with_entity_marker": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing ([E1]TAP[/E1]) and [E2]calreticulin[/E2], and that HLA-E expression is TAP-dependent and tapasin-dependent.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAP", "entity_1_idx": [[176, 179]], "entity_1_idx_in_text_with_entity_marker": [180, 183], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calreticulin", "entity_2_idx": [[185, 197]], "entity_2_idx_in_text_with_entity_marker": [198, 210], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1950_AIMed.d224.s1950.p16", "text": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.", "text_with_entity_marker": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing ([E1]TAP[/E1]) and calreticulin, and that [E2]HLA-E[/E2] expression is TAP-dependent and tapasin-dependent.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAP", "entity_1_idx": [[176, 179]], "entity_1_idx_in_text_with_entity_marker": [180, 183], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HLA-E", "entity_2_idx": [[208, 213]], "entity_2_idx_in_text_with_entity_marker": [221, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1950_AIMed.d224.s1950.p17", "text": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.", "text_with_entity_marker": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing ([E1]TAP[/E1]) and calreticulin, and that HLA-E expression is [E2]TAP[/E2]-dependent and tapasin-dependent.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAP", "entity_1_idx": [[176, 179]], "entity_1_idx_in_text_with_entity_marker": [180, 183], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAP", "entity_2_idx": [[228, 231]], "entity_2_idx_in_text_with_entity_marker": [241, 244], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1950_AIMed.d224.s1950.p18", "text": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.", "text_with_entity_marker": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and [E1]calreticulin[/E1], and that [E2]HLA-E[/E2] expression is TAP-dependent and tapasin-dependent.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "calreticulin", "entity_1_idx": [[185, 197]], "entity_1_idx_in_text_with_entity_marker": [189, 201], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HLA-E", "entity_2_idx": [[208, 213]], "entity_2_idx_in_text_with_entity_marker": [221, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1950_AIMed.d224.s1950.p19", "text": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.", "text_with_entity_marker": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and [E1]calreticulin[/E1], and that HLA-E expression is [E2]TAP[/E2]-dependent and tapasin-dependent.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "calreticulin", "entity_1_idx": [[185, 197]], "entity_1_idx_in_text_with_entity_marker": [189, 201], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAP", "entity_2_idx": [[228, 231]], "entity_2_idx_in_text_with_entity_marker": [241, 244], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1950_AIMed.d224.s1950.p20", "text": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that HLA-E expression is TAP-dependent and tapasin-dependent.", "text_with_entity_marker": "Further studies on the interaction of HLA-E with molecules in the endoplasmic reticulum revealed that HLA-E associates with the transporter associated with antigen processing (TAP) and calreticulin, and that [E1]HLA-E[/E1] expression is [E2]TAP[/E2]-dependent and tapasin-dependent.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HLA-E", "entity_1_idx": [[208, 213]], "entity_1_idx_in_text_with_entity_marker": [212, 217], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAP", "entity_2_idx": [[228, 231]], "entity_2_idx_in_text_with_entity_marker": [241, 244], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1951_AIMed.d224.s1951.p0", "text": "In addition, HLA-E dissociates from TAP upon binding of MHC class I leader sequence peptides.", "text_with_entity_marker": "In addition, [E1]HLA-E[/E1] dissociates from [E2]TAP[/E2] upon binding of MHC class I leader sequence peptides.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "HLA-E", "entity_1_idx": [[13, 18]], "entity_1_idx_in_text_with_entity_marker": [17, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAP", "entity_2_idx": [[36, 39]], "entity_2_idx_in_text_with_entity_marker": [49, 52], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1953_AIMed.d224.s1953.p0", "text": "The correlation between HLA-E and MHC class I surface expression might be relevant to the function of HLA-E.", "text_with_entity_marker": "The correlation between [E1]HLA-E[/E1] and MHC class I surface expression might be relevant to the function of [E2]HLA-E[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HLA-E", "entity_1_idx": [[24, 29]], "entity_1_idx_in_text_with_entity_marker": [28, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HLA-E", "entity_2_idx": [[102, 107]], "entity_2_idx_in_text_with_entity_marker": [115, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1954_AIMed.d224.s1954.p0", "text": "Our results also show that, although these HLA-E binding peptides are derived from signal sequences, they may be released back into the cytosol and subsequently translocated by the TAP complex and loaded onto HLA-E molecules.", "text_with_entity_marker": "Our results also show that, although these [E1]HLA-E[/E1] binding peptides are derived from signal sequences, they may be released back into the cytosol and subsequently translocated by the [E2]TAP[/E2] complex and loaded onto HLA-E molecules.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HLA-E", "entity_1_idx": [[43, 48]], "entity_1_idx_in_text_with_entity_marker": [47, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAP", "entity_2_idx": [[181, 184]], "entity_2_idx_in_text_with_entity_marker": [194, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1954_AIMed.d224.s1954.p1", "text": "Our results also show that, although these HLA-E binding peptides are derived from signal sequences, they may be released back into the cytosol and subsequently translocated by the TAP complex and loaded onto HLA-E molecules.", "text_with_entity_marker": "Our results also show that, although these [E1]HLA-E[/E1] binding peptides are derived from signal sequences, they may be released back into the cytosol and subsequently translocated by the TAP complex and loaded onto [E2]HLA-E[/E2] molecules.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HLA-E", "entity_1_idx": [[43, 48]], "entity_1_idx_in_text_with_entity_marker": [47, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HLA-E", "entity_2_idx": [[209, 214]], "entity_2_idx_in_text_with_entity_marker": [222, 227], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d224.s1954_AIMed.d224.s1954.p2", "text": "Our results also show that, although these HLA-E binding peptides are derived from signal sequences, they may be released back into the cytosol and subsequently translocated by the TAP complex and loaded onto HLA-E molecules.", "text_with_entity_marker": "Our results also show that, although these HLA-E binding peptides are derived from signal sequences, they may be released back into the cytosol and subsequently translocated by the [E1]TAP[/E1] complex and loaded onto [E2]HLA-E[/E2] molecules.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAP", "entity_1_idx": [[181, 184]], "entity_1_idx_in_text_with_entity_marker": [185, 188], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HLA-E", "entity_2_idx": [[209, 214]], "entity_2_idx_in_text_with_entity_marker": [222, 227], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d51.s455_AIMed.d51.s455.p0", "text": "Here we report the crystal structure of the FGFR2 ectodomain in a dimeric form that is induced by simultaneous binding to FGF1 and a heparin decasaccharide.", "text_with_entity_marker": "Here we report the crystal structure of the [E1]FGFR2[/E1] ectodomain in a dimeric form that is induced by simultaneous binding to [E2]FGF1[/E2] and a heparin decasaccharide.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGFR2", "entity_1_idx": [[44, 49]], "entity_1_idx_in_text_with_entity_marker": [48, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF1", "entity_2_idx": [[122, 126]], "entity_2_idx_in_text_with_entity_marker": [135, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d51.s458_AIMed.d51.s458.p0", "text": "The structure of the FGF1-FGFR2-heparin ternary complex provides a structural basis for the essential role of heparan sulphate in FGF signalling.", "text_with_entity_marker": "The structure of the [E1]FGF1[/E1]-[E2]FGFR2[/E2]-heparin ternary complex provides a structural basis for the essential role of heparan sulphate in FGF signalling.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGF1", "entity_1_idx": [[21, 25]], "entity_1_idx_in_text_with_entity_marker": [25, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR2", "entity_2_idx": [[26, 31]], "entity_2_idx_in_text_with_entity_marker": [39, 44], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d105.s884_AIMed.d105.s884.p0", "text": "Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signalling.", "text_with_entity_marker": "Two distinct and independent sites on [E1]IL-6[/E1] trigger [E2]gp 130[/E2] dimer formation and signalling.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-6", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp 130", "entity_2_idx": [[51, 57]], "entity_2_idx_in_text_with_entity_marker": [64, 70], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d105.s885_AIMed.d105.s885.p0", "text": "The helical cytokine interleukin (IL) 6 and its specific binding subunit IL-6R alpha form a 1:1 complex which, by promoting homodimerization of the signalling subunit gp130 on the surface of target cells, triggers intracellular responses.", "text_with_entity_marker": "The helical cytokine [E1]interleukin (IL) 6[/E1] and its specific binding subunit [E2]IL-6R alpha[/E2] form a 1:1 complex which, by promoting homodimerization of the signalling subunit gp130 on the surface of target cells, triggers intracellular responses.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "interleukin (IL) 6", "entity_1_idx": [[21, 39]], "entity_1_idx_in_text_with_entity_marker": [25, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6R alpha", "entity_2_idx": [[73, 84]], "entity_2_idx_in_text_with_entity_marker": [86, 97], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d105.s885_AIMed.d105.s885.p1", "text": "The helical cytokine interleukin (IL) 6 and its specific binding subunit IL-6R alpha form a 1:1 complex which, by promoting homodimerization of the signalling subunit gp130 on the surface of target cells, triggers intracellular responses.", "text_with_entity_marker": "The helical cytokine [E1]interleukin (IL) 6[/E1] and its specific binding subunit IL-6R alpha form a 1:1 complex which, by promoting homodimerization of the signalling subunit [E2]gp130[/E2] on the surface of target cells, triggers intracellular responses.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin (IL) 6", "entity_1_idx": [[21, 39]], "entity_1_idx_in_text_with_entity_marker": [25, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[167, 172]], "entity_2_idx_in_text_with_entity_marker": [180, 185], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d105.s885_AIMed.d105.s885.p2", "text": "The helical cytokine interleukin (IL) 6 and its specific binding subunit IL-6R alpha form a 1:1 complex which, by promoting homodimerization of the signalling subunit gp130 on the surface of target cells, triggers intracellular responses.", "text_with_entity_marker": "The helical cytokine interleukin (IL) 6 and its specific binding subunit [E1]IL-6R alpha[/E1] form a 1:1 complex which, by promoting homodimerization of the signalling subunit [E2]gp130[/E2] on the surface of target cells, triggers intracellular responses.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6R alpha", "entity_1_idx": [[73, 84]], "entity_1_idx_in_text_with_entity_marker": [77, 88], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[167, 172]], "entity_2_idx_in_text_with_entity_marker": [180, 185], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d105.s886_AIMed.d105.s886.p0", "text": "We expressed differently tagged forms of gp130 and used them in solution-phase binding assays to show that the soluble extracellular domains of gp130 undergo dimerization in the absence of membranes.", "text_with_entity_marker": "We expressed differently tagged forms of [E1]gp130[/E1] and used them in solution-phase binding assays to show that the soluble extracellular domains of [E2]gp130[/E2] undergo dimerization in the absence of membranes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp130", "entity_1_idx": [[41, 46]], "entity_1_idx_in_text_with_entity_marker": [45, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[144, 149]], "entity_2_idx_in_text_with_entity_marker": [157, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d105.s889_AIMed.d105.s889.p0", "text": "We demonstrate here that both the site 2 and site 3 IL-6 variants complexed with IL-6R alpha bind a single gp130 molecule but are unable to dimerize it, whereas the combined site 2/3 variants lose the ability to interact with gp130.", "text_with_entity_marker": "We demonstrate here that both the site 2 and site 3 [E1]IL-6[/E1] variants complexed with [E2]IL-6R alpha[/E2] bind a single gp130 molecule but are unable to dimerize it, whereas the combined site 2/3 variants lose the ability to interact with gp130.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-6", "entity_1_idx": [[52, 56]], "entity_1_idx_in_text_with_entity_marker": [56, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6R alpha", "entity_2_idx": [[81, 92]], "entity_2_idx_in_text_with_entity_marker": [94, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d105.s889_AIMed.d105.s889.p1", "text": "We demonstrate here that both the site 2 and site 3 IL-6 variants complexed with IL-6R alpha bind a single gp130 molecule but are unable to dimerize it, whereas the combined site 2/3 variants lose the ability to interact with gp130.", "text_with_entity_marker": "We demonstrate here that both the site 2 and site 3 [E1]IL-6[/E1] variants complexed with IL-6R alpha bind a single [E2]gp130[/E2] molecule but are unable to dimerize it, whereas the combined site 2/3 variants lose the ability to interact with gp130.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-6", "entity_1_idx": [[52, 56]], "entity_1_idx_in_text_with_entity_marker": [56, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[107, 112]], "entity_2_idx_in_text_with_entity_marker": [120, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d105.s889_AIMed.d105.s889.p2", "text": "We demonstrate here that both the site 2 and site 3 IL-6 variants complexed with IL-6R alpha bind a single gp130 molecule but are unable to dimerize it, whereas the combined site 2/3 variants lose the ability to interact with gp130.", "text_with_entity_marker": "We demonstrate here that both the site 2 and site 3 [E1]IL-6[/E1] variants complexed with IL-6R alpha bind a single gp130 molecule but are unable to dimerize it, whereas the combined site 2/3 variants lose the ability to interact with [E2]gp130[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[52, 56]], "entity_1_idx_in_text_with_entity_marker": [56, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[226, 231]], "entity_2_idx_in_text_with_entity_marker": [239, 244], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d105.s889_AIMed.d105.s889.p3", "text": "We demonstrate here that both the site 2 and site 3 IL-6 variants complexed with IL-6R alpha bind a single gp130 molecule but are unable to dimerize it, whereas the combined site 2/3 variants lose the ability to interact with gp130.", "text_with_entity_marker": "We demonstrate here that both the site 2 and site 3 IL-6 variants complexed with [E1]IL-6R alpha[/E1] bind a single [E2]gp130[/E2] molecule but are unable to dimerize it, whereas the combined site 2/3 variants lose the ability to interact with gp130.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-6R alpha", "entity_1_idx": [[81, 92]], "entity_1_idx_in_text_with_entity_marker": [85, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[107, 112]], "entity_2_idx_in_text_with_entity_marker": [120, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d105.s889_AIMed.d105.s889.p4", "text": "We demonstrate here that both the site 2 and site 3 IL-6 variants complexed with IL-6R alpha bind a single gp130 molecule but are unable to dimerize it, whereas the combined site 2/3 variants lose the ability to interact with gp130.", "text_with_entity_marker": "We demonstrate here that both the site 2 and site 3 IL-6 variants complexed with [E1]IL-6R alpha[/E1] bind a single gp130 molecule but are unable to dimerize it, whereas the combined site 2/3 variants lose the ability to interact with [E2]gp130[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6R alpha", "entity_1_idx": [[81, 92]], "entity_1_idx_in_text_with_entity_marker": [85, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[226, 231]], "entity_2_idx_in_text_with_entity_marker": [239, 244], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d105.s889_AIMed.d105.s889.p5", "text": "We demonstrate here that both the site 2 and site 3 IL-6 variants complexed with IL-6R alpha bind a single gp130 molecule but are unable to dimerize it, whereas the combined site 2/3 variants lose the ability to interact with gp130.", "text_with_entity_marker": "We demonstrate here that both the site 2 and site 3 IL-6 variants complexed with IL-6R alpha bind a single [E1]gp130[/E1] molecule but are unable to dimerize it, whereas the combined site 2/3 variants lose the ability to interact with [E2]gp130[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp130", "entity_1_idx": [[107, 112]], "entity_1_idx_in_text_with_entity_marker": [111, 116], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[226, 231]], "entity_2_idx_in_text_with_entity_marker": [239, 244], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d105.s890_AIMed.d105.s890.p0", "text": "The binding properties of these variants in vitro, and the result of using a neutralizing monoclonal antibody directed against site 3, lead to the conclusion that gp130 dimer is formed through direct binding at two independent and differently oriented sites on IL-6.", "text_with_entity_marker": "The binding properties of these variants in vitro, and the result of using a neutralizing monoclonal antibody directed against site 3, lead to the conclusion that [E1]gp130[/E1] dimer is formed through direct binding at two independent and differently oriented sites on [E2]IL-6[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp130", "entity_1_idx": [[163, 168]], "entity_1_idx_in_text_with_entity_marker": [167, 172], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[261, 265]], "entity_2_idx_in_text_with_entity_marker": [274, 278], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d105.s891_AIMed.d105.s891.p0", "text": "Immunoprecipitation experiments further reveal that the fully assembled receptor complex is composed of two IL-6, two IL-6R alpha and two gp130 molecules.", "text_with_entity_marker": "Immunoprecipitation experiments further reveal that the fully assembled receptor complex is composed of two [E1]IL-6[/E1], two [E2]IL-6R alpha[/E2] and two gp130 molecules.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-6", "entity_1_idx": [[108, 112]], "entity_1_idx_in_text_with_entity_marker": [112, 116], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6R alpha", "entity_2_idx": [[118, 129]], "entity_2_idx_in_text_with_entity_marker": [131, 142], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d105.s891_AIMed.d105.s891.p1", "text": "Immunoprecipitation experiments further reveal that the fully assembled receptor complex is composed of two IL-6, two IL-6R alpha and two gp130 molecules.", "text_with_entity_marker": "Immunoprecipitation experiments further reveal that the fully assembled receptor complex is composed of two [E1]IL-6[/E1], two IL-6R alpha and two [E2]gp130[/E2] molecules.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-6", "entity_1_idx": [[108, 112]], "entity_1_idx_in_text_with_entity_marker": [112, 116], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[138, 143]], "entity_2_idx_in_text_with_entity_marker": [151, 156], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d105.s891_AIMed.d105.s891.p2", "text": "Immunoprecipitation experiments further reveal that the fully assembled receptor complex is composed of two IL-6, two IL-6R alpha and two gp130 molecules.", "text_with_entity_marker": "Immunoprecipitation experiments further reveal that the fully assembled receptor complex is composed of two IL-6, two [E1]IL-6R alpha[/E1] and two [E2]gp130[/E2] molecules.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-6R alpha", "entity_1_idx": [[118, 129]], "entity_1_idx_in_text_with_entity_marker": [122, 133], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[138, 143]], "entity_2_idx_in_text_with_entity_marker": [151, 156], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d109.s916_AIMed.d109.s916.p0", "text": "Crystal structure of the heterodimeric bZIP transcription factor c-Fos-c-Jun bound to DNA.", "text_with_entity_marker": "Crystal structure of the heterodimeric bZIP transcription factor [E1]c-Fos[/E1]-[E2]c-Jun[/E2] bound to DNA.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "c-Fos", "entity_1_idx": [[65, 70]], "entity_1_idx_in_text_with_entity_marker": [69, 74], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[71, 76]], "entity_2_idx_in_text_with_entity_marker": [84, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d109.s917_AIMed.d109.s917.p0", "text": "The Fos and Jun families of eukaryotic transcription factors heterodimerize to form complexes capable of binding 5'-TGAGTCA-3' DNA elements.", "text_with_entity_marker": "The [E1]Fos[/E1] and [E2]Jun[/E2] families of eukaryotic transcription factors heterodimerize to form complexes capable of binding 5'-TGAGTCA-3' DNA elements.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Fos", "entity_1_idx": [[4, 7]], "entity_1_idx_in_text_with_entity_marker": [8, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jun", "entity_2_idx": [[12, 15]], "entity_2_idx_in_text_with_entity_marker": [25, 28], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d109.s918_AIMed.d109.s918.p0", "text": "We have determined the X-ray crystal structure of a heterodimer of the bZIP regions of c-Fos and c-Jun bound to DNA.", "text_with_entity_marker": "We have determined the X-ray crystal structure of a heterodimer of the bZIP regions of [E1]c-Fos[/E1] and [E2]c-Jun[/E2] bound to DNA.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "c-Fos", "entity_1_idx": [[87, 92]], "entity_1_idx_in_text_with_entity_marker": [91, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[97, 102]], "entity_2_idx_in_text_with_entity_marker": [110, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d109.s921_AIMed.d109.s921.p0", "text": "Comparison of the two crystallographically distinct protein-DNA complexes show that the coiled-coil is flexibly joined to the basic regions and that the Fos-Jun heterodimer does not recognize the asymmetric 5'-TGAGTCA-3' recognition element in a unique orientation.", "text_with_entity_marker": "Comparison of the two crystallographically distinct protein-DNA complexes show that the coiled-coil is flexibly joined to the basic regions and that the [E1]Fos[/E1]-[E2]Jun[/E2] heterodimer does not recognize the asymmetric 5'-TGAGTCA-3' recognition element in a unique orientation.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Fos", "entity_1_idx": [[153, 156]], "entity_1_idx_in_text_with_entity_marker": [157, 160], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jun", "entity_2_idx": [[157, 160]], "entity_2_idx_in_text_with_entity_marker": [170, 173], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1569_AIMed.d185.s1569.p0", "text": "Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain.", "text_with_entity_marker": "[E1]Stat3[/E1] recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the [E2]interleukin-10[/E2] receptor intracellular domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Stat3", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-10", "entity_2_idx": [[95, 109]], "entity_2_idx_in_text_with_entity_marker": [108, 122], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1569_AIMed.d185.s1569.p1", "text": "Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain.", "text_with_entity_marker": "[E1]Stat3[/E1] recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the [E2]interleukin-10 receptor[/E2] intracellular domain.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Stat3", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-10 receptor", "entity_2_idx": [[95, 118]], "entity_2_idx_in_text_with_entity_marker": [108, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1569_AIMed.d185.s1569.p2", "text": "Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain.", "text_with_entity_marker": "Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the [E1-E2]interleukin-10[/E1] receptor[/E2] intracellular domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-10", "entity_1_idx": [[95, 109]], "entity_1_idx_in_text_with_entity_marker": [102, 116], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-10[/E1] receptor", "entity_2_idx": [[95, 118]], "entity_2_idx_in_text_with_entity_marker": [102, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1571_AIMed.d185.s1571.p0", "text": "To define the mechanism underlying signal transducer and activator of transcription (STAT) protein recruitment to the interleukin 10 (IL-10) receptor, the STAT proteins activated by IL-10 in different cell populations were first defined using electrophoretic mobility shift assays.", "text_with_entity_marker": "To define the mechanism underlying signal transducer and activator of transcription (STAT) protein recruitment to the [E1]interleukin 10[/E1] ([E2]IL-10[/E2]) receptor, the STAT proteins activated by IL-10 in different cell populations were first defined using electrophoretic mobility shift assays.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin 10", "entity_1_idx": [[118, 132]], "entity_1_idx_in_text_with_entity_marker": [122, 136], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[134, 139]], "entity_2_idx_in_text_with_entity_marker": [147, 152], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1571_AIMed.d185.s1571.p1", "text": "To define the mechanism underlying signal transducer and activator of transcription (STAT) protein recruitment to the interleukin 10 (IL-10) receptor, the STAT proteins activated by IL-10 in different cell populations were first defined using electrophoretic mobility shift assays.", "text_with_entity_marker": "To define the mechanism underlying signal transducer and activator of transcription (STAT) protein recruitment to the [E1-E2]interleukin 10[/E1] (IL-10) receptor[/E2], the STAT proteins activated by IL-10 in different cell populations were first defined using electrophoretic mobility shift assays.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin 10", "entity_1_idx": [[118, 132]], "entity_1_idx_in_text_with_entity_marker": [125, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin 10[/E1] (IL-10) receptor", "entity_2_idx": [[118, 149]], "entity_2_idx_in_text_with_entity_marker": [125, 161], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1571_AIMed.d185.s1571.p2", "text": "To define the mechanism underlying signal transducer and activator of transcription (STAT) protein recruitment to the interleukin 10 (IL-10) receptor, the STAT proteins activated by IL-10 in different cell populations were first defined using electrophoretic mobility shift assays.", "text_with_entity_marker": "To define the mechanism underlying signal transducer and activator of transcription (STAT) protein recruitment to the [E1]interleukin 10[/E1] (IL-10) receptor, the STAT proteins activated by [E2]IL-10[/E2] in different cell populations were first defined using electrophoretic mobility shift assays.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin 10", "entity_1_idx": [[118, 132]], "entity_1_idx_in_text_with_entity_marker": [122, 136], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[182, 187]], "entity_2_idx_in_text_with_entity_marker": [195, 200], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1571_AIMed.d185.s1571.p3", "text": "To define the mechanism underlying signal transducer and activator of transcription (STAT) protein recruitment to the interleukin 10 (IL-10) receptor, the STAT proteins activated by IL-10 in different cell populations were first defined using electrophoretic mobility shift assays.", "text_with_entity_marker": "To define the mechanism underlying signal transducer and activator of transcription (STAT) protein recruitment to the [E1]interleukin 10 (IL-10) receptor[/E1][E2]IL-10[/E2]) receptor, the STAT proteins activated by IL-10 in different cell populations were first defined using electrophoretic mobility shift assays.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin 10 (IL-10) receptor", "entity_1_idx": [[118, 149]], "entity_1_idx_in_text_with_entity_marker": [122, 153], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[134, 139]], "entity_2_idx_in_text_with_entity_marker": [162, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1571_AIMed.d185.s1571.p4", "text": "To define the mechanism underlying signal transducer and activator of transcription (STAT) protein recruitment to the interleukin 10 (IL-10) receptor, the STAT proteins activated by IL-10 in different cell populations were first defined using electrophoretic mobility shift assays.", "text_with_entity_marker": "To define the mechanism underlying signal transducer and activator of transcription (STAT) protein recruitment to the interleukin 10 ([E1]IL-10[/E1]) receptor, the STAT proteins activated by [E2]IL-10[/E2] in different cell populations were first defined using electrophoretic mobility shift assays.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-10", "entity_1_idx": [[134, 139]], "entity_1_idx_in_text_with_entity_marker": [138, 143], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[182, 187]], "entity_2_idx_in_text_with_entity_marker": [195, 200], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1571_AIMed.d185.s1571.p5", "text": "To define the mechanism underlying signal transducer and activator of transcription (STAT) protein recruitment to the interleukin 10 (IL-10) receptor, the STAT proteins activated by IL-10 in different cell populations were first defined using electrophoretic mobility shift assays.", "text_with_entity_marker": "To define the mechanism underlying signal transducer and activator of transcription (STAT) protein recruitment to the [E1]interleukin 10 (IL-10) receptor[/E1], the STAT proteins activated by [E2]IL-10[/E2] in different cell populations were first defined using electrophoretic mobility shift assays.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin 10 (IL-10) receptor", "entity_1_idx": [[118, 149]], "entity_1_idx_in_text_with_entity_marker": [122, 153], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[182, 187]], "entity_2_idx_in_text_with_entity_marker": [195, 200], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1572_AIMed.d185.s1572.p0", "text": "In all cells tested, IL-10 activated Stat1 and Stat3 and induced the formation of three distinct DNA binding complexes that contained different combinations of these two transcription factors.", "text_with_entity_marker": "In all cells tested, [E1]IL-10[/E1] activated [E2]Stat1[/E2] and Stat3 and induced the formation of three distinct DNA binding complexes that contained different combinations of these two transcription factors.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-10", "entity_1_idx": [[21, 26]], "entity_1_idx_in_text_with_entity_marker": [25, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Stat1", "entity_2_idx": [[37, 42]], "entity_2_idx_in_text_with_entity_marker": [50, 55], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1572_AIMed.d185.s1572.p1", "text": "In all cells tested, IL-10 activated Stat1 and Stat3 and induced the formation of three distinct DNA binding complexes that contained different combinations of these two transcription factors.", "text_with_entity_marker": "In all cells tested, [E1]IL-10[/E1] activated Stat1 and [E2]Stat3[/E2] and induced the formation of three distinct DNA binding complexes that contained different combinations of these two transcription factors.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-10", "entity_1_idx": [[21, 26]], "entity_1_idx_in_text_with_entity_marker": [25, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Stat3", "entity_2_idx": [[47, 52]], "entity_2_idx_in_text_with_entity_marker": [60, 65], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1572_AIMed.d185.s1572.p2", "text": "In all cells tested, IL-10 activated Stat1 and Stat3 and induced the formation of three distinct DNA binding complexes that contained different combinations of these two transcription factors.", "text_with_entity_marker": "In all cells tested, IL-10 activated [E1]Stat1[/E1] and [E2]Stat3[/E2] and induced the formation of three distinct DNA binding complexes that contained different combinations of these two transcription factors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Stat1", "entity_1_idx": [[37, 42]], "entity_1_idx_in_text_with_entity_marker": [41, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Stat3", "entity_2_idx": [[47, 52]], "entity_2_idx_in_text_with_entity_marker": [60, 65], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1573_AIMed.d185.s1573.p0", "text": "IL-10 also activated Stat5 in Ba/F3 cells that stably expressed the murine IL-10 receptor.", "text_with_entity_marker": "[E1]IL-10[/E1] also activated [E2]Stat5[/E2] in Ba/F3 cells that stably expressed the murine IL-10 receptor.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-10", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Stat5", "entity_2_idx": [[21, 26]], "entity_2_idx_in_text_with_entity_marker": [34, 39], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1573_AIMed.d185.s1573.p1", "text": "IL-10 also activated Stat5 in Ba/F3 cells that stably expressed the murine IL-10 receptor.", "text_with_entity_marker": "[E1]IL-10[/E1] also activated Stat5 in Ba/F3 cells that stably expressed the murine [E2]IL-10[/E2] receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-10", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[75, 80]], "entity_2_idx_in_text_with_entity_marker": [88, 93], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1573_AIMed.d185.s1573.p2", "text": "IL-10 also activated Stat5 in Ba/F3 cells that stably expressed the murine IL-10 receptor.", "text_with_entity_marker": "[E1]IL-10[/E1] also activated Stat5 in Ba/F3 cells that stably expressed the murine [E2]IL-10 receptor[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-10", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10 receptor", "entity_2_idx": [[75, 89]], "entity_2_idx_in_text_with_entity_marker": [88, 102], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1573_AIMed.d185.s1573.p3", "text": "IL-10 also activated Stat5 in Ba/F3 cells that stably expressed the murine IL-10 receptor.", "text_with_entity_marker": "IL-10 also activated [E1]Stat5[/E1] in Ba/F3 cells that stably expressed the murine [E2]IL-10[/E2] receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Stat5", "entity_1_idx": [[21, 26]], "entity_1_idx_in_text_with_entity_marker": [25, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[75, 80]], "entity_2_idx_in_text_with_entity_marker": [88, 93], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1573_AIMed.d185.s1573.p4", "text": "IL-10 also activated Stat5 in Ba/F3 cells that stably expressed the murine IL-10 receptor.", "text_with_entity_marker": "IL-10 also activated [E1]Stat5[/E1] in Ba/F3 cells that stably expressed the murine [E2]IL-10 receptor[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Stat5", "entity_1_idx": [[21, 26]], "entity_1_idx_in_text_with_entity_marker": [25, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10 receptor", "entity_2_idx": [[75, 89]], "entity_2_idx_in_text_with_entity_marker": [88, 102], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1573_AIMed.d185.s1573.p5", "text": "IL-10 also activated Stat5 in Ba/F3 cells that stably expressed the murine IL-10 receptor.", "text_with_entity_marker": "IL-10 also activated Stat5 in Ba/F3 cells that stably expressed the murine [E1-E2]IL-10[/E1] receptor[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-10", "entity_1_idx": [[75, 80]], "entity_1_idx_in_text_with_entity_marker": [82, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10[/E1] receptor", "entity_2_idx": [[75, 89]], "entity_2_idx_in_text_with_entity_marker": [82, 101], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1574_AIMed.d185.s1574.p0", "text": "Using a structure-function mutagenesis approach, two tyrosine residues (Tyr427 and Tyr477) in the intracellular domain of the murine IL-10 receptor were found to be redundantly required for receptor function and for activation of Stat3 but not for Stat1 or Stat5.", "text_with_entity_marker": "Using a structure-function mutagenesis approach, two tyrosine residues (Tyr427 and Tyr477) in the intracellular domain of the murine [E1-E2]IL-10[/E1] receptor[/E2] were found to be redundantly required for receptor function and for activation of Stat3 but not for Stat1 or Stat5.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-10", "entity_1_idx": [[133, 138]], "entity_1_idx_in_text_with_entity_marker": [140, 145], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10[/E1] receptor", "entity_2_idx": [[133, 147]], "entity_2_idx_in_text_with_entity_marker": [140, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1574_AIMed.d185.s1574.p1", "text": "Using a structure-function mutagenesis approach, two tyrosine residues (Tyr427 and Tyr477) in the intracellular domain of the murine IL-10 receptor were found to be redundantly required for receptor function and for activation of Stat3 but not for Stat1 or Stat5.", "text_with_entity_marker": "Using a structure-function mutagenesis approach, two tyrosine residues (Tyr427 and Tyr477) in the intracellular domain of the murine [E1]IL-10[/E1] receptor were found to be redundantly required for receptor function and for activation of [E2]Stat3[/E2] but not for Stat1 or Stat5.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-10", "entity_1_idx": [[133, 138]], "entity_1_idx_in_text_with_entity_marker": [137, 142], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Stat3", "entity_2_idx": [[230, 235]], "entity_2_idx_in_text_with_entity_marker": [243, 248], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1574_AIMed.d185.s1574.p2", "text": "Using a structure-function mutagenesis approach, two tyrosine residues (Tyr427 and Tyr477) in the intracellular domain of the murine IL-10 receptor were found to be redundantly required for receptor function and for activation of Stat3 but not for Stat1 or Stat5.", "text_with_entity_marker": "Using a structure-function mutagenesis approach, two tyrosine residues (Tyr427 and Tyr477) in the intracellular domain of the murine [E1]IL-10[/E1] receptor were found to be redundantly required for receptor function and for activation of Stat3 but not for [E2]Stat1[/E2] or Stat5.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-10", "entity_1_idx": [[133, 138]], "entity_1_idx_in_text_with_entity_marker": [137, 142], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Stat1", "entity_2_idx": [[248, 253]], "entity_2_idx_in_text_with_entity_marker": [261, 266], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1574_AIMed.d185.s1574.p3", "text": "Using a structure-function mutagenesis approach, two tyrosine residues (Tyr427 and Tyr477) in the intracellular domain of the murine IL-10 receptor were found to be redundantly required for receptor function and for activation of Stat3 but not for Stat1 or Stat5.", "text_with_entity_marker": "Using a structure-function mutagenesis approach, two tyrosine residues (Tyr427 and Tyr477) in the intracellular domain of the murine [E1]IL-10 receptor[/E1] were found to be redundantly required for receptor function and for activation of [E2]Stat3[/E2] but not for Stat1 or Stat5.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-10 receptor", "entity_1_idx": [[133, 147]], "entity_1_idx_in_text_with_entity_marker": [137, 151], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Stat3", "entity_2_idx": [[230, 235]], "entity_2_idx_in_text_with_entity_marker": [243, 248], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1574_AIMed.d185.s1574.p4", "text": "Using a structure-function mutagenesis approach, two tyrosine residues (Tyr427 and Tyr477) in the intracellular domain of the murine IL-10 receptor were found to be redundantly required for receptor function and for activation of Stat3 but not for Stat1 or Stat5.", "text_with_entity_marker": "Using a structure-function mutagenesis approach, two tyrosine residues (Tyr427 and Tyr477) in the intracellular domain of the murine [E1]IL-10 receptor[/E1] were found to be redundantly required for receptor function and for activation of Stat3 but not for [E2]Stat1[/E2] or Stat5.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-10 receptor", "entity_1_idx": [[133, 147]], "entity_1_idx_in_text_with_entity_marker": [137, 151], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Stat1", "entity_2_idx": [[248, 253]], "entity_2_idx_in_text_with_entity_marker": [261, 266], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1574_AIMed.d185.s1574.p5", "text": "Using a structure-function mutagenesis approach, two tyrosine residues (Tyr427 and Tyr477) in the intracellular domain of the murine IL-10 receptor were found to be redundantly required for receptor function and for activation of Stat3 but not for Stat1 or Stat5.", "text_with_entity_marker": "Using a structure-function mutagenesis approach, two tyrosine residues (Tyr427 and Tyr477) in the intracellular domain of the murine IL-10 receptor were found to be redundantly required for receptor function and for activation of [E1]Stat3[/E1] but not for [E2]Stat1[/E2] or Stat5.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Stat3", "entity_1_idx": [[230, 235]], "entity_1_idx_in_text_with_entity_marker": [234, 239], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Stat1", "entity_2_idx": [[248, 253]], "entity_2_idx_in_text_with_entity_marker": [261, 266], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1575_AIMed.d185.s1575.p0", "text": "Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not Stat1 and blocked IL-10-induced Stat3 phosphorylation in a cell-free system.", "text_with_entity_marker": "Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated [E1]Stat3[/E1] but not [E2]Stat1[/E2] and blocked IL-10-induced Stat3 phosphorylation in a cell-free system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Stat3", "entity_1_idx": [[116, 121]], "entity_1_idx_in_text_with_entity_marker": [120, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Stat1", "entity_2_idx": [[130, 135]], "entity_2_idx_in_text_with_entity_marker": [143, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1575_AIMed.d185.s1575.p1", "text": "Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not Stat1 and blocked IL-10-induced Stat3 phosphorylation in a cell-free system.", "text_with_entity_marker": "Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated [E1]Stat3[/E1] but not Stat1 and blocked [E2]IL-10[/E2]-induced Stat3 phosphorylation in a cell-free system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Stat3", "entity_1_idx": [[116, 121]], "entity_1_idx_in_text_with_entity_marker": [120, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[148, 153]], "entity_2_idx_in_text_with_entity_marker": [161, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1575_AIMed.d185.s1575.p2", "text": "Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not Stat1 and blocked IL-10-induced Stat3 phosphorylation in a cell-free system.", "text_with_entity_marker": "Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated [E1]Stat3[/E1] but not Stat1 and blocked IL-10-induced [E2]Stat3[/E2] phosphorylation in a cell-free system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Stat3", "entity_1_idx": [[116, 121]], "entity_1_idx_in_text_with_entity_marker": [120, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Stat3", "entity_2_idx": [[162, 167]], "entity_2_idx_in_text_with_entity_marker": [175, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1575_AIMed.d185.s1575.p3", "text": "Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not Stat1 and blocked IL-10-induced Stat3 phosphorylation in a cell-free system.", "text_with_entity_marker": "Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not [E1]Stat1[/E1] and blocked [E2]IL-10[/E2]-induced Stat3 phosphorylation in a cell-free system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Stat1", "entity_1_idx": [[130, 135]], "entity_1_idx_in_text_with_entity_marker": [134, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[148, 153]], "entity_2_idx_in_text_with_entity_marker": [161, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1575_AIMed.d185.s1575.p4", "text": "Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not Stat1 and blocked IL-10-induced Stat3 phosphorylation in a cell-free system.", "text_with_entity_marker": "Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not [E1]Stat1[/E1] and blocked IL-10-induced [E2]Stat3[/E2] phosphorylation in a cell-free system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Stat1", "entity_1_idx": [[130, 135]], "entity_1_idx_in_text_with_entity_marker": [134, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Stat3", "entity_2_idx": [[162, 167]], "entity_2_idx_in_text_with_entity_marker": [175, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1575_AIMed.d185.s1575.p5", "text": "Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not Stat1 and blocked IL-10-induced Stat3 phosphorylation in a cell-free system.", "text_with_entity_marker": "Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not Stat1 and blocked [E1]IL-10[/E1]-induced [E2]Stat3[/E2] phosphorylation in a cell-free system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-10", "entity_1_idx": [[148, 153]], "entity_1_idx_in_text_with_entity_marker": [152, 157], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Stat3", "entity_2_idx": [[162, 167]], "entity_2_idx_in_text_with_entity_marker": [175, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1576_AIMed.d185.s1576.p0", "text": "In contrast, tyrosine-phosphorylated peptides containing Tyr374 or Tyr396 did not interact with Stat3 or block Stat3 activation.", "text_with_entity_marker": "In contrast, tyrosine-phosphorylated peptides containing Tyr374 or Tyr396 did not interact with [E1]Stat3[/E1] or block [E2]Stat3[/E2] activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Stat3", "entity_1_idx": [[96, 101]], "entity_1_idx_in_text_with_entity_marker": [100, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Stat3", "entity_2_idx": [[111, 116]], "entity_2_idx_in_text_with_entity_marker": [124, 129], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1577_AIMed.d185.s1577.p0", "text": "These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand-activated IL-10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.", "text_with_entity_marker": "These data demonstrate that [E1]Stat3[/E1] but not [E2]Stat1[/E2] or Stat5 is directly recruited to the ligand-activated IL-10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Stat3", "entity_1_idx": [[28, 33]], "entity_1_idx_in_text_with_entity_marker": [32, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Stat1", "entity_2_idx": [[42, 47]], "entity_2_idx_in_text_with_entity_marker": [55, 60], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1577_AIMed.d185.s1577.p1", "text": "These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand-activated IL-10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.", "text_with_entity_marker": "These data demonstrate that [E1]Stat3[/E1] but not Stat1 or [E2]Stat5[/E2] is directly recruited to the ligand-activated IL-10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Stat3", "entity_1_idx": [[28, 33]], "entity_1_idx_in_text_with_entity_marker": [32, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Stat5", "entity_2_idx": [[51, 56]], "entity_2_idx_in_text_with_entity_marker": [64, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1577_AIMed.d185.s1577.p2", "text": "These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand-activated IL-10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.", "text_with_entity_marker": "These data demonstrate that [E1]Stat3[/E1] but not Stat1 or Stat5 is directly recruited to the ligand-activated [E2]IL-10[/E2] receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Stat3", "entity_1_idx": [[28, 33]], "entity_1_idx_in_text_with_entity_marker": [32, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[103, 108]], "entity_2_idx_in_text_with_entity_marker": [116, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1577_AIMed.d185.s1577.p3", "text": "These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand-activated IL-10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.", "text_with_entity_marker": "These data demonstrate that [E1]Stat3[/E1] but not Stat1 or Stat5 is directly recruited to the ligand-activated [E2]IL-10 receptor[/E2] by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Stat3", "entity_1_idx": [[28, 33]], "entity_1_idx_in_text_with_entity_marker": [32, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10 receptor", "entity_2_idx": [[103, 117]], "entity_2_idx_in_text_with_entity_marker": [116, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1577_AIMed.d185.s1577.p4", "text": "These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand-activated IL-10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.", "text_with_entity_marker": "These data demonstrate that Stat3 but not [E1]Stat1[/E1] or [E2]Stat5[/E2] is directly recruited to the ligand-activated IL-10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Stat1", "entity_1_idx": [[42, 47]], "entity_1_idx_in_text_with_entity_marker": [46, 51], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Stat5", "entity_2_idx": [[51, 56]], "entity_2_idx_in_text_with_entity_marker": [64, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1577_AIMed.d185.s1577.p5", "text": "These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand-activated IL-10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.", "text_with_entity_marker": "These data demonstrate that Stat3 but not [E1]Stat1[/E1] or Stat5 is directly recruited to the ligand-activated [E2]IL-10[/E2] receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Stat1", "entity_1_idx": [[42, 47]], "entity_1_idx_in_text_with_entity_marker": [46, 51], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[103, 108]], "entity_2_idx_in_text_with_entity_marker": [116, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1577_AIMed.d185.s1577.p6", "text": "These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand-activated IL-10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.", "text_with_entity_marker": "These data demonstrate that Stat3 but not [E1]Stat1[/E1] or Stat5 is directly recruited to the ligand-activated [E2]IL-10 receptor[/E2] by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Stat1", "entity_1_idx": [[42, 47]], "entity_1_idx_in_text_with_entity_marker": [46, 51], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10 receptor", "entity_2_idx": [[103, 117]], "entity_2_idx_in_text_with_entity_marker": [116, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1577_AIMed.d185.s1577.p7", "text": "These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand-activated IL-10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.", "text_with_entity_marker": "These data demonstrate that Stat3 but not Stat1 or [E1]Stat5[/E1] is directly recruited to the ligand-activated [E2]IL-10[/E2] receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Stat5", "entity_1_idx": [[51, 56]], "entity_1_idx_in_text_with_entity_marker": [55, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[103, 108]], "entity_2_idx_in_text_with_entity_marker": [116, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1577_AIMed.d185.s1577.p8", "text": "These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand-activated IL-10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.", "text_with_entity_marker": "These data demonstrate that Stat3 but not Stat1 or [E1]Stat5[/E1] is directly recruited to the ligand-activated [E2]IL-10 receptor[/E2] by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Stat5", "entity_1_idx": [[51, 56]], "entity_1_idx_in_text_with_entity_marker": [55, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10 receptor", "entity_2_idx": [[103, 117]], "entity_2_idx_in_text_with_entity_marker": [116, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1577_AIMed.d185.s1577.p9", "text": "These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand-activated IL-10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.", "text_with_entity_marker": "These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand-activated [E1-E2]IL-10[/E1] receptor[/E2] by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-10", "entity_1_idx": [[103, 108]], "entity_1_idx_in_text_with_entity_marker": [110, 115], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10[/E1] receptor", "entity_2_idx": [[103, 117]], "entity_2_idx_in_text_with_entity_marker": [110, 129], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d175.s1476_AIMed.d175.s1476.p0", "text": "Physical interaction of mammalian CDC37 with CDK4", "text_with_entity_marker": "Physical interaction of mammalian [E1]CDC37[/E1] with [E2]CDK4[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CDC37", "entity_1_idx": [[34, 39]], "entity_1_idx_in_text_with_entity_marker": [38, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK4", "entity_2_idx": [[45, 49]], "entity_2_idx_in_text_with_entity_marker": [58, 62], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d175.s1477_AIMed.d175.s1477.p0", "text": ".CDC37 was originally identified as a Start gene in budding yeast and has been shown to be required for association of CDC28 with cyclins.", "text_with_entity_marker": "[E1].CDC37[/E1] was originally identified as a Start gene in budding yeast and has been shown to be required for association of [E2]CDC28[/E2] with cyclins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": ".CDC37", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDC28", "entity_2_idx": [[119, 124]], "entity_2_idx_in_text_with_entity_marker": [132, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d175.s1479_AIMed.d175.s1479.p0", "text": "CDK4 is a cyclin D-dependent kinase that controls progression through G1 of the mammalian cell cycle.", "text_with_entity_marker": "[E1]CDK4[/E1] is a [E2]cyclin D-dependent kinase[/E2] that controls progression through G1 of the mammalian cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDK4", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin D-dependent kinase", "entity_2_idx": [[10, 35]], "entity_2_idx_in_text_with_entity_marker": [23, 48], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d175.s1480_AIMed.d175.s1480.p0", "text": "We have detected a specific association of CDK4 with the molecular chaperon HSP90 and a 44-kDa protein that we identify as mammalian CDC37.", "text_with_entity_marker": "We have detected a specific association of [E1]CDK4[/E1] with the molecular chaperon [E2]HSP90[/E2] and a 44-kDa protein that we identify as mammalian CDC37.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CDK4", "entity_1_idx": [[43, 47]], "entity_1_idx_in_text_with_entity_marker": [47, 51], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HSP90", "entity_2_idx": [[76, 81]], "entity_2_idx_in_text_with_entity_marker": [89, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d175.s1480_AIMed.d175.s1480.p1", "text": "We have detected a specific association of CDK4 with the molecular chaperon HSP90 and a 44-kDa protein that we identify as mammalian CDC37.", "text_with_entity_marker": "We have detected a specific association of [E1]CDK4[/E1] with the molecular chaperon HSP90 and a 44-kDa protein that we identify as mammalian [E2]CDC37[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CDK4", "entity_1_idx": [[43, 47]], "entity_1_idx_in_text_with_entity_marker": [47, 51], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDC37", "entity_2_idx": [[133, 138]], "entity_2_idx_in_text_with_entity_marker": [146, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d175.s1480_AIMed.d175.s1480.p2", "text": "We have detected a specific association of CDK4 with the molecular chaperon HSP90 and a 44-kDa protein that we identify as mammalian CDC37.", "text_with_entity_marker": "We have detected a specific association of CDK4 with the molecular chaperon [E1]HSP90[/E1] and a 44-kDa protein that we identify as mammalian [E2]CDC37[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HSP90", "entity_1_idx": [[76, 81]], "entity_1_idx_in_text_with_entity_marker": [80, 85], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDC37", "entity_2_idx": [[133, 138]], "entity_2_idx_in_text_with_entity_marker": [146, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d175.s1481_AIMed.d175.s1481.p0", "text": "A physical interaction between CDC37 and CDK4 suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on CDK4.", "text_with_entity_marker": "A physical interaction between [E1]CDC37[/E1] and [E2]CDK4[/E2] suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on CDK4.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CDC37", "entity_1_idx": [[31, 36]], "entity_1_idx_in_text_with_entity_marker": [35, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK4", "entity_2_idx": [[41, 45]], "entity_2_idx_in_text_with_entity_marker": [54, 58], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d175.s1481_AIMed.d175.s1481.p1", "text": "A physical interaction between CDC37 and CDK4 suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on CDK4.", "text_with_entity_marker": "A physical interaction between [E1]CDC37[/E1] and CDK4 suggests that [E2]CDC37[/E2] may regulate the mammalian cell cycle through a direct effect on CDK4.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDC37", "entity_1_idx": [[31, 36]], "entity_1_idx_in_text_with_entity_marker": [35, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDC37", "entity_2_idx": [[60, 65]], "entity_2_idx_in_text_with_entity_marker": [73, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d175.s1481_AIMed.d175.s1481.p2", "text": "A physical interaction between CDC37 and CDK4 suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on CDK4.", "text_with_entity_marker": "A physical interaction between [E1]CDC37[/E1] and CDK4 suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on [E2]CDK4[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDC37", "entity_1_idx": [[31, 36]], "entity_1_idx_in_text_with_entity_marker": [35, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK4", "entity_2_idx": [[131, 135]], "entity_2_idx_in_text_with_entity_marker": [144, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d175.s1481_AIMed.d175.s1481.p3", "text": "A physical interaction between CDC37 and CDK4 suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on CDK4.", "text_with_entity_marker": "A physical interaction between CDC37 and [E1]CDK4[/E1] suggests that [E2]CDC37[/E2] may regulate the mammalian cell cycle through a direct effect on CDK4.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDK4", "entity_1_idx": [[41, 45]], "entity_1_idx_in_text_with_entity_marker": [45, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDC37", "entity_2_idx": [[60, 65]], "entity_2_idx_in_text_with_entity_marker": [73, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d175.s1481_AIMed.d175.s1481.p4", "text": "A physical interaction between CDC37 and CDK4 suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on CDK4.", "text_with_entity_marker": "A physical interaction between CDC37 and [E1]CDK4[/E1] suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on [E2]CDK4[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDK4", "entity_1_idx": [[41, 45]], "entity_1_idx_in_text_with_entity_marker": [45, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK4", "entity_2_idx": [[131, 135]], "entity_2_idx_in_text_with_entity_marker": [144, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d175.s1481_AIMed.d175.s1481.p5", "text": "A physical interaction between CDC37 and CDK4 suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on CDK4.", "text_with_entity_marker": "A physical interaction between CDC37 and CDK4 suggests that [E1]CDC37[/E1] may regulate the mammalian cell cycle through a direct effect on [E2]CDK4[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CDC37", "entity_1_idx": [[60, 65]], "entity_1_idx_in_text_with_entity_marker": [64, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK4", "entity_2_idx": [[131, 135]], "entity_2_idx_in_text_with_entity_marker": [144, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d175.s1482_AIMed.d175.s1482.p0", "text": "Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90.", "text_with_entity_marker": "Association of [E1]CDK4[/E1] with both [E2]CDC37[/E2] and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CDK4", "entity_1_idx": [[15, 19]], "entity_1_idx_in_text_with_entity_marker": [19, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDC37", "entity_2_idx": [[30, 35]], "entity_2_idx_in_text_with_entity_marker": [43, 48], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d175.s1482_AIMed.d175.s1482.p1", "text": "Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90.", "text_with_entity_marker": "Association of [E1]CDK4[/E1] with both CDC37 and [E2]HSP90[/E2] may also imply a mechanistic link between the functions of CDC37 and HSP90.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CDK4", "entity_1_idx": [[15, 19]], "entity_1_idx_in_text_with_entity_marker": [19, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HSP90", "entity_2_idx": [[40, 45]], "entity_2_idx_in_text_with_entity_marker": [53, 58], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d175.s1482_AIMed.d175.s1482.p2", "text": "Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90.", "text_with_entity_marker": "Association of [E1]CDK4[/E1] with both CDC37 and HSP90 may also imply a mechanistic link between the functions of [E2]CDC37[/E2] and HSP90.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDK4", "entity_1_idx": [[15, 19]], "entity_1_idx_in_text_with_entity_marker": [19, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDC37", "entity_2_idx": [[105, 110]], "entity_2_idx_in_text_with_entity_marker": [118, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d175.s1482_AIMed.d175.s1482.p3", "text": "Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90.", "text_with_entity_marker": "Association of [E1]CDK4[/E1] with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and [E2]HSP90[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDK4", "entity_1_idx": [[15, 19]], "entity_1_idx_in_text_with_entity_marker": [19, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HSP90", "entity_2_idx": [[115, 120]], "entity_2_idx_in_text_with_entity_marker": [128, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d175.s1482_AIMed.d175.s1482.p4", "text": "Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90.", "text_with_entity_marker": "Association of CDK4 with both [E1]CDC37[/E1] and [E2]HSP90[/E2] may also imply a mechanistic link between the functions of CDC37 and HSP90.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDC37", "entity_1_idx": [[30, 35]], "entity_1_idx_in_text_with_entity_marker": [34, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HSP90", "entity_2_idx": [[40, 45]], "entity_2_idx_in_text_with_entity_marker": [53, 58], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d175.s1482_AIMed.d175.s1482.p5", "text": "Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90.", "text_with_entity_marker": "Association of CDK4 with both [E1]CDC37[/E1] and HSP90 may also imply a mechanistic link between the functions of [E2]CDC37[/E2] and HSP90.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDC37", "entity_1_idx": [[30, 35]], "entity_1_idx_in_text_with_entity_marker": [34, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDC37", "entity_2_idx": [[105, 110]], "entity_2_idx_in_text_with_entity_marker": [118, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d175.s1482_AIMed.d175.s1482.p6", "text": "Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90.", "text_with_entity_marker": "Association of CDK4 with both [E1]CDC37[/E1] and HSP90 may also imply a mechanistic link between the functions of CDC37 and [E2]HSP90[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDC37", "entity_1_idx": [[30, 35]], "entity_1_idx_in_text_with_entity_marker": [34, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HSP90", "entity_2_idx": [[115, 120]], "entity_2_idx_in_text_with_entity_marker": [128, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d175.s1482_AIMed.d175.s1482.p7", "text": "Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90.", "text_with_entity_marker": "Association of CDK4 with both CDC37 and [E1]HSP90[/E1] may also imply a mechanistic link between the functions of [E2]CDC37[/E2] and HSP90.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HSP90", "entity_1_idx": [[40, 45]], "entity_1_idx_in_text_with_entity_marker": [44, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDC37", "entity_2_idx": [[105, 110]], "entity_2_idx_in_text_with_entity_marker": [118, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d175.s1482_AIMed.d175.s1482.p8", "text": "Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90.", "text_with_entity_marker": "Association of CDK4 with both CDC37 and [E1]HSP90[/E1] may also imply a mechanistic link between the functions of CDC37 and [E2]HSP90[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HSP90", "entity_1_idx": [[40, 45]], "entity_1_idx_in_text_with_entity_marker": [44, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HSP90", "entity_2_idx": [[115, 120]], "entity_2_idx_in_text_with_entity_marker": [128, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d175.s1482_AIMed.d175.s1482.p9", "text": "Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90.", "text_with_entity_marker": "Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of [E1]CDC37[/E1] and [E2]HSP90[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDC37", "entity_1_idx": [[105, 110]], "entity_1_idx_in_text_with_entity_marker": [109, 114], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HSP90", "entity_2_idx": [[115, 120]], "entity_2_idx_in_text_with_entity_marker": [128, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1062_AIMed.d125.s1062.p0", "text": "Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.", "text_with_entity_marker": "Interactions of the [E1]Bcl-2[/E1] protein with itself and other members of the [E2]Bcl-2[/E2] family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[20, 25]], "entity_1_idx_in_text_with_entity_marker": [24, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[71, 76]], "entity_2_idx_in_text_with_entity_marker": [84, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1062_AIMed.d125.s1062.p1", "text": "Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.", "text_with_entity_marker": "Interactions of the [E1]Bcl-2[/E1] protein with itself and other members of the Bcl-2 family, including [E2]Bcl-X-L[/E2], Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Bcl-2", "entity_1_idx": [[20, 25]], "entity_1_idx_in_text_with_entity_marker": [24, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-X-L", "entity_2_idx": [[95, 102]], "entity_2_idx_in_text_with_entity_marker": [108, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1062_AIMed.d125.s1062.p2", "text": "Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.", "text_with_entity_marker": "Interactions of the [E1]Bcl-2[/E1] protein with itself and other members of the Bcl-2 family, including Bcl-X-L, [E2]Bcl-X-S[/E2], Mcl-1, and Bax, were explored with a yeast two-hybrid system.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Bcl-2", "entity_1_idx": [[20, 25]], "entity_1_idx_in_text_with_entity_marker": [24, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-X-S", "entity_2_idx": [[104, 111]], "entity_2_idx_in_text_with_entity_marker": [117, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1062_AIMed.d125.s1062.p3", "text": "Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.", "text_with_entity_marker": "Interactions of the [E1]Bcl-2[/E1] protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, [E2]Mcl-1[/E2], and Bax, were explored with a yeast two-hybrid system.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Bcl-2", "entity_1_idx": [[20, 25]], "entity_1_idx_in_text_with_entity_marker": [24, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Mcl-1", "entity_2_idx": [[113, 118]], "entity_2_idx_in_text_with_entity_marker": [126, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1062_AIMed.d125.s1062.p4", "text": "Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.", "text_with_entity_marker": "Interactions of the [E1]Bcl-2[/E1] protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and [E2]Bax[/E2], were explored with a yeast two-hybrid system.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Bcl-2", "entity_1_idx": [[20, 25]], "entity_1_idx_in_text_with_entity_marker": [24, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bax", "entity_2_idx": [[124, 127]], "entity_2_idx_in_text_with_entity_marker": [137, 140], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1062_AIMed.d125.s1062.p5", "text": "Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.", "text_with_entity_marker": "Interactions of the Bcl-2 protein with itself and other members of the [E1]Bcl-2[/E1] family, including [E2]Bcl-X-L[/E2], Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[71, 76]], "entity_1_idx_in_text_with_entity_marker": [75, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-X-L", "entity_2_idx": [[95, 102]], "entity_2_idx_in_text_with_entity_marker": [108, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1062_AIMed.d125.s1062.p6", "text": "Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.", "text_with_entity_marker": "Interactions of the Bcl-2 protein with itself and other members of the [E1]Bcl-2[/E1] family, including Bcl-X-L, [E2]Bcl-X-S[/E2], Mcl-1, and Bax, were explored with a yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[71, 76]], "entity_1_idx_in_text_with_entity_marker": [75, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-X-S", "entity_2_idx": [[104, 111]], "entity_2_idx_in_text_with_entity_marker": [117, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1062_AIMed.d125.s1062.p7", "text": "Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.", "text_with_entity_marker": "Interactions of the Bcl-2 protein with itself and other members of the [E1]Bcl-2[/E1] family, including Bcl-X-L, Bcl-X-S, [E2]Mcl-1[/E2], and Bax, were explored with a yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[71, 76]], "entity_1_idx_in_text_with_entity_marker": [75, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Mcl-1", "entity_2_idx": [[113, 118]], "entity_2_idx_in_text_with_entity_marker": [126, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1062_AIMed.d125.s1062.p8", "text": "Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.", "text_with_entity_marker": "Interactions of the Bcl-2 protein with itself and other members of the [E1]Bcl-2[/E1] family, including Bcl-X-L, Bcl-X-S, Mcl-1, and [E2]Bax[/E2], were explored with a yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[71, 76]], "entity_1_idx_in_text_with_entity_marker": [75, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bax", "entity_2_idx": [[124, 127]], "entity_2_idx_in_text_with_entity_marker": [137, 140], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1062_AIMed.d125.s1062.p9", "text": "Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.", "text_with_entity_marker": "Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including [E1]Bcl-X-L[/E1], [E2]Bcl-X-S[/E2], Mcl-1, and Bax, were explored with a yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-X-L", "entity_1_idx": [[95, 102]], "entity_1_idx_in_text_with_entity_marker": [99, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-X-S", "entity_2_idx": [[104, 111]], "entity_2_idx_in_text_with_entity_marker": [117, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1062_AIMed.d125.s1062.p10", "text": "Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.", "text_with_entity_marker": "Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including [E1]Bcl-X-L[/E1], Bcl-X-S, [E2]Mcl-1[/E2], and Bax, were explored with a yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-X-L", "entity_1_idx": [[95, 102]], "entity_1_idx_in_text_with_entity_marker": [99, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Mcl-1", "entity_2_idx": [[113, 118]], "entity_2_idx_in_text_with_entity_marker": [126, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1062_AIMed.d125.s1062.p11", "text": "Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.", "text_with_entity_marker": "Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including [E1]Bcl-X-L[/E1], Bcl-X-S, Mcl-1, and [E2]Bax[/E2], were explored with a yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-X-L", "entity_1_idx": [[95, 102]], "entity_1_idx_in_text_with_entity_marker": [99, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bax", "entity_2_idx": [[124, 127]], "entity_2_idx_in_text_with_entity_marker": [137, 140], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1062_AIMed.d125.s1062.p12", "text": "Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.", "text_with_entity_marker": "Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, [E1]Bcl-X-S[/E1], [E2]Mcl-1[/E2], and Bax, were explored with a yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-X-S", "entity_1_idx": [[104, 111]], "entity_1_idx_in_text_with_entity_marker": [108, 115], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Mcl-1", "entity_2_idx": [[113, 118]], "entity_2_idx_in_text_with_entity_marker": [126, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1062_AIMed.d125.s1062.p13", "text": "Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.", "text_with_entity_marker": "Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, [E1]Bcl-X-S[/E1], Mcl-1, and [E2]Bax[/E2], were explored with a yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-X-S", "entity_1_idx": [[104, 111]], "entity_1_idx_in_text_with_entity_marker": [108, 115], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bax", "entity_2_idx": [[124, 127]], "entity_2_idx_in_text_with_entity_marker": [137, 140], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1062_AIMed.d125.s1062.p14", "text": "Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.", "text_with_entity_marker": "Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, [E1]Mcl-1[/E1], and [E2]Bax[/E2], were explored with a yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Mcl-1", "entity_1_idx": [[113, 118]], "entity_1_idx_in_text_with_entity_marker": [117, 122], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bax", "entity_2_idx": [[124, 127]], "entity_2_idx_in_text_with_entity_marker": [137, 140], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1066_AIMed.d125.s1066.p0", "text": "Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S.", "text_with_entity_marker": "[E1]Bcl-2[/E1] also interacted with [E2]Bcl-X-L[/E2] and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Bcl-2", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-X-L", "entity_2_idx": [[27, 34]], "entity_2_idx_in_text_with_entity_marker": [40, 47], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1066_AIMed.d125.s1066.p1", "text": "Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S.", "text_with_entity_marker": "[E1]Bcl-2[/E1] also interacted with Bcl-X-L and [E2]Mcl-1[/E2] and with the dominant inhibitors Bax and Bcl-X-S.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Bcl-2", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Mcl-1", "entity_2_idx": [[39, 44]], "entity_2_idx_in_text_with_entity_marker": [52, 57], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1066_AIMed.d125.s1066.p2", "text": "Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S.", "text_with_entity_marker": "[E1]Bcl-2[/E1] also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors [E2]Bax[/E2] and Bcl-X-S.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Bcl-2", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bax", "entity_2_idx": [[78, 81]], "entity_2_idx_in_text_with_entity_marker": [91, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1066_AIMed.d125.s1066.p3", "text": "Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S.", "text_with_entity_marker": "[E1]Bcl-2[/E1] also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and [E2]Bcl-X-S[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Bcl-2", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-X-S", "entity_2_idx": [[86, 93]], "entity_2_idx_in_text_with_entity_marker": [99, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1066_AIMed.d125.s1066.p4", "text": "Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S.", "text_with_entity_marker": "Bcl-2 also interacted with [E1]Bcl-X-L[/E1] and [E2]Mcl-1[/E2] and with the dominant inhibitors Bax and Bcl-X-S.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-X-L", "entity_1_idx": [[27, 34]], "entity_1_idx_in_text_with_entity_marker": [31, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Mcl-1", "entity_2_idx": [[39, 44]], "entity_2_idx_in_text_with_entity_marker": [52, 57], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1066_AIMed.d125.s1066.p5", "text": "Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S.", "text_with_entity_marker": "Bcl-2 also interacted with [E1]Bcl-X-L[/E1] and Mcl-1 and with the dominant inhibitors [E2]Bax[/E2] and Bcl-X-S.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-X-L", "entity_1_idx": [[27, 34]], "entity_1_idx_in_text_with_entity_marker": [31, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bax", "entity_2_idx": [[78, 81]], "entity_2_idx_in_text_with_entity_marker": [91, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1066_AIMed.d125.s1066.p6", "text": "Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S.", "text_with_entity_marker": "Bcl-2 also interacted with [E1]Bcl-X-L[/E1] and Mcl-1 and with the dominant inhibitors Bax and [E2]Bcl-X-S[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-X-L", "entity_1_idx": [[27, 34]], "entity_1_idx_in_text_with_entity_marker": [31, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-X-S", "entity_2_idx": [[86, 93]], "entity_2_idx_in_text_with_entity_marker": [99, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1066_AIMed.d125.s1066.p7", "text": "Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S.", "text_with_entity_marker": "Bcl-2 also interacted with Bcl-X-L and [E1]Mcl-1[/E1] and with the dominant inhibitors [E2]Bax[/E2] and Bcl-X-S.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Mcl-1", "entity_1_idx": [[39, 44]], "entity_1_idx_in_text_with_entity_marker": [43, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bax", "entity_2_idx": [[78, 81]], "entity_2_idx_in_text_with_entity_marker": [91, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1066_AIMed.d125.s1066.p8", "text": "Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S.", "text_with_entity_marker": "Bcl-2 also interacted with Bcl-X-L and [E1]Mcl-1[/E1] and with the dominant inhibitors Bax and [E2]Bcl-X-S[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Mcl-1", "entity_1_idx": [[39, 44]], "entity_1_idx_in_text_with_entity_marker": [43, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-X-S", "entity_2_idx": [[86, 93]], "entity_2_idx_in_text_with_entity_marker": [99, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1066_AIMed.d125.s1066.p9", "text": "Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S.", "text_with_entity_marker": "Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors [E1]Bax[/E1] and [E2]Bcl-X-S[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bax", "entity_1_idx": [[78, 81]], "entity_1_idx_in_text_with_entity_marker": [82, 85], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-X-S", "entity_2_idx": [[86, 93]], "entity_2_idx_in_text_with_entity_marker": [99, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1067_AIMed.d125.s1067.p0", "text": "Bcl-X-L displayed the same pattern of combinatorial interactions with Bcl-2 family proteins as Bcl-2.", "text_with_entity_marker": "[E1]Bcl-X-L[/E1] displayed the same pattern of combinatorial interactions with [E2]Bcl-2[/E2] family proteins as Bcl-2.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-X-L", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[70, 75]], "entity_2_idx_in_text_with_entity_marker": [83, 88], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1067_AIMed.d125.s1067.p1", "text": "Bcl-X-L displayed the same pattern of combinatorial interactions with Bcl-2 family proteins as Bcl-2.", "text_with_entity_marker": "[E1]Bcl-X-L[/E1] displayed the same pattern of combinatorial interactions with Bcl-2 family proteins as [E2]Bcl-2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-X-L", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[95, 100]], "entity_2_idx_in_text_with_entity_marker": [108, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1067_AIMed.d125.s1067.p2", "text": "Bcl-X-L displayed the same pattern of combinatorial interactions with Bcl-2 family proteins as Bcl-2.", "text_with_entity_marker": "Bcl-X-L displayed the same pattern of combinatorial interactions with [E1]Bcl-2[/E1] family proteins as [E2]Bcl-2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[70, 75]], "entity_1_idx_in_text_with_entity_marker": [74, 79], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[95, 100]], "entity_2_idx_in_text_with_entity_marker": [108, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1068_AIMed.d125.s1068.p0", "text": "Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.", "text_with_entity_marker": "Use of deletion mutants of [E1]Bcl-2[/E1] suggested that [E2]Bcl-2[/E2] homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[27, 32]], "entity_1_idx_in_text_with_entity_marker": [31, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[48, 53]], "entity_2_idx_in_text_with_entity_marker": [61, 66], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1068_AIMed.d125.s1068.p1", "text": "Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.", "text_with_entity_marker": "Use of deletion mutants of [E1]Bcl-2[/E1] suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the [E2]Bcl-2[/E2] protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[27, 32]], "entity_1_idx_in_text_with_entity_marker": [31, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[133, 138]], "entity_2_idx_in_text_with_entity_marker": [146, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1068_AIMed.d125.s1068.p2", "text": "Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.", "text_with_entity_marker": "Use of deletion mutants of [E1]Bcl-2[/E1] suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing [E2]Bcl-2[/E2] amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[27, 32]], "entity_1_idx_in_text_with_entity_marker": [31, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[180, 185]], "entity_2_idx_in_text_with_entity_marker": [193, 198], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1068_AIMed.d125.s1068.p3", "text": "Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.", "text_with_entity_marker": "Use of deletion mutants of [E1]Bcl-2[/E1] suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing [E2]Bcl-2[/E2] amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[27, 32]], "entity_1_idx_in_text_with_entity_marker": [31, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[275, 280]], "entity_2_idx_in_text_with_entity_marker": [288, 293], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1068_AIMed.d125.s1068.p4", "text": "Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.", "text_with_entity_marker": "Use of deletion mutants of [E1]Bcl-2[/E1] suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing [E2]Bcl-2[/E2] amino acids 83-218.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[27, 32]], "entity_1_idx_in_text_with_entity_marker": [31, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[353, 358]], "entity_2_idx_in_text_with_entity_marker": [366, 371], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1068_AIMed.d125.s1068.p5", "text": "Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.", "text_with_entity_marker": "Use of deletion mutants of Bcl-2 suggested that [E1]Bcl-2[/E1] homodimerization involves interactions between two distinct regions within the [E2]Bcl-2[/E2] protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[48, 53]], "entity_1_idx_in_text_with_entity_marker": [52, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[133, 138]], "entity_2_idx_in_text_with_entity_marker": [146, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1068_AIMed.d125.s1068.p6", "text": "Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.", "text_with_entity_marker": "Use of deletion mutants of Bcl-2 suggested that [E1]Bcl-2[/E1] homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing [E2]Bcl-2[/E2] amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[48, 53]], "entity_1_idx_in_text_with_entity_marker": [52, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[180, 185]], "entity_2_idx_in_text_with_entity_marker": [193, 198], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1068_AIMed.d125.s1068.p7", "text": "Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.", "text_with_entity_marker": "Use of deletion mutants of Bcl-2 suggested that [E1]Bcl-2[/E1] homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing [E2]Bcl-2[/E2] amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[48, 53]], "entity_1_idx_in_text_with_entity_marker": [52, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[275, 280]], "entity_2_idx_in_text_with_entity_marker": [288, 293], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1068_AIMed.d125.s1068.p8", "text": "Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.", "text_with_entity_marker": "Use of deletion mutants of Bcl-2 suggested that [E1]Bcl-2[/E1] homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing [E2]Bcl-2[/E2] amino acids 83-218.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[48, 53]], "entity_1_idx_in_text_with_entity_marker": [52, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[353, 358]], "entity_2_idx_in_text_with_entity_marker": [366, 371], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1068_AIMed.d125.s1068.p9", "text": "Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.", "text_with_entity_marker": "Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the [E1]Bcl-2[/E1] protein, since a LexA protein containing [E2]Bcl-2[/E2] amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[133, 138]], "entity_1_idx_in_text_with_entity_marker": [137, 142], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[180, 185]], "entity_2_idx_in_text_with_entity_marker": [193, 198], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1068_AIMed.d125.s1068.p10", "text": "Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.", "text_with_entity_marker": "Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the [E1]Bcl-2[/E1] protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing [E2]Bcl-2[/E2] amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[133, 138]], "entity_1_idx_in_text_with_entity_marker": [137, 142], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[275, 280]], "entity_2_idx_in_text_with_entity_marker": [288, 293], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1068_AIMed.d125.s1068.p11", "text": "Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.", "text_with_entity_marker": "Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the [E1]Bcl-2[/E1] protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing [E2]Bcl-2[/E2] amino acids 83-218.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[133, 138]], "entity_1_idx_in_text_with_entity_marker": [137, 142], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[353, 358]], "entity_2_idx_in_text_with_entity_marker": [366, 371], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1068_AIMed.d125.s1068.p12", "text": "Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.", "text_with_entity_marker": "Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing [E1]Bcl-2[/E1] amino acids 83-218 mediated functional interactions with a B42 fusion protein containing [E2]Bcl-2[/E2] amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[180, 185]], "entity_1_idx_in_text_with_entity_marker": [184, 189], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[275, 280]], "entity_2_idx_in_text_with_entity_marker": [288, 293], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1068_AIMed.d125.s1068.p13", "text": "Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.", "text_with_entity_marker": "Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing [E1]Bcl-2[/E1] amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing [E2]Bcl-2[/E2] amino acids 83-218.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[180, 185]], "entity_1_idx_in_text_with_entity_marker": [184, 189], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[353, 358]], "entity_2_idx_in_text_with_entity_marker": [366, 371], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1068_AIMed.d125.s1068.p14", "text": "Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.", "text_with_entity_marker": "Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing [E1]Bcl-2[/E1] amino acids 1-81 but did not complement a B42 fusion protein containing [E2]Bcl-2[/E2] amino acids 83-218.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[275, 280]], "entity_1_idx_in_text_with_entity_marker": [279, 284], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[353, 358]], "entity_2_idx_in_text_with_entity_marker": [366, 371], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1069_AIMed.d125.s1069.p0", "text": "In contrast to LexA/Bcl-2 fusion proteins, expression of a LexA/Bax protein was lethal to yeast.", "text_with_entity_marker": "In contrast to LexA/[E1]Bcl-2[/E1] fusion proteins, expression of a LexA/[E2]Bax[/E2] protein was lethal to yeast.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[20, 25]], "entity_1_idx_in_text_with_entity_marker": [24, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bax", "entity_2_idx": [[64, 67]], "entity_2_idx_in_text_with_entity_marker": [77, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1070_AIMed.d125.s1070.p0", "text": "This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).", "text_with_entity_marker": "This cytotoxicity could be abrogated by B42 fusion proteins containing [E1]Bcl-2[/E1], [E2]Bcl-X-L[/E2], or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[71, 76]], "entity_1_idx_in_text_with_entity_marker": [75, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-X-L", "entity_2_idx": [[78, 85]], "entity_2_idx_in_text_with_entity_marker": [91, 98], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1070_AIMed.d125.s1070.p1", "text": "This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).", "text_with_entity_marker": "This cytotoxicity could be abrogated by B42 fusion proteins containing [E1]Bcl-2[/E1], Bcl-X-L, or [E2]Mcl-1[/E2] but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[71, 76]], "entity_1_idx_in_text_with_entity_marker": [75, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Mcl-1", "entity_2_idx": [[90, 95]], "entity_2_idx_in_text_with_entity_marker": [103, 108], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1070_AIMed.d125.s1070.p2", "text": "This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).", "text_with_entity_marker": "This cytotoxicity could be abrogated by B42 fusion proteins containing [E1]Bcl-2[/E1], Bcl-X-L, or Mcl-1 but not those containing [E2]Bcl-X-S[/E2] (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[71, 76]], "entity_1_idx_in_text_with_entity_marker": [75, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-X-S", "entity_2_idx": [[121, 128]], "entity_2_idx_in_text_with_entity_marker": [134, 141], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1070_AIMed.d125.s1070.p3", "text": "This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).", "text_with_entity_marker": "This cytotoxicity could be abrogated by B42 fusion proteins containing [E1]Bcl-2[/E1], Bcl-X-L, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of [E2]Bcl-X[/E2] that lacks a well-conserved 63-amino acid region).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[71, 76]], "entity_1_idx_in_text_with_entity_marker": [75, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-X", "entity_2_idx": [[163, 168]], "entity_2_idx_in_text_with_entity_marker": [176, 181], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1070_AIMed.d125.s1070.p4", "text": "This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).", "text_with_entity_marker": "This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, [E1]Bcl-X-L[/E1], or [E2]Mcl-1[/E2] but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-X-L", "entity_1_idx": [[78, 85]], "entity_1_idx_in_text_with_entity_marker": [82, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Mcl-1", "entity_2_idx": [[90, 95]], "entity_2_idx_in_text_with_entity_marker": [103, 108], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1070_AIMed.d125.s1070.p5", "text": "This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).", "text_with_entity_marker": "This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, [E1]Bcl-X-L[/E1], or Mcl-1 but not those containing [E2]Bcl-X-S[/E2] (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-X-L", "entity_1_idx": [[78, 85]], "entity_1_idx_in_text_with_entity_marker": [82, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-X-S", "entity_2_idx": [[121, 128]], "entity_2_idx_in_text_with_entity_marker": [134, 141], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1070_AIMed.d125.s1070.p6", "text": "This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).", "text_with_entity_marker": "This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, [E1]Bcl-X-L[/E1], or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of [E2]Bcl-X[/E2] that lacks a well-conserved 63-amino acid region).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-X-L", "entity_1_idx": [[78, 85]], "entity_1_idx_in_text_with_entity_marker": [82, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-X", "entity_2_idx": [[163, 168]], "entity_2_idx_in_text_with_entity_marker": [176, 181], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1070_AIMed.d125.s1070.p7", "text": "This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).", "text_with_entity_marker": "This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or [E1]Mcl-1[/E1] but not those containing [E2]Bcl-X-S[/E2] (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Mcl-1", "entity_1_idx": [[90, 95]], "entity_1_idx_in_text_with_entity_marker": [94, 99], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-X-S", "entity_2_idx": [[121, 128]], "entity_2_idx_in_text_with_entity_marker": [134, 141], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1070_AIMed.d125.s1070.p8", "text": "This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).", "text_with_entity_marker": "This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or [E1]Mcl-1[/E1] but not those containing Bcl-X-S (an alternatively spliced form of [E2]Bcl-X[/E2] that lacks a well-conserved 63-amino acid region).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Mcl-1", "entity_1_idx": [[90, 95]], "entity_1_idx_in_text_with_entity_marker": [94, 99], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-X", "entity_2_idx": [[163, 168]], "entity_2_idx_in_text_with_entity_marker": [176, 181], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1070_AIMed.d125.s1070.p9", "text": "This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).", "text_with_entity_marker": "This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or Mcl-1 but not those containing [E1]Bcl-X-S[/E1] (an alternatively spliced form of [E2]Bcl-X[/E2] that lacks a well-conserved 63-amino acid region).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-X-S", "entity_1_idx": [[121, 128]], "entity_1_idx_in_text_with_entity_marker": [125, 132], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-X", "entity_2_idx": [[163, 168]], "entity_2_idx_in_text_with_entity_marker": [176, 181], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1071_AIMed.d125.s1071.p0", "text": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "text_with_entity_marker": "The findings suggest a model whereby [E1]Bax[/E1] and [E2]Bcl-X-S[/E2] differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bax", "entity_1_idx": [[37, 40]], "entity_1_idx_in_text_with_entity_marker": [41, 44], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-X-S", "entity_2_idx": [[45, 52]], "entity_2_idx_in_text_with_entity_marker": [58, 65], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1071_AIMed.d125.s1071.p1", "text": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "text_with_entity_marker": "The findings suggest a model whereby [E1]Bax[/E1] and Bcl-X-S differentially regulate [E2]Bcl-2[/E2] function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bax", "entity_1_idx": [[37, 40]], "entity_1_idx_in_text_with_entity_marker": [41, 44], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[77, 82]], "entity_2_idx_in_text_with_entity_marker": [90, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1071_AIMed.d125.s1071.p2", "text": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "text_with_entity_marker": "The findings suggest a model whereby [E1]Bax[/E1] and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for [E2]Bcl-2[/E2]/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bax", "entity_1_idx": [[37, 40]], "entity_1_idx_in_text_with_entity_marker": [41, 44], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[128, 133]], "entity_2_idx_in_text_with_entity_marker": [141, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1071_AIMed.d125.s1071.p3", "text": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "text_with_entity_marker": "The findings suggest a model whereby [E1]Bax[/E1] and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/[E2]Bax[/E2] heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bax", "entity_1_idx": [[37, 40]], "entity_1_idx_in_text_with_entity_marker": [41, 44], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bax", "entity_2_idx": [[134, 137]], "entity_2_idx_in_text_with_entity_marker": [147, 150], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1071_AIMed.d125.s1071.p4", "text": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "text_with_entity_marker": "The findings suggest a model whereby [E1]Bax[/E1] and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for [E2]Bcl-2[/E2]/Bcl-2 homodimerization.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bax", "entity_1_idx": [[37, 40]], "entity_1_idx_in_text_with_entity_marker": [41, 44], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[189, 194]], "entity_2_idx_in_text_with_entity_marker": [202, 207], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1071_AIMed.d125.s1071.p5", "text": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "text_with_entity_marker": "The findings suggest a model whereby [E1]Bax[/E1] and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/[E2]Bcl-2[/E2] homodimerization.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bax", "entity_1_idx": [[37, 40]], "entity_1_idx_in_text_with_entity_marker": [41, 44], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[195, 200]], "entity_2_idx_in_text_with_entity_marker": [208, 213], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1071_AIMed.d125.s1071.p6", "text": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "text_with_entity_marker": "The findings suggest a model whereby Bax and [E1]Bcl-X-S[/E1] differentially regulate [E2]Bcl-2[/E2] function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-X-S", "entity_1_idx": [[45, 52]], "entity_1_idx_in_text_with_entity_marker": [49, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[77, 82]], "entity_2_idx_in_text_with_entity_marker": [90, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1071_AIMed.d125.s1071.p7", "text": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "text_with_entity_marker": "The findings suggest a model whereby Bax and [E1]Bcl-X-S[/E1] differentially regulate Bcl-2 function, and indicate that requirements for [E2]Bcl-2[/E2]/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-X-S", "entity_1_idx": [[45, 52]], "entity_1_idx_in_text_with_entity_marker": [49, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[128, 133]], "entity_2_idx_in_text_with_entity_marker": [141, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1071_AIMed.d125.s1071.p8", "text": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "text_with_entity_marker": "The findings suggest a model whereby Bax and [E1]Bcl-X-S[/E1] differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/[E2]Bax[/E2] heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-X-S", "entity_1_idx": [[45, 52]], "entity_1_idx_in_text_with_entity_marker": [49, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bax", "entity_2_idx": [[134, 137]], "entity_2_idx_in_text_with_entity_marker": [147, 150], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1071_AIMed.d125.s1071.p9", "text": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "text_with_entity_marker": "The findings suggest a model whereby Bax and [E1]Bcl-X-S[/E1] differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for [E2]Bcl-2[/E2]/Bcl-2 homodimerization.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-X-S", "entity_1_idx": [[45, 52]], "entity_1_idx_in_text_with_entity_marker": [49, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[189, 194]], "entity_2_idx_in_text_with_entity_marker": [202, 207], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1071_AIMed.d125.s1071.p10", "text": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "text_with_entity_marker": "The findings suggest a model whereby Bax and [E1]Bcl-X-S[/E1] differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/[E2]Bcl-2[/E2] homodimerization.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-X-S", "entity_1_idx": [[45, 52]], "entity_1_idx_in_text_with_entity_marker": [49, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[195, 200]], "entity_2_idx_in_text_with_entity_marker": [208, 213], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1071_AIMed.d125.s1071.p11", "text": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "text_with_entity_marker": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate [E1]Bcl-2[/E1] function, and indicate that requirements for [E2]Bcl-2[/E2]/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[77, 82]], "entity_1_idx_in_text_with_entity_marker": [81, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[128, 133]], "entity_2_idx_in_text_with_entity_marker": [141, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1071_AIMed.d125.s1071.p12", "text": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "text_with_entity_marker": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate [E1]Bcl-2[/E1] function, and indicate that requirements for Bcl-2/[E2]Bax[/E2] heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[77, 82]], "entity_1_idx_in_text_with_entity_marker": [81, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bax", "entity_2_idx": [[134, 137]], "entity_2_idx_in_text_with_entity_marker": [147, 150], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1071_AIMed.d125.s1071.p13", "text": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "text_with_entity_marker": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate [E1]Bcl-2[/E1] function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for [E2]Bcl-2[/E2]/Bcl-2 homodimerization.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[77, 82]], "entity_1_idx_in_text_with_entity_marker": [81, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[189, 194]], "entity_2_idx_in_text_with_entity_marker": [202, 207], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1071_AIMed.d125.s1071.p14", "text": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "text_with_entity_marker": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate [E1]Bcl-2[/E1] function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/[E2]Bcl-2[/E2] homodimerization.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[77, 82]], "entity_1_idx_in_text_with_entity_marker": [81, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[195, 200]], "entity_2_idx_in_text_with_entity_marker": [208, 213], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1071_AIMed.d125.s1071.p15", "text": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "text_with_entity_marker": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for [E1]Bcl-2[/E1]/[E2]Bax[/E2] heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Bcl-2", "entity_1_idx": [[128, 133]], "entity_1_idx_in_text_with_entity_marker": [132, 137], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bax", "entity_2_idx": [[134, 137]], "entity_2_idx_in_text_with_entity_marker": [147, 150], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1071_AIMed.d125.s1071.p16", "text": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "text_with_entity_marker": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for [E1]Bcl-2[/E1]/Bax heterodimerization may be different from those for [E2]Bcl-2[/E2]/Bcl-2 homodimerization.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[128, 133]], "entity_1_idx_in_text_with_entity_marker": [132, 137], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[189, 194]], "entity_2_idx_in_text_with_entity_marker": [202, 207], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1071_AIMed.d125.s1071.p17", "text": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "text_with_entity_marker": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for [E1]Bcl-2[/E1]/Bax heterodimerization may be different from those for Bcl-2/[E2]Bcl-2[/E2] homodimerization.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[128, 133]], "entity_1_idx_in_text_with_entity_marker": [132, 137], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[195, 200]], "entity_2_idx_in_text_with_entity_marker": [208, 213], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1071_AIMed.d125.s1071.p18", "text": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "text_with_entity_marker": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/[E1]Bax[/E1] heterodimerization may be different from those for [E2]Bcl-2[/E2]/Bcl-2 homodimerization.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bax", "entity_1_idx": [[134, 137]], "entity_1_idx_in_text_with_entity_marker": [138, 141], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[189, 194]], "entity_2_idx_in_text_with_entity_marker": [202, 207], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1071_AIMed.d125.s1071.p19", "text": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "text_with_entity_marker": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/[E1]Bax[/E1] heterodimerization may be different from those for Bcl-2/[E2]Bcl-2[/E2] homodimerization.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bax", "entity_1_idx": [[134, 137]], "entity_1_idx_in_text_with_entity_marker": [138, 141], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[195, 200]], "entity_2_idx_in_text_with_entity_marker": [208, 213], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d125.s1071_AIMed.d125.s1071.p20", "text": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.", "text_with_entity_marker": "The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for [E1]Bcl-2[/E1]/[E2]Bcl-2[/E2] homodimerization.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Bcl-2", "entity_1_idx": [[189, 194]], "entity_1_idx_in_text_with_entity_marker": [193, 198], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[195, 200]], "entity_2_idx_in_text_with_entity_marker": [208, 213], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d21.s176_AIMed.d21.s176.p0", "text": "Many of the same signaling molecules, including protein kinase C (PKC), tyrosine kinase, phosphatidylinositol 3-kinase (P13-K), and protein phosphatase, regulate the transporters for different neurotransmitters.", "text_with_entity_marker": "Many of the same signaling molecules, including [E1]protein kinase C[/E1] ([E2]PKC[/E2]), tyrosine kinase, phosphatidylinositol 3-kinase (P13-K), and protein phosphatase, regulate the transporters for different neurotransmitters.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "protein kinase C", "entity_1_idx": [[48, 64]], "entity_1_idx_in_text_with_entity_marker": [52, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PKC", "entity_2_idx": [[66, 69]], "entity_2_idx_in_text_with_entity_marker": [79, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d21.s176_AIMed.d21.s176.p1", "text": "Many of the same signaling molecules, including protein kinase C (PKC), tyrosine kinase, phosphatidylinositol 3-kinase (P13-K), and protein phosphatase, regulate the transporters for different neurotransmitters.", "text_with_entity_marker": "Many of the same signaling molecules, including [E1]protein kinase C[/E1] (PKC), [E2]tyrosine kinase, phosphatidylinositol 3-kinase[/E2] (P13-K), and protein phosphatase, regulate the transporters for different neurotransmitters.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "protein kinase C", "entity_1_idx": [[48, 64]], "entity_1_idx_in_text_with_entity_marker": [52, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "tyrosine kinase, phosphatidylinositol 3-kinase", "entity_2_idx": [[72, 118]], "entity_2_idx_in_text_with_entity_marker": [85, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d21.s176_AIMed.d21.s176.p2", "text": "Many of the same signaling molecules, including protein kinase C (PKC), tyrosine kinase, phosphatidylinositol 3-kinase (P13-K), and protein phosphatase, regulate the transporters for different neurotransmitters.", "text_with_entity_marker": "Many of the same signaling molecules, including [E1]protein kinase C[/E1] (PKC), tyrosine kinase, phosphatidylinositol 3-kinase ([E2]P13-K[/E2]), and protein phosphatase, regulate the transporters for different neurotransmitters.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "protein kinase C", "entity_1_idx": [[48, 64]], "entity_1_idx_in_text_with_entity_marker": [52, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "P13-K", "entity_2_idx": [[120, 125]], "entity_2_idx_in_text_with_entity_marker": [133, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d21.s176_AIMed.d21.s176.p3", "text": "Many of the same signaling molecules, including protein kinase C (PKC), tyrosine kinase, phosphatidylinositol 3-kinase (P13-K), and protein phosphatase, regulate the transporters for different neurotransmitters.", "text_with_entity_marker": "Many of the same signaling molecules, including protein kinase C ([E1]PKC[/E1]), [E2]tyrosine kinase, phosphatidylinositol 3-kinase[/E2] (P13-K), and protein phosphatase, regulate the transporters for different neurotransmitters.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PKC", "entity_1_idx": [[66, 69]], "entity_1_idx_in_text_with_entity_marker": [70, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "tyrosine kinase, phosphatidylinositol 3-kinase", "entity_2_idx": [[72, 118]], "entity_2_idx_in_text_with_entity_marker": [85, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d21.s176_AIMed.d21.s176.p4", "text": "Many of the same signaling molecules, including protein kinase C (PKC), tyrosine kinase, phosphatidylinositol 3-kinase (P13-K), and protein phosphatase, regulate the transporters for different neurotransmitters.", "text_with_entity_marker": "Many of the same signaling molecules, including protein kinase C ([E1]PKC[/E1]), tyrosine kinase, phosphatidylinositol 3-kinase ([E2]P13-K[/E2]), and protein phosphatase, regulate the transporters for different neurotransmitters.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PKC", "entity_1_idx": [[66, 69]], "entity_1_idx_in_text_with_entity_marker": [70, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "P13-K", "entity_2_idx": [[120, 125]], "entity_2_idx_in_text_with_entity_marker": [133, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d21.s176_AIMed.d21.s176.p5", "text": "Many of the same signaling molecules, including protein kinase C (PKC), tyrosine kinase, phosphatidylinositol 3-kinase (P13-K), and protein phosphatase, regulate the transporters for different neurotransmitters.", "text_with_entity_marker": "Many of the same signaling molecules, including protein kinase C (PKC), [E1]tyrosine kinase, phosphatidylinositol 3-kinase[/E1] ([E2]P13-K[/E2]), and protein phosphatase, regulate the transporters for different neurotransmitters.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tyrosine kinase, phosphatidylinositol 3-kinase", "entity_1_idx": [[72, 118]], "entity_1_idx_in_text_with_entity_marker": [76, 122], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "P13-K", "entity_2_idx": [[120, 125]], "entity_2_idx_in_text_with_entity_marker": [133, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d158.s1332_AIMed.d158.s1332.p0", "text": "TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex.", "text_with_entity_marker": "TNF-dependent recruitment of the protein kinase [E1]RIP[/E1] to the [E2]TNF receptor-1[/E2] signaling complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RIP", "entity_1_idx": [[48, 51]], "entity_1_idx_in_text_with_entity_marker": [52, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF receptor-1", "entity_2_idx": [[59, 73]], "entity_2_idx_in_text_with_entity_marker": [72, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d158.s1333_AIMed.d158.s1333.p0", "text": "The death domain of tumor necrosis factor (TNF) receptor-1 (TNFR1) triggers distinct signaling pathways leading to apoptosis and NF-kappa B activation through its interaction with the death domain protein TRADD.", "text_with_entity_marker": "The death domain of [E1]tumor necrosis factor (TNF) receptor-1[/E1] ([E2]TNFR1[/E2]) triggers distinct signaling pathways leading to apoptosis and NF-kappa B activation through its interaction with the death domain protein TRADD.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tumor necrosis factor (TNF) receptor-1", "entity_1_idx": [[20, 58]], "entity_1_idx_in_text_with_entity_marker": [24, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFR1", "entity_2_idx": [[60, 65]], "entity_2_idx_in_text_with_entity_marker": [73, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d158.s1333_AIMed.d158.s1333.p1", "text": "The death domain of tumor necrosis factor (TNF) receptor-1 (TNFR1) triggers distinct signaling pathways leading to apoptosis and NF-kappa B activation through its interaction with the death domain protein TRADD.", "text_with_entity_marker": "The death domain of [E1]tumor necrosis factor (TNF) receptor-1[/E1] (TNFR1) triggers distinct signaling pathways leading to apoptosis and [E2]NF-kappa B[/E2] activation through its interaction with the death domain protein TRADD.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tumor necrosis factor (TNF) receptor-1", "entity_1_idx": [[20, 58]], "entity_1_idx_in_text_with_entity_marker": [24, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappa B", "entity_2_idx": [[129, 139]], "entity_2_idx_in_text_with_entity_marker": [142, 152], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d158.s1333_AIMed.d158.s1333.p2", "text": "The death domain of tumor necrosis factor (TNF) receptor-1 (TNFR1) triggers distinct signaling pathways leading to apoptosis and NF-kappa B activation through its interaction with the death domain protein TRADD.", "text_with_entity_marker": "The death domain of [E1]tumor necrosis factor (TNF) receptor-1[/E1] (TNFR1) triggers distinct signaling pathways leading to apoptosis and NF-kappa B activation through its interaction with the death domain protein [E2]TRADD[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "tumor necrosis factor (TNF) receptor-1", "entity_1_idx": [[20, 58]], "entity_1_idx_in_text_with_entity_marker": [24, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TRADD", "entity_2_idx": [[205, 210]], "entity_2_idx_in_text_with_entity_marker": [218, 223], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d158.s1333_AIMed.d158.s1333.p3", "text": "The death domain of tumor necrosis factor (TNF) receptor-1 (TNFR1) triggers distinct signaling pathways leading to apoptosis and NF-kappa B activation through its interaction with the death domain protein TRADD.", "text_with_entity_marker": "The death domain of tumor necrosis factor (TNF) receptor-1 ([E1]TNFR1[/E1]) triggers distinct signaling pathways leading to apoptosis and [E2]NF-kappa B[/E2] activation through its interaction with the death domain protein TRADD.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNFR1", "entity_1_idx": [[60, 65]], "entity_1_idx_in_text_with_entity_marker": [64, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappa B", "entity_2_idx": [[129, 139]], "entity_2_idx_in_text_with_entity_marker": [142, 152], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d158.s1333_AIMed.d158.s1333.p4", "text": "The death domain of tumor necrosis factor (TNF) receptor-1 (TNFR1) triggers distinct signaling pathways leading to apoptosis and NF-kappa B activation through its interaction with the death domain protein TRADD.", "text_with_entity_marker": "The death domain of tumor necrosis factor (TNF) receptor-1 ([E1]TNFR1[/E1]) triggers distinct signaling pathways leading to apoptosis and NF-kappa B activation through its interaction with the death domain protein [E2]TRADD[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TNFR1", "entity_1_idx": [[60, 65]], "entity_1_idx_in_text_with_entity_marker": [64, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TRADD", "entity_2_idx": [[205, 210]], "entity_2_idx_in_text_with_entity_marker": [218, 223], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d158.s1333_AIMed.d158.s1333.p5", "text": "The death domain of tumor necrosis factor (TNF) receptor-1 (TNFR1) triggers distinct signaling pathways leading to apoptosis and NF-kappa B activation through its interaction with the death domain protein TRADD.", "text_with_entity_marker": "The death domain of tumor necrosis factor (TNF) receptor-1 (TNFR1) triggers distinct signaling pathways leading to apoptosis and [E1]NF-kappa B[/E1] activation through its interaction with the death domain protein [E2]TRADD[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NF-kappa B", "entity_1_idx": [[129, 139]], "entity_1_idx_in_text_with_entity_marker": [133, 143], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TRADD", "entity_2_idx": [[205, 210]], "entity_2_idx_in_text_with_entity_marker": [218, 223], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d158.s1334_AIMed.d158.s1334.p0", "text": "Here, we show that TRADD interacts strongly with RIP, another death domain protein that was shown previously to associate with Fas antigen.", "text_with_entity_marker": "Here, we show that [E1]TRADD[/E1] interacts strongly with [E2]RIP[/E2], another death domain protein that was shown previously to associate with Fas antigen.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TRADD", "entity_1_idx": [[19, 24]], "entity_1_idx_in_text_with_entity_marker": [23, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RIP", "entity_2_idx": [[49, 52]], "entity_2_idx_in_text_with_entity_marker": [62, 65], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d158.s1334_AIMed.d158.s1334.p1", "text": "Here, we show that TRADD interacts strongly with RIP, another death domain protein that was shown previously to associate with Fas antigen.", "text_with_entity_marker": "Here, we show that [E1]TRADD[/E1] interacts strongly with RIP, another death domain protein that was shown previously to associate with [E2]Fas[/E2] antigen.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRADD", "entity_1_idx": [[19, 24]], "entity_1_idx_in_text_with_entity_marker": [23, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[127, 130]], "entity_2_idx_in_text_with_entity_marker": [140, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d158.s1334_AIMed.d158.s1334.p2", "text": "Here, we show that TRADD interacts strongly with RIP, another death domain protein that was shown previously to associate with Fas antigen.", "text_with_entity_marker": "Here, we show that TRADD interacts strongly with [E1]RIP[/E1], another death domain protein that was shown previously to associate with [E2]Fas[/E2] antigen.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "RIP", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[127, 130]], "entity_2_idx_in_text_with_entity_marker": [140, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d158.s1335_AIMed.d158.s1335.p0", "text": "We also show that RIP is a serine-threonine kinase that is recruited by TRADD to TNFR1 in a TNF-dependent process.", "text_with_entity_marker": "We also show that [E1]RIP[/E1] is a serine-threonine kinase that is recruited by [E2]TRADD[/E2] to TNFR1 in a TNF-dependent process.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RIP", "entity_1_idx": [[18, 21]], "entity_1_idx_in_text_with_entity_marker": [22, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TRADD", "entity_2_idx": [[72, 77]], "entity_2_idx_in_text_with_entity_marker": [85, 90], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d158.s1335_AIMed.d158.s1335.p1", "text": "We also show that RIP is a serine-threonine kinase that is recruited by TRADD to TNFR1 in a TNF-dependent process.", "text_with_entity_marker": "We also show that [E1]RIP[/E1] is a serine-threonine kinase that is recruited by TRADD to [E2]TNFR1[/E2] in a TNF-dependent process.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RIP", "entity_1_idx": [[18, 21]], "entity_1_idx_in_text_with_entity_marker": [22, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFR1", "entity_2_idx": [[81, 86]], "entity_2_idx_in_text_with_entity_marker": [94, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d158.s1335_AIMed.d158.s1335.p2", "text": "We also show that RIP is a serine-threonine kinase that is recruited by TRADD to TNFR1 in a TNF-dependent process.", "text_with_entity_marker": "We also show that RIP is a serine-threonine kinase that is recruited by [E1]TRADD[/E1] to [E2]TNFR1[/E2] in a TNF-dependent process.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRADD", "entity_1_idx": [[72, 77]], "entity_1_idx_in_text_with_entity_marker": [76, 81], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFR1", "entity_2_idx": [[81, 86]], "entity_2_idx_in_text_with_entity_marker": [94, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d158.s1336_AIMed.d158.s1336.p0", "text": "Overexpression of the intact RIP protein induces both NF-kappa B activation and apoptosis.", "text_with_entity_marker": "Overexpression of the intact [E1]RIP[/E1] protein induces both [E2]NF-kappa B[/E2] activation and apoptosis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RIP", "entity_1_idx": [[29, 32]], "entity_1_idx_in_text_with_entity_marker": [33, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappa B", "entity_2_idx": [[54, 64]], "entity_2_idx_in_text_with_entity_marker": [67, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d158.s1337_AIMed.d158.s1337.p0", "text": "However, expression of the death domain of RIP Induces apoptosis, but potently inhibits NF-kappa B activation by TNF.", "text_with_entity_marker": "However, expression of the death domain of [E1]RIP[/E1] Induces apoptosis, but potently inhibits [E2]NF-kappa B[/E2] activation by TNF.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RIP", "entity_1_idx": [[43, 46]], "entity_1_idx_in_text_with_entity_marker": [47, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappa B", "entity_2_idx": [[88, 98]], "entity_2_idx_in_text_with_entity_marker": [101, 111], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d158.s1338_AIMed.d158.s1338.p0", "text": "These results suggest that distinct domains of RIP participate in the TNF signaling cascades leading to apoptosis and NF-kappa B activation.", "text_with_entity_marker": "These results suggest that distinct domains of [E1]RIP[/E1] participate in the TNF signaling cascades leading to apoptosis and [E2]NF-kappa B[/E2] activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RIP", "entity_1_idx": [[47, 50]], "entity_1_idx_in_text_with_entity_marker": [51, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappa B", "entity_2_idx": [[118, 128]], "entity_2_idx_in_text_with_entity_marker": [131, 141], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
